Foamix Pharmaceuticals Ltd
Annual Report 2016

Plain-text annual report

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 20-FANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the fiscal year ended December 31, 2016Commission file number: 001-36621Foamix Pharmaceuticals Ltd.(Exact name of Registrant as specified in its charter)State of Israel(Jurisdiction of incorporation or organization)2 Holzman Street, Weizmann Science ParkRehovot 7670402, IsraelTel: +972-8-9316233(Address of principal executive offices)Mr. Ilan Hadar, Chief Financial Officer2 Holzman Street, Weizmann Science ParkRehovot 7670402, IsraelTel: +972-8-931-6233(Name, Telephone and/or Facsimile number and Address of Company Contact Person)Securities registered or to be registered pursuant to Section 12(b) of the Act:Title of each className of each exchange on which registeredOrdinary Shares, par value of NIS 0.16NASDAQ Global MarketSecurities registered or to be registered pursuant to Section 12(g) of the Act: NoneSecurities for which there is a reporting obligation pursuant to Section 15(d) of the Act: NoneIndicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report.37,167,791 Ordinary Shares, par value NIS 0.16 per share.Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.☐ Yes ☒ NoIf this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934.☐ Yes ☒ NoIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.☒ Yes ☐ NoIndicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required tobe submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit and post such files). ☒ Yes ☐ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Act).☐ Large Accelerated Filer☒ Accelerated Filer☐ Non-Accelerated FilerIndicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: U.S. GAAP ☒International Financial Reporting Standards as issued by the International Accounting Standards Board ☐Other ☐ If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant haselected to follow.Item 17 ☐ Item 18 ☐If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐ Yes ☒ NoiiTABLE OF CONTENTS Item NumberTitlePage PART ONE Item 1Identity of directors, senior management and advisers2Item 2Offer statistics and expected timetable2Item 3Key information2Item 4Information on the company28Item 4AUnresolved staff comments28Item 5Operating and financial review and prospects46Item 6Directors, senior management and employees54Item 7Major shareholders and related party transactions65Item 8Financial Information67Item 9The Offer and Listing68Item 10Additional information69Item 11Quantitative and qualitative disclosures about market risk74Item 12Description of securities other than equity securities75 PART TWO Item 13Defaults, dividend arrearages and delinquencies76Item 14Material modifications to the rights of security holders and use of proceeds76Item 15Controls and procedures76Item 16AAudit committee financial expert77Item 16BCode of ethics77Item 16CPrincipal accountant fees and services77Item 16DExemptions from the listing standards for audit committees77Item 16EPurchases of equity securities by the issuer and affiliated purchasers77Item 16FChange in registrant's certifying accountant77Item 16GCorporate governance77Item 16HMine safety disclosure82 PART THREE Item 17Financial statements83Item 18Financial statements83Item 19Exhibits84 iiiINTRODUCTION Unless otherwise indicated, all references to the "Company," "we," "us," "our" and "Foamix" refer to Foamix Pharmaceuticals Ltd. and its subsidiary,Foamix Pharmaceuticals Inc., a Delaware corporation. References to "U.S. dollars" and "$" are to currency of the United States of America, and references to"NIS" are to new Israeli shekels. References to "Ordinary Shares" are to our ordinary shares, par value of NIS 0.16 per share. We do not endorse or adopt any third-party research or forecast firms' statements or reports referred to in this annual report and assume no responsibilityfor the contents or opinions represented in such statements or reports, nor for the updating of any information contained therein. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This annual report contains express or implied "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995and other U.S. Federal securities laws. These forward-looking statements include, but are not limited to, statements regarding the following matters: ·U.S. Food and Drug Administration, or FDA, approval of, or other regulatory action in the U.S. and elsewhere with respect to, our product candidates; ·the commercial launch and current products or future candidates; ·our ability to achieve favorable pricing for our product candidates; ·our expectations regarding the commercial supply of our product candidates; ·third-party payor reimbursement for our product candidates; ·our estimates regarding anticipated expenses, capital requirements and needs for additional financing; ·the patient market size of any diseases and market adoption of our products by physicians and patients; ·the timing, cost or other aspects of the commercial launch of our product candidates; ·completion and receiving favorable results of clinical trials for our product candidates; ·application for and issuance of patents to us by the United States Patent and Trademark Office, or U.S. PTO, and other governmental patent agencies; ·development and approval of the use of our product candidates for additional indications; and ·our expectations regarding licensing, business transactions and strategic operations. In some cases, forward-looking statements are identified by terminology such as "may," "will," "could," "should," "expects," "plans," "anticipates,""believes," "intends," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other comparable terminology. Such forward-lookingstatements involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from thoseprojected. These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our orour industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-lookingstatements. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trialswould not be different, and historic results referred to in this press release may be interpreted differently in light of additional research and clinical andpreclinical trials results. The forward-looking statements contained in this annual report are subject to risks and uncertainties, including those discussedunder "Item 3.D. Risk Factors" and in our other filings with the Securities and Exchange Commission, or the SEC. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as of the date hereof. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we areunder no duty to (and expressly disclaim any such obligation to) update or revise any of the forward-looking statements, whether as a result of newinformation, future events or otherwise, after the date of this annual report.  Year ended December 31, 2016 2015 2014 2013 2012 Cost of revenues $3 $2 $15 $16 $23 Research and development 1,135 588 80 59 83 Selling, general and administrative 1,774 1,187 102 430 249 Total share-based compensation $2,912 $1,777 $197 $505 $355 PART ONE ITEM 1.IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable. ITEM 2.OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable. ITEM 3.KEY INFORMATION 3.A.Selected financial data Our historical consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States and arepresented in U.S. dollars. The selected historical consolidated financial information as of December 31, 2016 and 2015 and for the years ended December 31,2016, 2015 and 2014 have been derived from, and should be read in conjunction with, the consolidated financial statements of Foamix Pharmaceuticals Ltd.and notes thereto appearing elsewhere in this annual report. The selected financial data as of December 31, 2014, 2013 and 2012 and for the year ended 2013and 2012, have been derived from audited consolidated financial statements of Foamix Pharmaceuticals Ltd. not included in this annual report. The information presented below is qualified by the more detailed historical consolidated financial statements set forth in this annual report, and shouldbe read in conjunction with those consolidated financial statements, the notes thereto and the discussion under "Item 5. Operating and Financial Review andProspects" - included elsewhere in this annual report. Consolidated Statement of Operations Data – Year Ended December 31 (in thousands of U.S. dollars, except per share data) Year ended December 31, 2016 2015 2014 2013 2012 Statements of operations data: Revenues $5,527 $849 $5,414 $1,404 $1,086 Cost of revenues(1) 59 70 527 453 491 Gross profit 5,468 779 4,887 951 595 Operating expenses: Research and development(1) 25,897 10,680 3,557 1,086 1,202 Selling, general and administrative(1) 9,221 7,029 2,964 1,221 953 Total operating expenses 35,118 17,709 6,521 2,307 2,155 Operating loss 29,650 16,930 1,634 1,356 1,560 Net Loss $29,336 $16,517 $11,484 $2,431 $2,169 Loss per share basic and diluted 0.91 0.58 0.79 0.22 0.20 _________________________________________________(1)Includes share-based compensation expenses as follows: Consolidated Balance Sheet Data – Year Ended December 31 (in thousands of U.S. dollars) As of December 31, 2016 2015 2014 2013 2012 Balance sheet data: Cash, cash equivalents, restricted cash, bank deposits,marketable securitiesand restricted marketable securities $130,988 $103,779 $49,966 $2,308 $950 Working capital(1) 111,730 53,091 48,757 1,144 836 Total assets 135,635 105,245 51,277 3,086 1,389 Total long-term liabilities 379 385 381 4,917 3,967 Total shareholders' equity (capital deficiency) 129,985 100,802 48,762 (3,582) (2,941)Capital stock $1,561 $1,284 $954 $471 $459 Number of ordinary shares 37,167,791 30,639,134 22,443,934 11,408,490 11,151,719 _________________________________________________(1)Working capital is defined as total current assets minus total current liabilities.23.B.Capitalization and indebtedness Not applicable. 3.C.Reasons for the offer and use of proceeds Not applicable. 3.D.Risk factors In conducting our business, we face many risks that may interfere with our business objectives. Some of these risks could materially and adversely affectour business, financial condition and results of operations. In particular, we are subject to various risks resulting from changing economic, political, industry,business and financial conditions. The risks and uncertainties described below are not the only ones we face. You should carefully consider the following factors and other information in this annual report. If any of the negative events referred to below occur, ourbusiness, financial condition and results of operations could suffer. In any such case, the trading price of our ordinary shares could decline. Risks Related to Our Business and Industry We are largely dependent on the success of our lead product candidates, FMX101 and FMX103 for the treatment of acne and rosacea. We have invested a majority of our efforts and financial resources in the research and development of FMX101 for the treatment of moderate-to-severeacne and FMX103 for the treatment of moderate-to-severe papulo-pustular rosacea, which have both completed Phase II clinical trials. We continue todedicate our resources toward (i) completion of our Phase III clinical trials for FMX101 during the first half of 2017 and filing a new drug application, orNDA, with the FDA during 2018; (ii) commencing Phase III clinical trials for FMX103 during 2017; and (iii) advancing our other pipeline candidates. Thesuccess of our business depends largely on our ability to fund, execute and complete the development of, obtain regulatory approval for and successfullycommercialize FMX101 and FMX103 in a timely manner. If we fail to do so, we may not be able to obtain adequate funding to continue to operate ourbusiness. We have not completed Phase III clinical trials for any of our product candidates, nor have we applied for regulatory approvals to market any of ourproduct candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize our product candidates. The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, anddelays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA, andforeign regulatory agencies. These regulations are agency-specific and differ by jurisdiction. We are not permitted to market any of our product candidates inthe U.S. until we receive approval of a NDA, from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatoryagencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatoryauthority with clinical data that demonstrates the continued safety, purity and potency of the product for the intended indication. Before we can submit an NDA to the FDA or similar applications to foreign regulatory authorities, for FMX101 or FMX103, our leading productcandidates, we must complete Phase III clinical trials for them. These clinical trials are substantially broader than our Phase II clinical trials and have required(or will require) us to enlist a considerably larger number of patients in multiple clinics and medical centers. We have not received formal regulatoryclearance to file an NDA with the FDA or comparable applications to foreign regulatory authorities. Our other product candidates are at similar or earlierstages of development and therefore subject to similar or even greater uncertainty and risk than FMX101 and FMX103. 3Phase III clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may beunsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatoryagencies may suspend one or all of our clinical trials or require that we conduct additional clinical, nonclinical, manufacturing, validation or drug productquality studies and submit that data before considering or reconsidering any NDA or similar foreign regulatory application we may submit. Depending on theextent of these additional studies, approval of any applications that we submit may be significantly delayed, or may require us to expend more resources thanwe have available. It is also possible that additional studies we conduct may not be considered sufficient by the FDA or applicable foreign regulatoryagencies to provide regulatory approval. If any of these outcomes occur, we would not receive approval for FMX101, FMX103 or our other product candidates and may be forced to ceaseoperations. We have conducted only one Phase II clinical trial relating to each of FMX101, FMX102, FMX103 and FDX104, in each case outside the U.S., the resultsof which may not be predictive of future trial results. Positive results in preclinical testing and early clinical trials do not ensure that later clinical trials will be successful. A number of pharmaceuticalcompanies have suffered significant setbacks in clinical trials, including in Phase III, after promising results in preclinical testing and early clinical trials.These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse events. To date, we have conducted only one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104 which met their respective primaryefficacy and secondary endpoints. Our Phase III clinical trials for our lead product candidates may not be successful, and even if they are, the FDA may notapprove our NDA for such product candidates, should we be in position to file one, and may not agree that the benefits of such product candidates outweighits risks, or may raise new concerns regarding our clinical trial designs. If the FDA does not conclude that FMX101 or FMX103 satisfy the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetics Act, orSection 505(b)(2), or if the requirements for this product candidate under Section 505(b)(2) are not as we expect, the approval pathway for this productcandidate will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and ineither case may not be successful. We expect to complete our pivotal Phase III trials for FMX101 and commence pivotal Phase III trials for FMX103 under the FDA's 505(b)(2) regulatorypathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to theFederal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approvalcomes from studies that were not conducted by or for the applicant, and for which the applicant has not received a right of reference, which could expeditethe development program for FMX101 and FMX103 by potentially decreasing the amount of clinical data that we would need to generate in order to obtainFDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway, we may need to conduct additional clinical trials, provideadditional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required toobtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely increase significantly.Moreover, inability to pursue the Section 505(b)(2) regulatory pathway could result in new competitive products reaching the market more quickly than ourproduct candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatorypathway, our product candidates may not receive the requisite approvals for commercialization. In addition, notwithstanding the approval of certain products by the FDA under Section 505(b)(2) over the last few years, certain competitors and othershave objected to the FDA's interpretation of Section 505(b)(2). If the FDA's interpretation of Section 505(b)(2) is successfully challenged, the FDA may berequired to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protectthe patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patentlitigation and mandatory delays in approval of our NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for amanufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for,pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDAultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able toutilize the Section 505(b)(2) regulatory pathway for FMX101 and FMX103, there is no guarantee this would ultimately lead to faster product development orearlier approval. Moreover, even if these product candidates are approved under Section 505(b)(2), the approval may be subject to limitations on the indicated uses forwhich the product may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance tomonitor the safety or efficacy of the products. 4Our Phase II clinical trials were not conducted head-to-head with the current standard of care drugs, the comparison of our results to those of existingdrugs, and the conclusions we have drawn from such comparisons, may be inaccurate, and the FDA may require our Phase III trials to be controlledagainst such drugs. Our Phase II clinical trials for FMX101, FMX102, FMX103 and FDX104 were not conducted in head-to-head comparison with the drugs considered thecurrent standard of care for the relevant indications, namely Solodyn for moderate-to-severe acne, Bactroban for impetigo, topical antimicrobials (such assuch as Metrogel, generic metronidazole and Finacea) for rosacea and oral doxycycline for chemotherapy induced rash. This means that none of the patientgroups participating in these trials were treated with the standard of care drugs alongside the groups treated with our product candidates. Instead, we havecompared the results of our clinical trials with historical data from prior clinical trials conducted for the standard of care drugs, as presented in their respectiveproduct labels. Direct comparison generally provides more reliable information about how two or more drugs compare, and reliance on indirect comparison for evaluatingtheir relative efficacy or other qualities is problematic due to lack of objective or validated methods to assess trial similarity. For example, the various trialswere likely conducted in different countries with different demographic features and in patients with different baseline conditions and different hygienestandards, among other relevant asymmetries. Therefore, the conclusions we have drawn from comparing the results of our trials with those published in theproduct labels for these current standards of care drugs, including conclusions regarding the relative efficacy and expediency of FMX101, FMX102, FMX103and FDX104, may be distorted by the inaccurate methodology of the comparison. The FDA may require the Phase III clinical trials of our product candidates to be controlled against the drugs that are currently considered the standards ofcare for the treatment of the relevant indications, instead of being controlled against a placebo or against a different dosage of our minocycline foam, as wasthe case in our Phase II clinical trials. Furthermore, even if the FDA does not impose such a requirement in connection with our Phase III clinical trials, theFDA generally requires adequate, well-controlled head-to-head clinical trials to support comparative claims regarding marketed products. As a result, we maydecide to conduct comparative studies of FMX101, FMX103 or any of our other product candidates that are commercialized to support comparative claimsused in the marketing of those product candidates. Significant additional time and expense will be required to design and conduct any head-to-head trials.For example, in the case of FMX101 for moderate-to-severe acne, the standard of care is an oral drug, Solodyn, whereas FMX101 is a topical drug. To conducta double blind study comparing the two treatments, all patients would need to receive both modalities, with either the oral or topical treatment consisting of aplacebo, increasing the complexity and cost. If we are unable to conduct head-to-head trials for one or more of our product candidates, even if such productcandidates are approved for marketing in the U.S., we will not be able to make claims comparing such product candidates to the current standards of care orother competitor products which may negatively impact sales of these products. Our ability to finance our operations and generate revenues depends on the clinical and commercial success of FMX101, FMX103 and our other productcandidates and failure to achieve such success will negatively impact our business. Our near-term prospects, including our ability to finance our operations and generate revenues, depend on the successful development, regulatoryapproval and commercialization of FMX101 and FMX103, as well as our other product candidates. The clinical and commercial success of FMX101,FMX103 and our other product candidates depends on a number of factors, many of which are beyond our control, including: ·the FDA's and foreign regulatory agencies' acceptance of our parameters for regulatory approval relating to FMX101, FMX103 and our other productcandidates, including our proposed indications, primary endpoint assessments, primary endpoint measurements and regulatory pathways; ·the FDA's and foreign regulatory agencies' acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocolsand the interpretation of data from preclinical studies or clinical trials; ·the FDA's and foreign regulatory agencies' acceptance of the sufficiency of the data we collected from our preclinical studies and early clinical trials ofFMX101 and FMX103 to support the submission of an NDA or similar foreign regulatory application without requiring additional preclinical orclinical trials; ·the FDA's and foreign regulatory agencies' willingness to schedule an advisory committee meeting in a timely manner to evaluate and decide on theapproval of our NDA or similar foreign regulatory application; ·the recommendation of the FDA and foreign regulatory agencies' advisory committee to approve our application without limiting the approvedlabeling, specifications, distribution or use of the products, or imposing other restrictions; ·the FDA's and foreign regulatory agencies' willingness to grant separate approvals for adults and children, where we may have successful clinical trialresults for children but not for adults, or vice versa; ·the FDA's and foreign regulatory agencies' satisfaction with the safety and efficacy of FMX101 and FMX103 or our other product candidates; 5·the prevalence and severity of adverse events associated with FMX101, FMX103 and our other product candidates; ·the timely and satisfactory performance by third party contractors of their obligations in relation to our clinical trials, including any future Phase IIIclinical trials for FMX101 and FMX103; ·our success in educating dermatologists, pediatricians and patients about the benefits, administration and use of FMX101, FMX103 and our otherproduct candidates, if approved; ·our ability to raise additional capital on acceptable terms in order to achieve our goals; ·the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments; ·the effectiveness of our marketing, sales and distribution strategy and operations, as well as that of our current and future licensees; ·our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturingpractices, or cGMP; ·our ability to obtain, protect and enforce our intellectual property rights with respect to FMX101 or our other product candidates; and ·our ability to avoid third party claims of patent infringement or intellectual property violations. If we fail to achieve these objectives or to overcome the challenges presented above, many of which are beyond our control, in a timely manner, we couldexperience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we may not be able to generate sufficientrevenues through the sale of FMX101 or our other product candidates to enable us to continue our business. We may encounter delays in completing clinical trials for FMX101, FMX103 and our other product candidates and may even be prevented fromcommencing such trials due to factors that are largely beyond our control. We have in the past and may in the future experience delays in completing our ongoing clinical trials and in commencing future clinical trials. We havealready experienced delays in our Phase III clinical trials with FMX101 for acne, due to quality control issues with certain active ingredients supplied to usby a third party, and in our Phase II clinical trial with FMX102 for impetigo that took place in Israel, due to our difficulty in enlisting a sufficient number ofpediatric patients with the necessary severity of the disease to participate in the trial. Such difficulties may arise again in future trials for other indications andfor our other product candidates. We rely on contract research organizations, or CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we haveagreements governing the committed activities of our CROs, we have limited influence over their actual performance. A failure of one or more of our clinicaltrials can occur at any time during the clinical trial process. Clinical trials can be delayed or aborted for a variety of other reasons, including delay or failureto: ·obtain regulatory approval to commence a trial; ·reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which may be subject to extensive negotiation andvary significantly among different CROs and trial sites; ·obtain institutional review board, or IRB, approval at each site; ·enlist suitable patients to participate in a trial; ·have patients complete a trial or return for post-treatment follow-up; ·ensure clinical sites observe trial protocol or continue to participate in a trial; ·address any patient safety concerns that arise during the course of a trial; ·address any conflicts with new or existing laws or regulations; ·add a sufficient number of clinical trial sites; or ·manufacture sufficient quantities of the product candidate for use in clinical trials. Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patientpopulation, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials andclinicians' and patients' perceptions as to the potential advantages of the drug being studied in relation to available alternatives, including any new drugs ortreatments that may be approved for the indications we are investigating. We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted,by the trial's data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one ormore of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements orclinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinicalhold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations oradministrative actions or lack of adequate funding to continue the clinical trial. 6If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates maybe harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing ourclinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence productsales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors thatcause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our productcandidates. FMX101, FMX103 and other product candidates may produce undesirable side effects that we may not have detected in our Phase II clinical trials. Thiscould prevent us from gaining marketing approval or market acceptance for this product candidate, or from maintaining such approval and acceptance,and could substantially increase commercialization costs and even force us to cease operations. FMX101, FMX102, FMX103 and FDX104 have so far been shown in Phase I and Phase II to have no drug-related systemic side effects and only a fewcases of mild and temporary skin reactions have been reported, most of which disappeared on their own within 12 weeks from the beginning of the treatment. Nonetheless, in further Phase III clinical trials, which involve large patient populations, and upon commercialization of FMX101,FMX103 or other productcandidates, if approved, the clinical exposure of the drugs will be significantly expanded to a wider and more diverse group of patients than thoseparticipating in the clinical trials, which may reveal undesirable side effects caused by these products that were not previously observed or reported in thecurrent clinical trials. The FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if our products may havecaused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date on which we become aware of theadverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail toappreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that isunexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency couldtake action including criminal prosecution, the imposition of civil monetary penalties or seizure of our products. Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our product candidates, a number of otherpotentially significant negative consequences could result, including: ·the FDA or foreign regulatory authorities may suspend or withdraw their approval of the product; ·the FDA or foreign regulatory authorities may require the addition of labeling statements, such as warnings or contraindications or distribution and userestrictions; ·the FDA or foreign regulatory authorities may require us to issue specific communications to healthcare professionals, such as letters alerting them tonew safety information about our product, changes in dosage or other important information; ·the FDA or foreign regulatory authorities may issue negative publicity regarding the affected product, including safety communications; ·we may be limited with respect to the safety-related claims that we can make in our marketing or promotional materials; ·we may be required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease thedistribution or use of the product; and ·we could be sued and held liable for harm caused to patients. Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increasecommercialization costs or even force us to cease operations. Even if FMX101, FMX103 or our other product candidates receive marketing approval, we may continue to face future developmental and regulatorydifficulties. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market ourproposed product candidates. Even if we complete clinical testing and receive approval of any regulatory filing for FMX101, FMX103 or any of our other product candidates, the FDAor applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials, risk mitigationrequirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues orincreasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit theapproved uses of our products, if any. 7The FDA or applicable foreign regulatory agency may also approve FMX101, FMX103 or any of our other product candidates for a more limitedindication or a narrower patient population than we originally requested, or may not approve the labeling that we believe is necessary or desirable for thesuccessful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements,including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution andrecordkeeping. If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems withany approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposedsanctions or other setbacks, including the following: ·suspend or impose restrictions on operations, including costly new manufacturing requirements; ·refuse to approve pending applications or supplements to applications; ·suspend any ongoing clinical trials; ·suspend or withdraw marketing approval; ·seek an injunction or impose civil or criminal penalties or monetary fines; ·seize or detain products; ·ban or restrict imports and exports; ·issue warning letters or untitled letters; ·suspend or impose restrictions on operations, including costly new manufacturing requirements; or ·refuse to approve pending applications or supplements to applications. In addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time.Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and,consequently, could adversely affect our business operations and financial performance. Even if FMX101, FMX103 or our other product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoptionand use and market acceptance necessary for commercial success. Even if we obtain FDA or foreign regulatory approvals for FMX101, FMX103 or any of our other product candidates, the commercial success of suchproducts will depend significantly on their broad adoption and use by dermatologists, pediatricians and other physicians for approved indications, including,in the case of FMX101 and FMX103, for the treatment of moderate-to-severe acne, moderate-to-sever rosacea and other therapeutic indications that we mayseek to pursue. Moreover, if the treatment of acne with FMX101 or rosacea with FMX103 is deemed to be an elective procedure, the cost of which is borne by the patient,it will not be reimbursable through government or private health insurance. The degree and rate of physician and patient adoption of FMX101, FMX103 and any of our other product candidates, if approved, will depend on anumber of factors, including: ·the clinical indications for which the product is approved; ·the safety and efficacy of our product as compared to existing therapies for those indications; ·the prevalence and severity of adverse side effects; ·patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of useand avoidance of, or reduction in, adverse side effects; ·patient demand for the treatment of moderate-to-severe acne and rosacea or other indications; ·overcoming biases of physicians and patients towards topical treatments for moderate-to-severe acne, rosacea or other indications and their willingnessto adopt new therapies for these indications; ·the cost of treatment in relation to alternative treatments, the extent to which these costs are reimbursed by third party payors, and patients' willingnessto pay for our products; ·proper training and administration of our products by dermatologists, pediatricians and medical staff; 8·the revenues and profitability that our products will offer physicians as compared to alternative therapies; and ·the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward dermatologists,pediatricians, other physicians, clinics and any direct-to-consumer marketing efforts we may initiate. If FMX101, FMX103 or any of our other product candidates are approved for use but fail to achieve the broad degree of physician adoption and marketacceptance necessary for commercial success, our operating results and financial condition will be adversely affected. Our ability to market FMX101 and FMX103, if approved, may be limited to use for the treatment of moderate-to-severe acne or moderate-to-severerosacea, respectively, in the U.S., and if we want to expand the indications for which we may market FMX101 or the territories in which we may marketthese products, we will need to obtain additional regulatory approvals, which may not be granted. We plan to seek regulatory approval in the U.S. for FMX101 and FMX103 for the treatment of moderate-to-severe acne and moderate-to-severe rosacea,respectively, in the U.S. If FMX101 is approved, the FDA will likely restrict our ability to market or advertise FMX101 and/or FMX103 for other indications,which could limit physician and patient adoption. We may seek to promote and commercialize our products, FMX101 and FMX103, in Europe as well, byapplying for marketing approval from the European Medicines Agency, or EMA, or in other jurisdictions, or we may develop new or additional uses orprotocols for FMX101and/or FMX103 in the future, but we may not receive the clearances required to do so. If we proceeded to submit for marketingapproval in Europe we would likely be required to conduct additional clinical trials or studies to support approvals for such additional jurisdictions orindications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required toobtain approval in other countries might differ from that required to obtain FDA approval. The marketing approval process in other countries may include allof the risks detailed above regarding FDA approval in the U.S. as well as other risks. In particular, in many countries outside the U.S., it is required that aproduct receives pricing and reimbursement approval before the product can be commercialized. This can result in substantial delays in such countries. Inother countries, product approval depends on showing superiority to an approved alternative therapy. This may lead to conducting complex clinical trialsthat require additional significant resources. None of our products are currently approved for sale in any jurisdiction, including the U.S. or any international markets. If we fail to comply withregulatory requirements in the U.S. or any international market we decide to enter, or to obtain and maintain required approvals, or if regulatory approvals inthe U.S. or the relevant international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our productswill be harmed. Marketing approval in one jurisdiction does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in onejurisdiction may have a negative effect on the regulatory process in others. Failure to obtain a marketing approval in other countries or any delay or setbackin obtaining such approval would impair our ability to develop foreign markets for FMX101 and FMX103. This would reduce our target market and limit thefull commercial potential of FMX101 and FMX103. If we are not successful in developing, acquiring regulatory approval for and commercializing additional product candidates beyond FMX101 orFMX103, our ability to expand our business and achieve our strategic objectives will be impaired. Although we will devote a substantial portion of our resources on the continued clinical testing and potential approval of FMX101 for the treatment ofmoderate-to-severe acne and FMX103 for the treatment of moderate-to-severe rosacea, another key element of our strategy is to discover, develop andcommercialize a portfolio of products based on our proprietary foam platforms to serve additional therapeutic markets. We are seeking to do so through ourinternal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval forFMX101 and FMX103. We may also explore strategic collaborations for the development or acquisition of new products, but we may not be successful inentering into such relationships. While we have commenced Phase III clinical trials for our lead product candidate, FMX101 for the treatment of moderate-to-severe acne, and plan to commence a Phase III clinical trial for FMX103 for the treatment of rosacea, all of our other potential product candidates remain insimilar or earlier stages of development. Research programs to identify product candidates require substantial technical, financial and human resources,regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential productcandidates, yet fail to yield product candidates for clinical development for many reasons, including: ·the research methodology used may not be successful in identifying potential product candidates; ·competitors may develop alternatives that render our product candidates obsolete or less attractive; ·product candidates we develop may nevertheless be covered by third parties' patents or other proprietary rights; 9·a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective orotherwise does not meet applicable regulatory criteria; ·a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; ·a product candidate may not be accepted as safe and effective by patients, the medical community or third party payors, if applicable; ·intellectual property rights, such as patents, which are necessary to protect our interests in a product candidate, may be difficult to obtain orunobtainable; and ·intellectual property rights of third parties may potentially block our entry into certain markets, or make such entry economically impracticable. If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will bemore vulnerable to any problems that we encounter in developing and commercializing FMX101 and FMX103. Our product candidates, if approved, will face significant competition and our failure to compete effectively may prevent us from achieving significantmarket penetration and expansion. If we receive marketing approval, the expected indication of FMX101 will be moderate-to-severe acne and the expected indication of FMX103 will bemoderate-to-severe rosacea. The facial aesthetic market in general, and the market for acne treatments in particular, is highly competitive and dynamic, and ischaracterized by rapid and substantial technological development and product innovations. FMX101, if approved, may face significant competition fromother acne products, including oral drugs such as Solodyn, Doryx, Dynacin, Acticlate and Minocin, and topical anti-acne drugs such as Acanya, Ziana,Epiduo, Benzaclin, Aczone and Differin. FMX103, if approved, may face significant competition from other rosacea products, including oral drugs such asOracea®, and topical anti-rosacea drugs such as Metrogel, Soolantra and Finacea, all of which have been approved for marketing and are available toconsumers. If approved, FMX101 and FMX103 may also compete with non-prescription anti-acne and rosacea products and unapproved and off-labeltreatments. To compete successfully in the acne and rosacea treatment markets, we will have to demonstrate that FMX101 is safe and effective for thetreatment of moderate-to-severe acne and FMX103 is safe and effective for the treatment of moderate-to-severe rosacea, and that they do not infringe theintellectual property rights of any third parties. Competing in the acne and rosacea markets could result in price-cutting, reduced profit margins and loss ofmarket share, any of which would harm our business, financial condition and results of operations. Due to less stringent regulatory requirements, there are many more acne products and procedures available for use in international markets than areapproved for use in the U.S. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness oftheir products and the manner in which they can market them. As a result, we may face more competition in these markets than in the U.S. In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with current standard of careproducts or their price may drop considerably due to factors outside our control. If this happens or the price of materials and manufacture increasesdramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize FMX101 or FMX103successfully. Other pharmaceutical companies may develop competing products for acne, rosacea and other indications we are pursuing and enter the market ahead ofus. Other pharmaceutical companies are engaged in developing, patenting, manufacturing and marketing healthcare products that compete with those that weare developing. These potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greaterfinancial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise inobtaining marketing approvals from the FDA and foreign regulatory authorities. Several of these potential competitors are privately-owned companies that are not bound by public disclosure requirements and closely guard theirdevelopment plans, marketing strategies and other trade secrets. Publicly-traded pharmaceutical companies are also able to maintain a certain degree ofconfidentiality over their pipeline developments and other sensitive information. As a result, we do not know whether these potential competitors are alreadydeveloping, or plan to develop, foam-based or other topical treatments for acne, rosacea, impetigo or other indications we are pursuing, and we will likely beunable to ascertain whether such activities are underway in the future. These potential competitors may therefore introduce competing products without ourprior knowledge and without our ability to take preemptive measures in anticipation of their commercial launch. In this regard we became aware at the end of 2014 that an active pharmaceutical ingredient and drug product intermediate manufacturer, Hovione, hassubmitted an IND for Phase I and II clinical trials of a new topical product containing minocycline for the treatment of inflammatory skin disease includingacne and rosacea. Hovione is a privately-held company and we do not know if they have commenced a clinical trial for such new topical minocyclineproduct. Hovione also currently manufactures and supplies Foamix with pharmaceutical-grade minocycline for use in FMX101, FMX103 and other products.Although we have not experienced unique difficulties in procuring minocycline from Hovione, we could experience such difficulties in the future. During2015 we became aware that another company, BioPharmX Corporation (NYSE MKT: BPMX), is developing a topical hydrophilic gel containingminocycline for the treatment of acne, known as BPX-01, for which BioPharmX has announced Phase IIa clinical trials results. If ultimately approved andcommercialized in the U.S., such products would become direct competitors of FMX101, FMX103 and other potential pipeline products. 10Furthermore, such potential competitors may enter the market before us, and their products may be designed to circumvent our granted patents andpending patent applications. Potential competitors may also challenge, narrow, invalidate or seek to design around our granted patents or our patentapplications, and such patents and patent applications may fail to provide adequate protection for our product candidates. We have agreements with third party licensees to develop new product candidates for them utilizing our foam technology, and our ability to benefit fromsuch product candidates could be impaired or delayed if our licensees' efforts to develop and commercialize these product candidates are unsuccessful. In parallel to our core business focused on the development of FMX101, FMX103 and other product candidates, we are pursuing development and licenseagreements with various pharmaceutical companies for the development and commercialization of product candidates that combine our proprietarytechnology with the licensees' drugs for the treatment of various indications. These license agreements generally provide rights to the licensees for a singleactive pharmaceutical ingredient, and grant the licensee exclusivity in the development and commercialization of the specific licensed product candidatesincorporating such active pharmaceutical ingredient. Our entitlement to contingent payments and royalties from such potential product candidates istherefore dependent upon the licensees' performance of their responsibilities and their continued cooperation in developing and commercializing thepotential product candidates. Our licensees may not cooperate with us or perform their obligations under our agreements with them. Furthermore, the obligations of the licensees undersuch agreements are, for the most part, limited to 'commercially reasonable efforts,' and they do not face penalties or other repercussions for failing to developor commercialize the relevant product candidates within the designated timetable other than potentially forfeiting their rights to the relevant productcandidate and assigning such rights to us. However, there is no guarantee that we will be able to develop, manufacture or commercialize successfully anysuch product candidate assigned to us. We cannot control the scope or timing of the resources that will be devoted by our licensees to performing theirresponsibilities under our agreements with them. Our licensees may choose to pursue alternative technologies in preference to those being developed with us.Several of these agreements may also be terminated for convenience by the licensee. The development and commercialization of these licensed productcandidates as well as the anticipated contingent payments and royalties we hope to generate from them will be delayed or never obtained if the licensees failto conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements, or if they breach their agreements with us.Disputes with our licensees could also impair our reputation or result in development delays, decreased revenues and litigation expenses. We have granted several of our licensees the right to commercialize the licensed products for any indication, including acne and rosacea, which may allowthem to compete against us using our own technology. The licenses we granted to several of our licensees, with whom we are developing certain topical products based on our technology and the licensees'proprietary drugs, allow them to commercialize the developed products for any topical application, and not only for the specific indication for which eachproduct was originally intended. If any such licensed products prove to be effective for moderate-to-severe acne, rosacea or any other indication that we arepursuing with FMX101, FMX103 or other product candidates, we may face competition from these licensed products, as the licensees are not bound by anynon-compete restrictions. We expect the healthcare industry to face increased limitations on reimbursement, rebates and other payments as a result of healthcare reform, whichcould adversely affect third-party coverage of our products and how much or under what circumstances healthcare providers will prescribe or administerour products, if approved. In both the U.S. and other countries, sales of our products, if approved for marketing, will depend in part upon the availability of reimbursement fromthird-party payors, which include governmental authorities, managed care organizations and other private health insurers. Third-party payors are increasinglychallenging the price and examining the cost effectiveness of medical products and services. Increasing expenditures for healthcare have been the subject of considerable public attention in the U.S. Both private and government entities are seekingways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been introduced or proposed inCongress and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels at which consumers andhealthcare providers are reimbursed for purchases of pharmaceutical products. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for anyapproved products, which in turn would affect the price we can receive for those products. Any reduction in reimbursement that results from federallegislation or regulation may also result in a similar reduction in payments from private payors, as private payors often follow Medicare coverage policy andpayment limitations in setting their own reimbursement rates. 11In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education AffordabilityReconciliation Act of 2010, or the Affordable Care Act, a law intended, among other things, to broaden access to health insurance and reduce or constrain thegrowth of healthcare spending. The Affordable Care Act increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, orAMP, to 23.1% of AMP and capped the total rebate amount for innovator drugs at 100.0% of AMP. On February 1, 2016, the Centers for Medicare & Medicaid Services, or CMS, the federal agency that administers the Medicare and Medicaid programs,issued final regulations to implement the changes to the Medicaid Drug Rebate Program under the Affordable Care Act. These regulations became effectiveon April 1, 2016. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that manufacture or import certain brandedprescription drug products. Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcarepractitioners, and a significant number of provisions are not yet, or have only recently become, effective. Although it is too early to determine the effect ofthe Affordable Care Act, it appears likely to continue to put pressure on pharmaceutical pricing, especially under the Medicare program, and may alsoincrease our regulatory burdens and operating costs. In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. Beginning April 1, 2013, Medicarepayments for all items and services, including drugs and biologics, were reduced by up to 2% per fiscal year under the sequestration (i.e., automatic spendingreductions) required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. Due to the Bipartisan Budget Act of2015, these reductions will remain in effect until 2025 unless additional action is taken by Congress. It is unclear how the Affordable Care Act and other laws ultimately will be implemented. Some of the provisions of the Affordable Care Act have yet to befully implemented, while certain provisions have been subject to judicial and Congressional challenges. In January 2017, Congress voted to adopt a budgetresolution for fiscal year 2017, that while not a law, is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of theAffordable Care Act. Further, on January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilitiesunder the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that wouldimpose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers ofpharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the Affordable Care Act that are repealed.Thus, while the full impact of the Affordable Care Act, or any law replacing elements of it, on our business remains unclear, if we ever obtain regulatoryapproval and commercialization of one or more of our product candidates, these laws may result in reductions in healthcare funding, which could have amaterial adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changeswill be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvalsof our product candidates may be. Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislationpursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, ourproducts could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could materiallyand adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees and market our products. In addition,we believe the increasing emphasis on managed care in the U.S. has and will continue to put pressure on the price and usage of pharmaceutical products,which may adversely impact product sales. It will be difficult for us to profitably sell FMX101, FMX103 or our other product candidates if reimbursement for these products is limited by governmentauthorities and third-party payor policies. In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of FMX101, FMX103 and our other productcandidates, if approved, will depend on the reimbursement policies of government authorities and third-party payors. Government authorities and third-partypayors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted tocontrol costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that reimbursement will be available forFMX101 or FMX103, or, if reimbursement is available, the level of reimbursement. 12Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. In addition, third-party payors are likelyto impose strict requirements for reimbursement in order to limit off-label use of a higher priced drug. Reimbursement by a third-party payor may dependupon a number of factors including the third-party payor's determination that use of a product is: ·a covered benefit under its health plan; ·safe, effective and medically necessary; ·appropriate for the specific patient; ·cost-effective; and ·neither experimental nor investigational. Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process thatcould require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. We may not be able to providedata sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be availablefor our product candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our futureproducts. If reimbursement is not available, or is available only to limited levels, we may not be able to commercialize our product candidates, profitably orat all, even if approved. Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of ourproduct candidates and to produce, market, and distribute our products after clearance or approval is obtained. From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatoryclearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are oftenrevised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretationsof existing regulations may impose additional costs or lengthen review times of FMX101, FMX103 or any of our other product candidates. We cannotdetermine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our businessin the future. Such changes could, among other things, require: ·changes to manufacturing methods; ·recall, replacement, or discontinuance of one or more of our products; and ·additional recordkeeping. Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or atall, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts. We are currently investing the majority of our resources towards (i) completing Phase III clinical trials for FMX101 during 2017, filing an NDA in 2018and developing a commercialization plan for such product candidate that we will initiate during 2018, (ii) bringing FMX103 to commence Phase III clinicaltrials in 2017 and (iii) continuing the development and advancement of the clinical trials of our other product candidates. However, we may not havesufficient funds to carry out and complete all of these plans, and may need to raise additional funds for such purposes. We anticipate that we will continue to expend substantial resources for the foreseeable future for the clinical development of FMX101, FMX103, and thedevelopment of other indications and product candidates. These expenditures will include costs associated with research and development, conductingpreclinical studies and clinical trials, and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, otherunanticipated costs may arise. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary tosuccessfully complete the development and commercialization of any of our product candidates. We believe that the net proceeds from our initial and follow-on public offerings will allow us to fund our operating expenses and capital expenditurerequirements throughout the Phase III clinical trials for our lead product candidate, FMX101, which we expect to complete in 2017. Such proceeds shouldalso fund our Phase III clinical program for FMX103, which we expect to commence in 2017. However, our operating plan may change as a result of manyfactors currently unknown to us, and we may need to seek additional capital sooner than planned, through public or private equity or debt financings or othersources, such as strategic collaborations or additional license arrangements. Such financings may result in dilution to shareholders, imposition of debtcovenants and repayment obligations or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable marketconditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. 13Our future capital requirements depend on many factors, including: ·the results of the clinical trials of our products candidates; ·the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; ·the number and characteristics of any additional product candidates we develop or acquire; ·the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials; ·the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs; ·the cost of manufacturing our product candidates and any products we successfully commercialize and maintaining our related facilities; ·our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing of such arrangements; ·the degree and rate of market acceptance of any future approved products; ·the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products ortreatments; ·any product liability or other lawsuits related to our products; ·the expenses needed to attract and retain skilled personnel; ·the costs associated with being a public company; ·the costs associated with evaluation of our product candidates; ·the costs associated with evaluation of third party intellectual property; ·the costs associated with obtaining and maintaining licenses; ·the costs associated with obtaining, protecting and enforcing intellectual property, such as costs involved in preparing, filing, prosecuting,maintaining, defending and enforcing patent claims, litigation costs and the outcome of such litigation; and ·the timing, receipt and amount of sales of, or royalties on, future approved products, if any. Additional capital may not be available when we need it, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timelybasis, we may be required to: ·delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for FMX101, FMX103 or any of our other productcandidates; ·delay, limit, reduce or terminate our research and development activities; or ·delay, limit, reduce or terminate our establishment of manufacturing, sales and marketing or distribution capabilities or other activities that may benecessary to commercialize FMX101, FMX103 or any of our other product candidates. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements withthird parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grantlicenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of ourexisting shareholders will be diluted and the terms of any new equity securities may have a preference over our ordinary shares. If we raise additional capitalthrough debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or makingcapital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our product candidates or operate as a business. We have a limited operating history and have incurred significant losses since our inception and we anticipate that we will continue to incur losses for theforeseeable future. We have only four product candidates that have completed any clinical trials and have no sales, which, together with our limitedoperating history, make it difficult to assess our future commercial viability. We are a small clinical-stage specialty pharmaceutical company with a limited operating history. Pharmaceutical product development is a highlyspeculative undertaking and involves a substantial degree of risk. We are not profitable and have incurred losses in each year since we commencedoperations in 2003. We have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have limitedexperience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies innew and rapidly evolving fields, particularly in the pharmaceutical industry. 14To date, we have not obtained any regulatory approvals for any of our product candidates or generated any revenues from product sales relating toFMX101, FMX103 or any of our other product candidates. We have generated revenues only from service payments, and contingent payments paid towardsor in the course of projects carried out under several of our development and license agreements with various pharmaceutical companies. We have alsoreceived (and continue to receive) royalty payments with respect to Finacea®, a prescription foam product that we developed in collaboration with Bayer. We continue to incur significant research and development and other expenses related to our ongoing clinical trials and operations. We have recorded anet loss of $29.3 million, $16.5 million and $11.5 million for the twelve months ended December 31, 2016, 2015 and 2014, respectively. As of December 31,2016, we had an accumulated deficit of $75.6 million and had a working capital surplus of $111.7 million. We expect to continue to incur losses for theforeseeable future, and we anticipate these losses will increase substantially as we continue our development of, and seek regulatory approvals for, FMX101,FMX103 and our other product candidates, and begin to commercialize such product candidates. Our ability to achieve revenues and profitability is dependent on our ability to complete the development of our product candidates, obtain necessaryregulatory approvals and successfully manufacture, market and commercialize our products. Even if we achieve profitability in the future, we may not be ableto sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our ordinaryshares and our ability to raise capital and continue operations. We currently contract with third party subcontractors and suppliers for certain compounds and components necessary to produce FMX101 andFMX103 for clinical trials and expect to continue to do so to support commercial scale production if one or more of such product candidates is approved.This increases the risk that we will not have sufficient quantities of FMX101 and FMX103 or such quantities at an acceptable cost, which could delay,prevent or impair our development or commercialization efforts. We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce FMX101and FMX103 for ourclinical trials, including minocycline and other active ingredients, excipients used in the formulation of the foam, delivery apparatus comprising canisters,valves and propellants. We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements if FMX101 andFMX103 or any of our other product candidates is approved for marketing by the FDA or foreign regulatory authorities. Reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and qualityassurance, the possible breach of the manufacturing or supply agreement by the third party, the possibility that the supply is inadequate or delayed , the riskthat the third party may enter the field and seek to compete and may no longer be willing to continue supplying, and the possible termination or nonrenewalof the agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors and suppliers may not be able tocomply with cGMP or quality system regulation, or QSR, or similar regulatory requirements outside the U.S. If any of these risks transpire, we may be unableto timely retain alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disruptand delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved. Our failure or the failure of our third party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed onus, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operatingrestrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates that we may develop. Although we have not experienced unique difficulties in procuring compounds and components for FMX101, FMX103, FDX104 or any other productcandidates, and while we are acting to secure additional suppliers for such compounds and components, we could experience such difficulties in the future. We will rely on third parties and consultants to assist us in conducting our trials and studies. If these third parties or consultants will not successfully carryout their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates. We do not have the ability to independently perform all aspects of our preclinical studies and clinical trials. We will rely on medical institutions, clinicalinvestigators, contract laboratories, collaborative partners and other third parties, such as CROs, to assist us in conducting our Phase III clinical trials forFMX101, FMX103 and studies and clinical trials for our other product candidates. The third parties with whom we contract for execution of our clinical trialsplay a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees,and except for contractual duties and obligations, we will have limited ability to control the amount or timing of resources that they devote to our programs. 15Although we rely on these third parties to conduct certain aspects of our Phase III clinical trials and other studies and clinical trials, we remain responsiblefor ensuring that each of our clinical trials and preclinical studies is conducted in accordance with its investigational plan and protocol. Moreover, the FDAand foreign regulatory authorities require us to comply with regulations and standards, commonly referred to as current good clinical practices, or GCPs, forconducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, andthat the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on our consultants to assist us in theexecution, including data collection and analysis of our clinical trials. In addition, the execution of clinical trials and preclinical studies, and the subsequent compilation and analysis of the data produced, will requirecoordination among these various third parties. In order for these functions to be carried out effectively and efficiently, it will be imperative that these partiescommunicate and coordinate with one another, which may prove difficult to achieve. Moreover, these third parties may also have relationships with othercommercial entities, some of which may compete with us. Our agreement with these third parties may inevitably enable them to terminate such agreementsupon reasonable prior written notice under certain circumstances. If the third parties or consultants that assist us in conducting our clinical trials do not perform their contractual duties or obligations, experience workstoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data theyobtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinicaltrials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended,delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining,regulatory approval for the product candidates being tested in such trials, and will not be able to, or may be delayed in our efforts to, successfullycommercialize these product candidates. We have no experience manufacturing our product candidates at full commercial scale. If our product candidates are approved, we intend to outsourceour manufacturing to third parties, and will face certain risks associated with such outsourcing. We have a small-scale integrated research, development and testing facility located at our corporate headquarters in Rehovot, Israel. However, we havenot equipped our facility with manufacturing capabilities other than small scale manufacture, and do not currently plan to do so. We do not have experiencein manufacturing our product candidates at commercial scale, and if our product candidates are approved, we will outsource all or a significant portion of themanufacturing of our products to third parties, including our drug substances and finished dose forms. Reliance on third parties to manufacture our productsentails various risks, including the possibility of increased costs associated with the large- scale production of our products. These risks are similar to thoseinvolved in our current use of subcontractors and suppliers for certain compounds and components necessary to produce FMX101, FMX103 and any other ofour other product candidates, as explained above. If we are unsuccessful in outsourcing our manufacturing to third parties who are compliant with regulatory requirements, we may encounter delays oradditional costs in achieving our commercialization objectives, which could materially damage our business and financial position. We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own orthrough third parties, we will be unable to successfully commercialize FMX101, FMX103 or any other of our other product candidates, if approved, orgenerate product revenues. We currently have limited marketing capabilities and no sales organization. To commercialize FMX101, FMX103 or any other of our other productcandidates, if approved, in the U.S. and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If FMX101 or FMX103receive regulatory approval, we expect to market them in the U.S. through a specialized internal sales force or a combination of our internal sales force anddistributors, which will be expensive and time-consuming. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualifiedindividuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersedsales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact thecommercialization of our product candidates. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales forceand distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or atall, we may not be able to successfully commercialize FMX101, FMX103 or any of our other product candidates. If we are not successful in commercializing FMX101, FMX103 or any of our other product candidates, either on our own or through collaborations withone or more third parties, our revenues will suffer and we will incur significant additional losses. 16To establish our sales and marketing infrastructure and manufacturing capabilities, we will need to increase the size of our organization, and we mayexperience difficulties in managing this expansion. As of December 31, 2016, we had 68 employees. We will need to continue to expand our managerial, operational, finance and other resources to manageour operations and clinical trials, continue our development activities and commercialize FMX101, FMX103 and any other product candidates, if approved.Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute ourexpansion strategy requires that we: ·manage our clinical trials effectively; ·identify, recruit, retain, incentivize and integrate additional employees; ·manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and ·continue to improve our operational, financial and management controls, reporting systems and procedures. Due to our limited financial resources and our limited experience in managing a company with such anticipated expansion, we may not be able toeffectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead tosignificant costs and may divert our management and business development resources. Any inability to manage expansion could delay the execution of ourdevelopment and strategic objectives, or disrupt our operations. We currently develop our clinical drug products exclusively in one research and development facility and may utilize this facility in the future to supportcommercial production if our product candidates are approved. If this or any future facility or our equipment were to be damaged or destroyed, or if weexperience a significant disruption in our operations for any other reason, our ability to continue to operate our business would be materially harmed. We currently research and develop our product candidates primarily in our laboratory located in Rehovot, Israel. If this or any future facility were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods,hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research anddevelopment facility is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved and we chooseto manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likelyexpect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within atimeframe that meets our prospective customers' expectations, our business, prospects, financial results and reputation could be materially harmed. Currently, we maintain insurance coverage totaling $1.2 million against damage to our property and equipment and $5.0 million in workerscompensation coverage, subject to deductibles and other limitations. If we have underestimated our insurance needs with respect to an interruption, or if aninterruption is not subject to coverage under our insurance policies, we may not be able to cover our losses. If product liability lawsuits are brought against us, we may incur substantial liabilities that may not be fully covered by our insurance policies and we maybe required to limit commercialization of any of our other products we develop. We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if wecommercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable duringproduct testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, afailure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumerprotection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limitcommercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits oreventual outcome, liability claims may result in: ·decreased demand for FMX101, FMX103 or any of our other product candidates or products we develop; ·injury to our reputation and significant negative media attention; ·withdrawal of clinical trial participants or cancellation of clinical trials; ·costs to defend the related litigation, which may be only partially recoverable even in the event of successful defense; ·a diversion of management's time and our resources; ·substantial monetary awards to trial participants or patients; 17·regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; ·loss of revenues; and ·the inability to commercialize any products we develop. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential productliability claims could prevent or inhibit the commercialization of FMX101, FMX103 or any other product we may develop. We currently carry general thirdparty liability insurance up to an amount of $10 million per annum. Although we maintain such insurance, any claim that may be brought against us couldresult in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurancecoverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have nocoverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered byour insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintaininsurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing of one or more ofFMX101, FMX103 or any other product we may develop, we intend to expand our insurance coverage to include their sale; however, we may be unable toobtain this liability insurance on commercially reasonable terms. If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop FMX101, FMX103 or any of ourother product candidates, conduct our clinical trials and commercialize FMX101, FMX103 or any of our other products we develop. Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. Webelieve that our future success is highly dependent upon the contributions of our senior management, particularly our Chief Executive Officer, as well as oursenior technologists and scientists. The loss of services of any of these individuals could delay or prevent the successful development of our productpipeline, completion of our planned clinical trials or the commercialization of FMX101, FMX103 or any of our other product candidates. Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems inthe future. For example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess theskills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities.We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we maybe subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that theirformer employers own their research output. We have incurred, and will continue to incur significant increased costs as a result of operating as a public company in the U.S., and our management willbe required to devote substantial time to new compliance initiatives. As a public company in the U.S., we are subject to an extensive regulatory regime, requiring us to maintain various internal controls and to prepare andfile periodic and current reports and statements, including reports on the effectiveness of our internal control over financial reporting pursuant to Section 404of the Sarbanes-Oxley Act of 2002, or Section 404. Complying with these requirements is costly and time consuming. In the event that we are unable todemonstrate compliance with our obligations as a public company in the U.S. in a timely manner, or are unable to produce timely or accurate financialstatements, we may be subject to sanctions or investigations by regulatory authorities, such as the U.S. Securities and Exchange Commission, or the NASDAQGlobal Market, and investors may lose confidence in our operating results and the price of our ordinary shares could decline. Our independent registered public accounting firm was not engaged to perform an audit of our internal control over financial reporting, and as long as weremain an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we are exempt from the requirementto have an independent registered public accounting firm perform such audit. Accordingly, no such opinion was expressed. Once we cease to qualify as an"emerging growth company," our independent registered public accounting firm will need to attest to our management's annual assessment of theeffectiveness of our internal controls over financial reporting, which will entail additional costs and expenses. Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must comply with environmental laws andregulations, which can be expensive and restrict how we do business. Our research and development activities and our third party subcontractors' and suppliers' activities involve the controlled storage, use and disposal ofhazardous materials owned by us, including minocycline and doxycycline, key components of our product candidates, and other hazardous compounds. Weand our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardousmaterials. We are licensed by the Israeli Ministry of Health to manufacture small batches of product in topical dose form for Phase I and II clinical trials. Insome cases, these hazardous materials are stored at our and our subcontractors' facilities pending their use and disposal. 18Despite our efforts, we cannot eliminate the risk of contamination. This could cause an interruption of our commercialization efforts and businessoperations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling anddisposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliersfor handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this isthe case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damagesand such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt ourbusiness operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict theimpact of such changes and cannot be certain of our future compliance. We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral,false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. While we do not expect that FMX101, FMX103 or any other of our other product candidates, if approved, will subject us to the various U.S. federal andstate laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The federal anti-kickback statute prohibits theoffer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for inwhole or part by Medicare or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash,improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as privatepayors. Violations of the anti-kickback laws can result in exclusion from federal and state health care programs and substantial civil and criminal penalties. The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims forpayment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, thatare for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individualsto bring actions on behalf of the federal government and share a portion of the recovery of successful claims. If our marketing or other arrangements weredetermined to violate anti-kickback or related laws, including the FCA, then our revenues could be adversely affected, which would likely harm our business,financial condition, and results of operations. State and federal authorities have aggressively targeted medical technology companies for alleged violations of these anti-fraud statutes, based onimproper research or consulting contracts with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, andother improper promotional practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more,have been forced to implement extensive corrective action plans, and have often become subject to consent decrees severely restricting the manner in whichthey conduct their business. If we become the target of such an investigation or prosecution based on our contractual relationships with providers orinstitutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from makingimproper payments to government officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect usfrom reckless or negligent acts committed by our employees, future distributors, licensees or agents. Violations of these laws, or allegations of suchviolations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. Although we believe the market for acne and rosacea therapies is less vulnerable to unfavorable economic conditions due to the significant discomfortand distress that these conditions inflict, our results of operations could be adversely affected by general conditions in the global economy and in the globalfinancial markets. We currently have very limited visibility regarding the prospects of FMX101, FMX103 or our other product candidates becoming eligiblefor reimbursement by any government or third party payor and the possible scope of such reimbursement, and we must assume that demand for these productcandidates may be tied to discretionary spending levels of our targeted patient population. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for FMX101, FMX103 or any ofour other product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economycould also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. 19Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial marketconditions could adversely impact our business. Exchange rate fluctuations between the U.S. dollar and the Israeli shekel may negatively affect our earnings. The dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in Israeli shekels. As a result, weare exposed to the risks that the shekel may appreciate relative to the dollar, or, if the shekel instead devalues relative to the dollar, that the inflation rate inIsrael may exceed such rate of devaluation of the shekel, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, thedollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict anyfuture trends in the rate of inflation or deflation in Israel or the rate of devaluation or appreciation of the shekel against the dollar. For example, the rate ofappreciation of the shekel against the dollar was 1.5% and 0.3% in 2016 and 2015, respectively, which was compounded by deflation in Israel at a rate of -0.2% and -1.0%, respectively. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Ouroperations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future. Risks Related to Our Intellectual Property If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to FMX101, FMX103 or any of our other productcandidates are not adequate, we may not be able to compete effectively and we otherwise may be harmed. Our commercial success depends in part on our ability to obtain and maintain patent protection and other intellectual property rights and to utilize tradesecret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringingupon the proprietary rights of others. We rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of inventionagreements and other contractual arrangements to protect the intellectual property related to FMX101, FMX103 and our other development programs.Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competingagainst us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are existing compounds andour granted patents and pending patent applications are directed to, among other things, novel formulations of these existing compounds that are dispensedas a foam. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations thatdesign around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Moreover any disclosure to ormisappropriation by third parties of our confidential proprietary information, unless we have sufficient patent and/or trade secret protection and we are ableto enforce such rights successfully, could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitiveposition in our market. We currently have several granted patents related to FMX101, FMX103 and our other product candidates in the U.S., which are expected to remain ineffect until 2030. These patents relate to a composition of matter comprising a claim to a formulation of a tetracycline antibiotic which can includeminocycline or doxycycline, and therefore may be less protective than patents that claim a new drug. We also have patent applications claimingcompositions of matter, which relate to FMX101, FMX103 and our other product candidates, pending in each of the following international markets,Australia, Brazil, Canada, China, the European Union, India, Israel and Mexico. As of December 31, 2016, we had 149 granted patents and over 50 patent applications pending worldwide covering our various foam-based platforms andother technology. However, the patent applications that we own or license may fail to result in granted patents in the U.S. or foreign jurisdictions, or ifgranted the patent claims may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitorsin the field of topically-administered therapies comprising an active ingredient in foam presentation have created a substantial amount of scientificpublications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceablepatents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them allow ourtechnology to be patentable. Patent applications and patents granted from them are complex, lengthy and highly technical documents that are often preparedunder very limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have amaterially adverse effect on the patent, its scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patentapplications that do issue may be too narrow or inadequate to protect our competitive advantage. Also, our granted patents may be subject to challenges orconstrued in a way that may not provide adequate protection. Even if these patents do successfully issue, third parties may challenge the validity, enforceability or scope of such granted patents or any other grantedpatents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the EuropeanPatent Office may be opposed by any person within 9 months from the publication of their grant. Also, patents granted by the U.S. Patent and TrademarkOffice, or USPTO, may be subject to review, reexamination and other challenges. Changes to the patent laws of the U.S. in 2012 provide additionalprocedures for third parties to challenge the validity of patents issuing from patent applications including post-grant review, which generally applies topatents first filed after March 15, 2013. A post-grant review petition must be filed on or prior to the date which is 9 months after the patent is granted. Theprocedures also expand and reform the proceedings for challenging issued patents on grounds of prior art and publications, also known as inter partes reviewor IPR. For patents filed after March 15, 2013, a petition for IPR may be filed the later of 9 months after grant of the patent or after a post-grant reviewproceeding on the patent has terminated. For patents filed prior to March 15, 2013, the rules regarding IPR filing remain unchanged and an IPR petition maybe filed any time following issuance of the patent.20Furthermore, efforts to enforce our patents could give rise to challenges to their validity or unenforceability in court proceedings. If the patents and patentapplications we hold or pursue with respect to FMX101, FMX103 or any of our other product candidates are challenged, it could threaten our competitiveadvantage for FMX101, FMX103 or any of our other product candidates. Furthermore, even if they are not challenged, our patents and patent applicationsmay not adequately protect our intellectual property or prevent others from designing around our claims. To meet such challenges, which are part of the risksand uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, toseek licenses for such third party intellectual property or to challenge such third party intellectual property, which may be costly and may or may not besuccessful, which could also have a material adverse effect on the commercial potential for FMX101, FMX103 and any of our other product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market FMX101, FMX103 or any of our other productcandidates under patent protection could be reduced. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to(i) file any patent application related to FMX101, FMX103 or any of our other product candidates or (ii) conceive and invent any of the inventions claimedin our patents or patent applications. Furthermore, for applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be invoked by a thirdparty, or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications andpatents. As of March 16, 2013, the U.S. transitioned to a "first-to-file" system for deciding which party should be granted a patent when two or more patentapplications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO under the new first-to-filesystem before we did could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the thirdparty. The change to "first-to-file" from "first-to-invent" is one of the changes to the patent laws of the U.S. resulting from the Leahy-Smith America Invents Actsigned into law on September 16, 2011. Among some of the other changes to the patent laws are changes that limit where a patentee may file a patentinfringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. Because of a lower evidentiary standard incertain USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentiallyprovide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence may be insufficient to invalidatethe claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims thatwould not have been invalidated if first challenged by the third party as a defendant in a district court action. USPTO statistics indicate that a high rate ofchallenged claims are being invalidated in these USPTO procedures. Even where patent, trade secret and other intellectual property laws provide protection, costly and time-consuming litigation could be necessary toenforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring toenforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and our competitors have intellectualproperty portfolios of their own, some of which are substantial. An unfavorable outcome could have a material adverse effect on our business and could resultin the challenged patent or one or more of its claims being interpreted narrowly or invalidated, or one or more of our patent applications may be not begranted. We also rely on trade secret protection and confidentiality agreements to protect our know-how, data and information prior to filing patent applicationsand during the period before they are published. We further rely on trade secret protection and confidentiality agreements to protect proprietary know-howthat may not be patentable, processes for which patents may be difficult to obtain or enforce and other elements of our product development processes thatinvolve proprietary know-how, information or technology that is not covered by patents. In an effort to protect our trade secrets and other confidential information, we incorporate confidentiality provisions in all our employees' agreements andrequire our consultants, contractors and licensees to which we disclose such information to execute confidentiality agreements upon the commencement oftheir relationships with us. These agreements require that confidential information, as defined in the agreement and disclosed to the individual by us duringthe course of the individual's relationship with us, be kept confidential and not disclosed to third parties for an agreed term. These agreements, however, maynot provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequateremedies may not exist in the event of unauthorized use or disclosure of our confidential information. A breach of confidentiality could significantly affectour competitive position and we could lose our trade secrets or they could become otherwise known or be independently discovered by our competitors.Also, to the extent that our employees, consultants or contractors use any intellectual property owned by others in their work for us, disputes may arise as tothe rights in any related or resulting know-how and inventions. Additionally, others may independently develop the same or substantially equivalentproprietary information and techniques or otherwise gain access to our trade secrets and other confidential information. Any of the foregoing coulddeteriorate our competitive advantages, undermine the trade secret and contractual protections afforded to our confidential information and have materialadverse effects on our business. 21Changes in U.S. or foreign patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. As is the case with other companies in the markets in which we participate, our success is heavily dependent on intellectual property, particularly patents.The strength of patents in the pharmaceutical field involves complex legal and scientific questions and in the U.S. and many foreign jurisdictions patentpolicy and case law also continues to evolve and change and the issuance, scope, validity, enforceability and commercial value of our patent rights arehighly uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action thatmay reinterpret or expand on existing law in ways affecting the scope or validity of granted patents, or both. Particularly in recent years in the U.S., there havebeen several major legislative developments and court decisions that have affected patent laws in significant ways and there may be more developments inthe future that may weaken or undermine our ability to obtain patents or to enforce our existing and future patents. We have agreed to share ownership in certain patents that may result from our development and license agreements with certain major pharmaceuticalcompanies, which may detract from our rights to such patents. We have agreed with several of the pharmaceutical companies with whom we are developing certain topical products, based on our foam technology andthe licensees' active ingredients, to jointly own and have an undivided interest in patents that arise from the relevant projects, where the licensee made itsown material contributions to the invention. In certain agreements, we have further agreed that inventions achieved exclusively or primarily by the licenseesin the course of the development without significant contribution by us will be owned solely by them, and they will be allowed to file patent applicationscovering such inventions without our participation. We have granted certain licensees the right to provide input during the prosecution of licensed patent applications. We have further granted certainlicensees the primary right to enforce several of our existing patents, which we have licensed to these licensees to allow them to commercialize our jointly-developed product, in the event that any infringement of the licensed patents adversely affects the licensees' ability to utilize the licenses for the purposethey were granted. Such rights may detract from our rights and title to such patents. In addition, any negative proceedings against our technology couldimpact any or all of our licensees, and we may be contractually responsible for the payment of certain claims and losses as a result of such impact. If we infringe or are alleged to infringe or otherwise violate intellectual property rights of third parties, our business could be harmed. Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patentsowned or controlled by other parties. Competitors in the field of topical and oral drugs for the treatment of acne, impetigo, rosacea, chemotherapy-inducedrash and other indications have developed large portfolios of patents and patent applications relating to our business. In particular, there are patents held bythird parties that relate to the treatment with minocycline-based and doxycycline-based products for indications we are pursuing with our product candidates,namely FMX101, FMX103 and any other of our other product candidates. There may be granted patents that could be asserted against us in relation to suchproduct candidates. There may also be granted patents held by third parties that may be infringed or otherwise violated by our other product candidates andactivities, and we do not know whether or to what extent we are infringing or otherwise violating third party patents. There may also be third party patentapplications that if approved and granted as patents may be asserted against us in relation to FMX101, FMX103 or any of our other product candidates oractivities. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us topay substantial damages and legal fees. Further, if a patent infringement suit were brought against us, we could be temporarily or permanently enjoined orotherwise forced to stop or delay research, development, manufacturing or sales of the product candidate that is the subject of the suit. As a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties. These licenses maynot be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties orboth, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property, or suchrights might be restrictive and limit our present and future activities. Ultimately, we or a licensee could be prevented from commercializing a product, or beforced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses onacceptable terms. 22There has been and there currently is substantial litigation and other proceedings regarding patent and other intellectual property rights in thepharmaceutical industry. In addition to possible infringement claims against us, we may become a party to other patent litigation and other proceedings,including interference, derivation, review, re-examination or other post-grant proceedings declared or granted by the USPTO and similar proceedings inforeign countries, regarding intellectual property rights with respect to our current or any future products. The cost to us of any patent litigation or otherproceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedingsmore effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significantmanagement time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings and their outcome could impair ourability to compete in the marketplace and impose a substantial financial burden on us. The occurrence of any of the foregoing could have a material adverseeffect on our business, financial condition or results of operations. Furthermore, several of our employees were previously employed at universities or other pharmaceutical companies, including potential competitors.While we take steps to prevent our employees from using the proprietary information or know-how of others that is not in the public domain or that has notalready been independently developed by us earlier, we may be subject to claims that we or these employees have inadvertently or otherwise used ordisclosed intellectual property, trade secrets or other proprietary information of any such employee's former employer. Litigation may be necessary to defendagainst these claims and, even if we are successful in defending ourselves, could result in substantial costs to us or be distracting to our management. If we donot succeed with respect to any such claims, in addition to paying monetary damages and possible ongoing royalties, we may lose valuable intellectualproperty rights or personnel. If we are unable to protect our trademarks from infringement, our business prospects may be harmed. We own trademarks that identify "Foamix", and have registered these trademarks in the U.S. and Israel. Although we take steps to monitor the possibleinfringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized useof our trademarks could harm our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be undulyexpensive and time-consuming, and the outcome may be an inadequate remedy. We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could beexpensive and time-consuming. Competitors may infringe our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to fileinfringement claims to stop third party infringement or unauthorized use. This can be expensive and burdensome, particularly for a company of our size, andtime-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop theother party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant aninjunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowlyand could put our patent applications at risk of not issuing. Interference, derivation review, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions withrespect to our patent applications or those of our licensors or licensees. Litigation or USPTO proceedings brought by us may fail or may be invoked againstus by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs anddistraction to our management. We may not be able, alone or with our licensors or licensees, to prevent misappropriation of our proprietary rights,particularly in countries where the laws may not protect such rights as fully as in the U.S. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is arisk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during thecourse of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings ordevelopments or public access to related documents. If investors perceive these results to be negative, the market price for our ordinary shares could besignificantly harmed. We may not obtain intellectual property rights or otherwise be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. We primarilyfile patent applications in the U.S., and may file in some other selected jurisdictions on a case-by-case basis. As a result, our intellectual property rights incountries outside the U.S. are generally less extensive than those in the U.S. In addition, the laws of some foreign countries and jurisdictions, particularly ofcertain developing countries and jurisdictions, do not protect intellectual property rights to the same extent as federal and state laws in the U.S., and thesecountries and jurisdictions may limit the scope of what can be claimed, and in some cases may even force us to grant a compulsory license to competitors orother third parties. Consequently, we may not be able to prevent third parties from practicing our inventions outside the U.S., or from selling or importingproducts made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have notsought or obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patentprotection, but protection and enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or otherintellectual property rights may not be effective or sufficient to prevent them from competing. Moreover, competitors or others may raise legal challenges toour intellectual property rights or may infringe upon our intellectual property rights, including through means that may be difficult to prevent or detect. 23Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legalsystems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,especially those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing productsin violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert ourefforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applicationsat risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or otherremedies awarded, if any, may not be commercially meaningful. Further, third parties may prevail in their claims against us, which could potentially result inthe award of injunctions or substantial damages against us. Accordingly, our efforts to enforce our intellectual property rights around the world may beinadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreignintellectual property laws. We have received notices of opposition to our European patent no. 1556009 Two notices of opposition have been filed with regard to our patent entitled "Cosmetic and Pharmaceutical Foam", which relates to an alcohol-freefoamable pharmaceutical or cosmetic carrier and its use. The notices of opposition were filed by Guderma and Henkel in Germany, with supportingdocumentation prior to the close of the opposition period on September 24, 2015. We have defended these proceedings, and at a hearing on January 23, 2017the Opposition Division of the Europen Patent Office, or EPO, decided to maintain the patent in amended form. One or both of the unsuccessful opponentsmay file an appeal. The deadline for doing so depends on when the Opposition Division issues its reasoned decision in writing. In the event of an appeal, theopposition proceedings may ultimately result in such patent either being upheld as decided by the Opposition Decision; or in the patent being narrowedfurther; or in the patent being cancelled. The opposition documents are available through the online EPO file for the patent. Although the patent involved isbelieved by Foamix to be of no material interest to our lead product candidates, it may be of interest in relation to one or more of our licensed products. Weare unable to predict what will be the effect of the opposition proceedings or outcome of an appeal, which may potentially have a negative impact on thefuture commercialization of one or more licensed products. Under applicable employment laws, we may not be able to enforce covenants not to compete. We generally enter into non-competition agreements as part of our employment agreements with our employees. These agreements generally prohibit ouremployees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable toenforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors frombenefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli labor courts place emphasis on freedom of employment and have required employers seeking to enforce non-compete undertakings ofa former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of theemployer which have been recognized by the courts, such as the protection of a company's trade secrets or other intellectual property. Risks Related to Our Ordinary Shares We do not know whether a market for our ordinary shares will be sustained and as a result it may be difficult for holders of our ordinary shares to sell theirshares. Although our ordinary shares are quoted on the NASDAQ Global Market, an active trading market for our shares may not be sustained. The lack of anactive market may impair holders of our ordinary shares ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable.The lack of an active market may also reduce the fair market value of our shares, and may cause the trading price of our ordinary shares to be more volatile.An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other companies by using our shares asconsideration. 24The market price of our ordinary shares may be subject to fluctuation and holders of our ordinary shares could lose all or part of their investment. The stock market in general has been, and the market price of our ordinary shares in particular will likely be, subject to fluctuation, whether due to, orirrespective of, our operating results and financial condition. The market price of our ordinary shares on the NASDAQ Global Market may fluctuate as a resultof a number of factors, some of which are beyond our control, including, but not limited to: ·actual or anticipated variations in our and our competitors' results of operations and financial condition; ·market acceptance of our products; ·the mix of products that we sell and related services that we provide; ·the success or failure of our licensees to develop, obtain approval for and commercialize our licensed products, for which we are entitled to contingentpayments and royalties; ·changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; ·development of technological innovations or new competitive products by others; ·announcements of technological innovations or new products by us; ·publication of the results of preclinical or clinical trials for FMX101, FMX103 or our other product candidates; ·failure by us to achieve a publicly announced milestone; ·delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products; ·developments concerning intellectual property rights, including our involvement in litigation brought by or against us, including patent oppositionand review proceedings before national patent offices; ·regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; ·changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; ·changes in our expenditures to promote our products; ·our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future; ·changes in key personnel; ·success or failure of our research and development projects or those of our competitors; ·the trading volume of our ordinary shares; and ·general economic and market conditions and other factors, including factors unrelated to our operating performance. These factors and any corresponding price fluctuations may materially and adversely affect the market price of our ordinary shares and result insubstantial losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have often institutedsecurities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attentionof our management from our business. If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinaryshares, the price of our ordinary shares could decline. The trading market for our ordinary shares relies in part on the research and reports that equity research analysts publish about us and our business, if atall. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The price of our ordinaryshares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrades our ordinary shares orif those analysts issue other unfavorable commentary or cease publishing reports about us or our business. Future sales of our ordinary shares could reduce the market price of our ordinary shares. If our shareholders, particularly our directors and their affiliates or our executive officers, sell a substantial number of our ordinary shares in the publicmarket, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinaryshares could also depress the market price of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equitysecurities. In addition, our sale of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the shareprice of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinaryshares or other equity securities, and may cause holders of our ordinary shares to lose part or all of their investment. 25The significant share ownership position of affiliates of our co-founders, Dr. Dov Tamarkin and Meir Eini, may limit your ability to influence corporatematters. Tamarkin Medical Innovation Ltd., a company beneficially owned by Dr. Dov Tamarkin, or Tamarkin, our co-founder and chief executive officer,beneficially owns or controls, directly or indirectly, 7.6% of our outstanding ordinary shares, and Meir Eini Holdings Ltd., a company beneficially owned byMeir Eini, or Eini, our co-founder and chief innovation officer, beneficially owns or controls, directly or indirectly, 8% of our outstanding ordinary shares, asof December 31, 2016. Accordingly, Tamarkin and Eini are able to significantly influence, though not independently determine, the outcome of mattersrequired to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors and the outcome of anyproposed merger or consolidation of our company. Tamarkin's and Eini's interests may not be consistent with those of our other shareholders. In addition,Tamarkin's and Eini's significant interest in us may discourage third parties from seeking to acquire control of us, which may adversely affect the market priceof our ordinary shares. We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future. We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in theforeseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result,capital appreciation, if any, of our ordinary shares will be investors' sole source of gain for the foreseeable future. In addition, Israeli law limits our ability todeclare and pay dividends, and may subject our dividends to Israeli withholding taxes. As a foreign private issuer, we are permitted to follow, and are following, certain home country corporate governance practices instead of otherwiseapplicable SEC and NASDAQ requirements. As a foreign private issuer, we are permitted to follow, and are following, certain home country corporate governance practices instead of those otherwiserequired under the NASDAQ Stock Market for domestic U.S. issuers. For instance, we follow home country practice in Israel with regard to (i) the quorumrequirement for shareholder meetings, and (ii) the requirement for independent director oversight of director nominations. See "Item 16G. CorporateGovernance." We may in the future elect to follow home country practices in Israel (and consequently avoid the requirements that would otherwise apply to a U.S.company listed on the NASDAQ Global Market) with regard to other matters as well, such as (i) the formation of a nominating and governance committee, (ii)separate executive sessions of independent directors and non-management directors and (iii) the requirement to obtain shareholder approval for certaindilutive events such as (a) for the establishment or amendment of certain equity-based compensation plans, (b) issuances that will result in a change ofcontrol of the company, (c) certain transactions other than a public offering involving issuances of a 20% or more interest in the company and (d) certainacquisitions of the stock or assets of another company. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the NASDAQGlobal Market may provide less protection to holders of our ordinary shares than what is accorded to investors under the NASDAQ Stock Market rulesapplicable to domestic U.S. issuers. As a foreign private issuer, we are not subject to U.S. proxy rules and are exempted from filing certain Exchange Act reports. As a foreign private issuer we are exempted from the rules and regulations under the Exchange Act related to the furnishing and content of proxystatements, and our officers, directors and principal shareholders are exempted from the reporting and short-swing profit recovery provisions contained inSection 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual and current reports and financial statements with theSEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act, we are permitted to disclosecompensation information for our executive officers on an aggregate basis, rather than an individual, basis and we are generally exempted from filingquarterly reports with the SEC under the Exchange Act. Moreover, we are not required to comply with Regulation FD, which restricts the selective disclosureof material information. These exemptions and leniencies reduce the frequency and scope of information and protections to which you may otherwise havebeen eligible in relation to a U.S. domestic issuer. We would lose our foreign private issuer status if a majority of our directors or executive officers are U.S. citizens or residents and we fail to meetadditional requirements necessary to avoid loss of foreign private issuer status. Although we have elected to comply with certain U.S. regulatory provisions,our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S.domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements onU.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We may also be requiredto modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications willinvolve additional costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stockexchanges that are available to foreign private issuers. 26We are an "emerging growth company" and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary sharesless attractive to investors. We are an "emerging growth company," as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that areapplicable to other public companies that are not "emerging growth companies." Most of such requirements relate to disclosures that we would only berequired to make if we cease to be a foreign private issuer in the future. Nevertheless, as a foreign private issuer that is an emerging growth company, we willnot be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act for up to five fiscal years after the date of ourinitial public offering. We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of atleast $1.0 billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of our initial public offering; (iii) the date on which we have,during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the date on which we are deemed to be a "largeaccelerated filer" under the Exchange Act. When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above.We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors findour ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile. Our U.S. shareholders may suffer adverse tax consequences if we are characterized as a passive foreign investment company. Generally, if, for any taxable year, 75% or more of our gross income is passive income, or at least 50% of the average quarterly value of our assets (whichmay be determined in part by the market value of our ordinary shares, which is subject to change) are held for the production of, or produce, passive income,we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Based on certain estimates of our gross income and gross assets, our use of proceeds of our initial public offering, and the nature of our business, webelieve that we were not classified as a PFIC for the taxable year ended December 31, 2016, and do not anticipate being classified as a PFIC for the taxableyear ending December 31, 2017. Because we currently hold, and expect to continue to hold, a substantial amount of cash and cash equivalents and otherpassive assets used in our business, and because the value of our gross assets is likely to be determined in large part by reference to our market capitalization,a decline in the value of our ordinary shares may result in our becoming a PFIC. Accordingly, we may be considered a PFIC for any taxable year. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinaryshares treated as ordinary income, rather than as capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares byindividuals who are U.S. Holders (as defined in "Item 10.E. Taxation—U.S. Federal Income Tax Consequences"), and having interest charges apply todistributions by us and the proceeds of share sales. Certain elections exist that may alleviate some of the adverse consequences of PFIC status and wouldresult in an alternative treatment (such as mark-to-market treatment) of our ordinary shares; however, we do not intend to provide the information necessaryfor U.S. holders to make qualified electing fund elections if we are classified as a PFIC. See "Item 10.E. Taxation—U.S. Federal Income Tax Consequences—Passive Foreign Investment Company Considerations." Risks Related to Our Operations in Israel Our headquarters, research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected bypolitical, economic and military instability in Israel. Our headquarters, and research and development facilities are located in Rehovot, Israel. In addition, the majority of our key employees, officers anddirectors are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Since the establishment ofthe State of Israel in 1948, a number of armed conflicts have taken place between Israel, its neighboring countries and other organizations. Any hostilitiesinvolving Israel or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our operations and resultsof operations. Further, our operations could be disrupted by the obligations of personnel to perform military reserve service. Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of,us, even when the terms of such a transaction are favorable to us and our shareholders. Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals fortransactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. Forexample, a tender offer for all of a company's issued and outstanding shares can only be completed if the acquirer receives positive responses from the holdersof at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personalinterest in the tender offer unless, following consummation of the tender offer, the acquirer would hold at least 98% of the company's outstanding shares.Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following thecompletion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that ashareholder that accepts the offer may not seek such appraisal rights. 27Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does nothave a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the sameextent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on thefulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales anddispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the taxdeferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors in Israel or the U.S., to assert U.S. securities laws claims inIsrael or to serve process on our officers and directors. We are incorporated in Israel. Most of our executive officers and the majority of our directors listed in this annual report reside outside of the U.S., andmost of our assets and most of the assets of these persons are located outside of the U.S. Therefore, a judgment obtained against us, or any of these persons,including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the U.S. and may not be enforced byan Israeli court. It also may be difficult for you to effect service of process on these persons in the U.S. or to assert U.S. securities law claims in original actionsinstituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the mostappropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. lawis applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be atime consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgmentagainst us in Israel, holders of our ordinary shares may not be able to collect any damages awarded by either a U.S. or foreign court. The rights and responsibilities of our shareholders are governed by Israeli law, which differs in some material respects from the rights and responsibilitiesof shareholders of U.S. companies. The rights and responsibilities of the holders of our ordinary shares are governed by our amended articles of association and by Israeli law. These rightsand responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S.-based companies. In particular, a shareholderof an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the companyand other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholderson matters such as amendments to a company's articles of association, increases in a company's authorized share capital, mergers and acquisitions and relatedparty transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at ameeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward thecompany with regard to such vote or appointment. There is limited case law available to assist us in understanding the nature of this duty or the implicationsof these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are nottypically imposed on shareholders of U.S. companies. ITEM 4.INFORMATION ON THE COMPANY 4.A.History and development Our legal and commercial name is Foamix Pharmaceuticals Ltd. (formerly Foamix Ltd.). We were incorporated as a limited liability company under thelaws of the State of Israel on January 19, 2003. We are registered with the Israeli Registrar of Companies. Our registration number is 51-336881-1. Article 3 ofour articles of association provides that our objectives are to conduct all types of business as are permitted by law. Our principal executive offices are located at 2 Holzman St., Weizmann Science Park, Rehovot 7670402, Israel, and our telephone number is +972-8-9316233. Our website is www.foamixpharma.com. The information contained on, or that can be accessed through, our website does not constitute a part ofthis form and is not incorporated by reference herein. Foamix Pharmaceuticals Inc., our wholly-owned subsidiary, was incorporated on May 6, 2014 underthe laws of the State of Delaware, with the intent to serve as our marketing and sales arm in the U.S. Foamix Pharmaceuticals Inc. has been appointed as ouragent in the United States and is located at 520 U.S. Highway 22, Suite 305, Bridgewater, New Jersey 08807. 28We are an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the JOBS Act. Assuch, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies thatare not "emerging growth companies" such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-OxleyAct of 2002. We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual grossrevenues of at least $1.0 billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of our initial public offering; (iii) the date onwhich we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the date on which we are deemed to be a"large accelerated filer" under the Exchange Act. For information regarding our capital expenditures, see "Item 5.B. Liquidity and Capital Resources." 4.B.Business overview Who We Are We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for thetreatment of acne, rosacea and other skin conditions. Our lead product candidates, FMX101 for moderate-to-severe acne and FMX103 for treatment ofmoderate-to-severe papulo-pustular rosacea, are novel topical foam formulations of the antibiotic minocycline. Our clinically and statistically significantPhase II clinical trial results demonstrate that our minocycline foam products, FMX101 and FMX103, provide a fast, effective, and well-tolerated treatmentfor their respective indications. Currently, oral minocycline and oral doxycycline are the most commonly utilized treatments for moderate-to-severe acne andmoderate-to-severe rosacea, respectively. Based on the results demonstrated in our Phase II clinical trials, we believe that FMX101 and FMX103 have thepotential to become the new standards of care for moderate-to-severe acne and moderate-to-severe rosacea. We are currently investing the majority of our efforts and resources to advance our two pivotal Phase III clinical trials for FMX101 and our Phase IIIclinical program for FMX103 in the U.S. We completed enrollment of our Phase III clinical trials for FMX101 in November 2016. We expect to have top-lineresults from the blinded stage of these trials in the first half of 2017 and to complete these trials, including their safety extension, by the end of 2017. We are also developing FMX103, minocycline foam for rosacea. In September 2016, we announced the successful results of a Phase II clinical trial forFMX103 in patients with moderate-to-severe rosacea. We plan to commence a Phase III clinical program of FMX103 for the treatment of moderate-to-severerosacea in 2017. In addition, we successfully completed a Phase II clinical trial with FDX104, our proprietary doxycycline foam for the management of moderate-to-severerash associated with the epidermal growth factor receptor inhibitor, or EGFRI, anticancer treatments. We have also successfully completed a Phase II clinicaltrial of FMX102, our minocycline foam for the treatment of impetigo, including impetigo caused by methicillin-resistant staphylococcus aureus, or MRSA.While the FMX101 and FMX103 development programs address widespread dermatological indications, our product candidates FMX102 and FDX104represent smaller opportunities and are not focused within the dermatological market, and therefore, are of lower priority in our R&D pipeline development. We developed FMX101, FMX102, FMX103 and FDX104 using our proprietary technology, which includes our foam-based platforms. This technologyenables us to formulate and stabilize a wide variety of drugs and deliver them directly to their target site. Our foam platforms have significant advantagesover alternative delivery options and are suitable for multiple application sites, creating a potential pipeline of products across a range of conditions to drivefuture growth. Parallel to our in-house developments, we have entered into development and license agreements relating to our technology with various pharmaceuticalcompanies such as Bayer HealthCare AG (formerly, Intendis), Sebela Pharmaceuticals Inc. (following the assignment to Sebela of our development andlicense agreement with Merz Pharmaceuticals, LLC in 2016), Mylan N.V. (following the acquisition of Renaissance Acquisition Holdings, LLC by Mylan in2016) and Actavis Laboratories, a subsidiary of Teva Pharmaceutical Industries Ltd. Our total revenues from such agreements from our inception to December31, 2016 were approximately $24.5 million. In the third quarter of 2015, Bayer Healthcare began selling Finacea® Foam (azelaic acid) 15% for the treatment of rosacea in the U.S. Finacea is aprescription foam product which was developed as part of a research and development collaboration between Foamix and Bayer, utilizing Foamix'sproprietary foam technology platform. According to our license agreement with Bayer, we are entitled to royalties and certain contingent payments uponcommercialization of Finacea Foam, based on Bayer's net sales of Finacea. In 2016 we were entitled to $3.0 million from Bayer in royalties and $2.5 millionin contingent payments related to the achievement of certain revenue targets, on account of its sales of Finacea. Proprietary, innovative technology comprising different foam platforms We have independently developed a series of proprietary foam platforms, each having unique pharmacological features and characteristics, which enableus to formulate, stabilize and deliver a wide variety of drugs directly to their target site. For example, minocycline is known to be very unstable and rapidlydegrades in the presence of most commonly-used formulation components. Utilizing our proprietary technology, we successfully stabilized minocycline in anovel topical foam formulation. Our choice to develop foams over other platforms stems from foam's significant advantages over alternative delivery systems,being that it spreads easily and can be applied to large skin areas, is readily absorbed, avoids a messy residue and is highly tolerable due to its use of gentleingredients. All ingredients used in our minocycline foam are listed in the FDA Inactive Ingredient Database, or IID, and are used in concentrations that donot exceed the maximum concentrations given in the IID. Our foam platforms are generally designed to be suitable for dermal, vaginal, nasal and otherapplications and to treat a range of diseases and disorders. 29Product candidate pipeline The following chart provides a summary of the developmental pipeline for our clinical-stage product candidates: FMX101 for moderate-to-severe acne Our lead product candidate, FMX101, minocycline foam 4%, is a novel topical foam formulation of minocycline for the treatment of moderate-to-severeacne. Market opportunity Acne is characterized by areas of scaly red skin, non-inflammatory blackheads and whiteheads, inflammatory lesions, papules and pustules andoccasionally boils and scarring. It affects approximately 40 to 50 million people in the U.S. alone, of whom approximately 10 million suffer from moderate-to-severe acne. For most people, acne diminishes over time and tends to disappear or decrease, by age 25. However, some individuals continue to suffer fromacne well into their 30s, 40s and later. The market segment for aesthetic dermatology in general, and for indications such as acne in particular, is especially attractive because patients are highlymotivated and more willing to pay out-of-pocket for treatments that will relieve them of the negative aesthetic aspects of the condition. As a result, webelieve that patients will tolerate less favorable reimbursement schemes than they would when paying for drugs for other indications. We also believeFMX101 can expand the overall acne market by attracting new patients who currently avoid medication for their condition altogether, due to theunsatisfactory results of their previous treatment methods, and prefer a more tolerable treatment. Limitations of oral minocycline for acne Oral minocycline, such as Solodyn, is the current standard of care for moderate-to-severe acne. According to its product label, Solodyn did notdemonstrate any effect on non-inflammatory acne lesions and reduced inflammatory lesions by 44% over the 12 week treatment period. According to itsproduct label, the most common adverse systemic side effects of Solodyn include diarrhea, dizziness, drowsiness, indigestion, lightheadedness, loss ofappetite, nausea, sore mouth, throat or tongue and vomiting. In 2009, the FDA added oral minocycline to its Adverse Event Reporting System, a list of medications under investigation by the FDA, due to its severeside effects. In 2011, we conducted a blind survey of 40 U.S. dermatologists. The results of the survey revealed that 90% of the dermatologists surveyed whoprescribed oral minocycline were concerned about its side effects, and 76% of these dermatologists stated they would prefer prescribing a topicalminocycline drug over an existing oral medication, assuming the topical treatment was safe, effective and approved by the FDA. FMX101 clinical results We conducted a randomized, double-blind, dose-ranging, controlled Phase II clinical trial in Israel over 12 weeks with 150 patients between 12 and 25years old with a mean age of approximately 16.5 years, each suffering from at least 20 inflammatory and 25 non-inflammatory facial lesions. The patientswere randomly divided into three groups of 50 patients each, with one group receiving a 1% concentration of our minocycline foam, a second groupreceiving a 4% concentration and a third control group receiving our foam vehicle without minocycline, which we refer to as the vehicle. Each patientreceived one application daily before bedtime. 30The primary efficacy endpoints of the trial were: ·the reduction in inflammatory and non-inflammatory lesions (as well as the total counts of facial lesions) over the course of the 12 week treatment; ·the investigator's global assessment, or IGA, based on the uniform graded scale adopted for the trial, ranging from "clear" skin with no inflammatory ornon-inflammatory lesions, through "almost clear" skin, to "severe acne"; and ·safety and tolerability. The trial was completed in 2013 and showed a dose-dependent effect that was statistically significant for both primary endpoints of the trial, namelyreduction in inflammatory and non-inflammatory lesions and decrease of the IGA score. Notably, the effect on inflammatory lesions became statisticallysignificant in the 4% dosage group versus the vehicle-only treatment group (placebo) after just three weeks of therapy, and the full therapeutic effect ofapproximately 71% reduction in inflammatory lesions was reached in the 4% dosage group after six weeks of treatment. Additionally, for the patients in the4% dosage group, the effect on non-inflammatory lesions also became statistically significant versus the vehicle-only group after twelve weeks of therapy,with approximately a 73% reduction in non-inflammatory lesions. The percent of patients with IGA improvement of at least two grades and a grading of clear or almost clear (score of 0 or1) at the completion of the trialwas 20% in the 4% dosage group, compared with 4% in the 1% dosage group and 2% in the vehicle-only treatment. The safety and tolerability profile of the drug was also favorable, with no serious adverse events and no reported drug-related systemic side effects. Thecases of skin reaction in the trial were few, mild and transient, with all reactions subsiding by week 12 of treatment, and there was equal incidence of skinreaction in all three groups. The following charts show the reduction of inflammatory from baseline and over the trial period for the 4% dosage, 1% dosage and vehicle treatmentgroups and the percentage of patients who met the IGA success criterion. Additionally, in questionnaires filled out upon completion of the trial, 86% of the patients receiving the 4% dosage rated the drug as "very-highly" or"highly" effective compared to drugs they had formerly used, 98% of all patients were generally satisfied with the ease of use of the foam and 92% of allpatients indicated they preferred the foam-based treatment over alternative topical products they had used in the past. While we did not file a formal application for an IND with the FDA in connection with the FMX101 Phase II clinical trial, the trial was conducted incompliance with the International Conference of Harmonization, or ICH, good clinical practice, or GCP, guidelines and applicable Israel Ministry of Healthregulations. The trial protocol complied with the procedures, criteria and endpoints specified by the FDA's 2005 draft industry guidance for acne trials.Because minocycline, the active ingredient in FMX101, is a well-known drug with an established safety profile, the ethical committee for our Phase IIclinical trial and the Israeli Ministry of Health allowed us to conduct Phase II clinical trials of FMX101 without having first conducted a Phase I clinical trial. 31We also completed a Phase I maximum use pharmacokinetics study of FMX101, intended to characterize the systemic absorption of minocycline afterrepeated maximum-dose applications in patients with moderate-to-severe acne, and to assess the relative bioavailability of topically-applied FMX101compared to orally-administered Solodyn (minocycline HCl). The study enrolled 30 patients with moderate-to-severe acne on their face and on two or moreother regions (neck, upper chest, upper back or arms) in a single-center, nonrandomized, open-label, active-controlled, two-period and two-treatmentevaluation. Each of the patients received a single dose of Solodyn, 1 mg/kg in accordance with its approved instructions for use, and one week later received4 grams of FMX101 applied topically once daily for 21 days. The study showed that the bioavailability, or systemic exposure, of minocycline followingtopical FMX101 administration was approximately 700 times lower than that of Solodyn, and that FMX101 was well tolerated with no serious adverse eventsbeing reported. We hope these results will provide a clinical bridge to the minocycline systemic safety data known to the FDA. A series of Phase I human safety studies, were completed in 2016. Results of these trials to date are as expected and indicate no safety signals have beendetected. As part of our overall development plan for FMX101, we have conducted a series of animal safety studies, which revealed no signs of toxicity to date. Werecently completed a long-term, 39-week dermal toxicity study in mini pigs, which included concentrations of our minocycline foam up to 16%. Initialresults from this study also reflect no toxicity associated with our drug product. This study also is intended to support the NDA, as well as a long-termextension of the Phase III human studies, in which patients will be dosed for up to 12 months. We also held an End of Phase II meeting with the FDA to review the clinical development plan for FMX101, and implemented the comments we receivedfrom the FDA regarding overall study design, primary efficacy endpoints, and safety assessments in the FMX101 Phase III program. FMX101 Phase III clinical trials Based on the results of the Phase II clinical trial, as described above, and guidance from the FDA in a pre-IND meeting, we initiated two multi-centerpivotal Phase III clinical trials for FMX101 (minocycline foam 4%) in moderate-to severe acne, which are currently underway simultaneously in the U.S. InNovember 2016, we completed patient enrollment, with a total of 960 patients with moderate-to-severe acne enrolled between the two trials. Patients wererandomized on a 2:1 basis (active compound vs. vehicle-only), initially into a 12-week double-blind phase where they are treated topically once daily witheither FMX101 (minocycline foam 4%) or the respective foam vehicle. The two co-primary efficacy endpoints of both trials are: (1) the absolute change frombaseline in inflammatory lesion counts in each treatment group at week 12; and (2) the proportion of patients achieving success at week 12 as defined by anIGA score of "clear" or "almost clear" and at least a two-grade improvement from baseline at week 12. Safety evaluation includes reported adverse events,assessments of tolerability, clinical laboratory tests and vital signs. Patients who complete the 12 week double-blind portion of the trials have the option tocontinue in a long-term open-label safety extension, aimed at evaluating the safety of intermittent use of FMX101 for up to nine additional months. Weexpect to report top-line results from the blinded phase of these Phase III clinical trials in the first half of 2017. We expect to develop FMX101 through the FDA's 505(b)(2) regulatory pathway, which permits the filing of a new drug application, where at least some ofthe information required for approval comes from studies that were not conducted by or for the applicant, and for which the applicant has not received a rightof reference. This approach could expedite the development program for FMX101 by potentially decreasing the amount of clinical data that we would needto generate in order to obtain FDA approval. For additional information see "Risk Factors - If the FDA does not conclude that FMX101 or FMX103 satisfy therequirements under Section 505(b)(2) of the Federal Food Drug and Cosmetics Act, or Section 505(b)(2), or if the requirements for this product candidateunder Section 505(b)(2) are not as we expect, the approval pathway for this product candidate will likely take significantly longer, cost significantly moreand entail significantly greater complications and risks than anticipated, and in either case may not be successful." FMX103 for moderate -to-severe papulo-pustular rosacea Our product candidate, FMX103, minocycline foam 1.5%, is a novel topical foam formulation of minocycline for the treatment of moderate-to-severePapulopustular rosacea. Market opportunity Papulopustular rosacea is a chronic skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. It can createpsychosocial burdens, such as embarrassment, anxiety and low self-esteem that adversely affect quality of life. Rosacea is most frequently seen in adultsbetween 30 and 50 years of age and affects more than 16 million people in the U.S. alone. There is no known cure for rosacea and the exact root cause of thedisease remains unknown as well, though both genetic and environmental factors are thought to have an impact on its outbreak. Mild papulopustular rosaceais treated by topical antimicrobials (such as metronidazole, clindamycin and ivermectin), or azelaic acid, while the mainstay for the treatment of moderate-to-severe rosacea are systemic antibiotics such as minocycline and doxycycline. 32The current U.S. market size for rosacea is estimated to be approximately $1.2 billion, and we believe that our FMX103 product candidate for thisindication, if approved, can offer a significant advantage over other currently available products. FMX103 clinical results In the third quarter of 2016, we announced positive top-line results from our Phase II trial evaluating FMX103. The double-blind, randomized, placebo-controlled Phase II trial was conducted in 18 sites in Germany and included 233 patients with moderate-to-severe rosacea. Patients were randomized toreceive either one of two doses of FMX103 minocycline foam (3% or 1.5%) or vehicle foam once daily over 12 weeks, followed up by a four-week post-treatment evaluation. The efficacy endpoints were (i) the absolute change in the number of inflammatory lesions – papules and pustules (primary endpoint),and (ii) improvement of the IGA (first secondary endpoint). Safety and tolerability were also evaluated. ·Baseline severity. The mean baseline lesion count for all groups ranged from 30.6 to 34.5 and the IGA scores were all moderate (score 3) or severe(score 4); with about 50-60% of the subjects having a severe rating. ·Significant reduction in the number of inflammatory lesions. At the week 12 time point designated for the primary efficacy analysis, the 1.5% and 3%doses of FMX103 both significantly reduced the number of papules and pustules vs. the vehicle (1.5% and 3%, both p<0.001, , intent-to-treatanalysis). The mean reduction in lesion count of each treatment group vs. its baseline was 21.1 for the 1.5% dose, 19.9 for the 3% dose and 7.8 forvehicle; the corresponding percent reductions were 61.4% and 55.5% for the FMX103 1.5% and 3% groups, respectively, and 29.7% for the vehicle. ·Significant improvement in Investigator's Global Assessment (IGA) scores. Both the 1.5% and 3% doses of FMX-103 were significantly bettercompared to vehicle alone in reducing the IGA score by two grades and in reaching a "clear" (score=0) or "almost clear" (score=1) rating at week 12 (P< 0.01 and P < 0.05, respectively. The percentage of subjects achieving at least a two grade point reduction and a rating of clear or almost clear (scoreof 0 or 1) was 25.3 for the 1.5% dose, 17.3 for the 3% dose, and 7.7 for vehicle. Both the 1.5% and 3% doses were efficacious and there was nostatistically significant difference between these two doses. ·Safety and tolerability. FMX103 appeared to be generally safe and well-tolerated. There were no serious adverse events and no drug related systemicadverse events were reported. A few subjects overall exhibited treatment-related dermal adverse events (four and five in the 3% and vehicle groups,respectively and none in the 1.5% group). Four subjects discontinued the trial due to an adverse event (three in the 3% group and one in the vehiclegroup). 33The following charts show the percentage reduction of inflammatory lesions from baseline and over the trial period for the 3% dose, 1.5% dose andvehicle-only treatment groups and the percentage of patients who met the IGA success criterion. In December 2016, we conducted a pre-IND meeting with the FDA to confirm that our clinical and non-clinical programs outlined were sufficient tosubmit an IND and to begin our Phase III clinical trials. Utilizing the results of toxicology, pharmacology and human safety studies that were completed forFMX101, we now plan to conduct two independent Phase III clinical trials of FMX103, for moderate-to-severe papulo-pustular rosacea commencing duringthe first half of 2017. The Phase III clinical trials will be conducted primarily in the U.S. and will include two treatment groups, with one group receivingFMX103 in a 1.5% concentration and the other receiving the foam vehicle alone. The trials will be double-blinded and vehicle-controlled, and theirprotocols and endpoints will be conducted in accordance with the FDA's guidance, as provided in the pre-IND meeting. FDX104 for chemotherapy-induced rash FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. Between 45% and 95% of patients taking epidermal growth-factor receptor inhibitors (EGRFI), such as cetuximab (Erbitux®, Eli Lilly), panitumumab(Vectibix®, Amgen) and erlotinib (Tarceva®, Genentech), are affected by these severe acne-like rashes, which typically occur in cosmetically sensitive areassuch as the face and upper trunk. These symptoms can lead to patients modifying their dosage of EGFRI drugs and potentially stop treatment altogether.While there are no approved drugs for treatment of these rashes, oral doxycycline and minocycline are often used to treat these conditions, but they havesignificant shortcomings, including systemic side effects such as diarrhea, nausea and skin redness. In the third quarter of 2015, we completed a Phase II clinical trial for FDX104 on patients with metastatic colon cancer who were treated with cetuximab orpanitumumab. The results showed a statistically significant effect of FDX104 in reducing the severity of the rash. 34Twenty-four patients were enrolled and received study drug in a multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the safetyand efficacy of FDX104. Each patient acted as his or her own control by treating one side of the face with FDX104 and the other side with the matching foamvehicle (Placebo) in a blinded and randomized manner. Photographs of the face were taken at each study visit and were used for the grading of rash severityin a blinded manner by an independent dermatologist at the end of the study (General Rash Severity Score, GSS). Rash severity was also performed at eachvisit by the investigator (modified MASCC EGFR Inhibitor Papulopustular Eruption Grading Scale, MESTT). The GSS ratings of rash severity were: None =0, Mild = 1, Moderate = 2 and Severe = 3. The key findings were: ·In the entire study population, (in all 24 patients in the study) the severity of rash on the FDX104 treatment side of the face was overall better than inthe placebo-treated side. ·The mean maximal rash severity (in all 24 patients in the study) was 1.33 and 1.71 in the FDX104-treated and placebo-treated sides respectively. ·9 of the 24 patients in the study (37.5%) developed severe (Grade 3) rash during the study on the placebo-treated side, while only 4 of the 24 patientsin the study (16.7%) developed severe rash on the FDX104-treated side. Comparison of the two treatments on the prevention of severe rash reached statistical significance (p<0.05, Wilcoxon Signed-Rank test. MESTT-basedanalyses had similar but non-statistically significant results. FDX104 was well-tolerated during the study. No drug-related systemic adverse events wererecorded. Local reactions were noted in 6 patients, all were mild and 5 were resolved before the end of the study. Based on the results of the FDX104 Phase II clinical trial, we are evaluating various clinical development options, as well as the potential marketopportunity for this product. FMX102 for impetigo FMX102 is a formulation of our minocycline foam currently being developed for the treatment of impetigo. We conducted a randomized, double-blind Phase II clinical trial in Israel over seven days with 32 pediatric patients ages two to 15 with at least twoimpetigo lesions. Of these patients, 32% were diagnosed with MRSA infection. The patients were randomly divided into two groups of 16 patients each, withone group receiving a 1% concentration of our minocycline foam and the other group receiving a 4% concentration of our minocycline foam, applied to eachpatient twice a day. No vehicle-only control was used, as ethical guidelines for pediatric trials in Israel do not permit the use of control groups. The primary efficacy endpoints of the trial were (1) clinical success, defined as a total absence of treated lesions or certain specific improvements in thelesions during the trial and the continuous absence of the treated lesions or certain specific improvements in the lesions at follow-up; (2) bacteriologicalsuccess, measured by elimination of the bacteria in the lesion as shown by a bacterial culture at end of treatment or follow-up or by the lack of any material toculture as a result of the lesion healing; and (3) safety and tolerability. The trial was completed in 2012 and showed that approximately 80% of the patients in both groups met the clinical success criteria after three days oftreatment. Clinical response at the end of the treatment (on day 7) was 92% for the 1% dosage and 100% for the 4% dosage, and all patients (100%) showedsuccess by the fourteenth day of the trial. In a post-hoc analysis of the clinical trial results, eleven of the patients in this trial were also diagnosed withMethicillin-resistant Staphylococcus aureus (MRSA). Bacteriological success was reached in all 11 patients by the end of the trial and no presence of MRSAwas detected. The safety and tolerability profile of the drug was favorable, and no drug-related side effects were reported during the trial. In October 2015, we held a Pre-IND meeting with the FDA, to seek guidance with regards to the preclinical and clinical activities that are required toadvance the development program of FMX102. The FDA requested that we conduct a photo-safety study prior to further evaluation of our clinicaldevelopment plan. We began this photo-safety study in 2016, which remains ongoing. We are evaluating the clinical development plan and the businessopportunity for this product. 35Development roadmap and priorities In view of the success of the Phase II trials for both FMX101 and FMX103, and the fact that these product candidates address widespread dermatologicalindications and significant market potential, we have decided to focus on these projects and invest the majority of our resources in FMX101 and FMX103. Asa result, we will expand fewer resources on FMX102 and FDX104, which represent smaller opportunities and are not focused within the dermatologicalmarket. Development and license agreements Parallel to the development of our product candidates, we have entered into development and license agreements with various pharmaceutical companies,including such as Bayer HealthCare AG (formerly, Intendis), Sebela Pharmaceuticals Inc. (following the assignment to Sebela of our development and licenseagreement with Merz Pharmaceuticals, LLC in 2016), Mylan N.V. (following the acquisition of Renaissance Acquisition Holdings, LLC by Mylan in 2016)and Actavis Laboratories, a subsidiary of Teva Pharmaceutical Industries Ltd., combining our foam technology with drugs selected by the licensee to createnew products with improved efficacy and ease-of-use. Each license agreement entitles us to service payments, contingent payments and royalties from salesof any new products that are commercialized. Each agreement is exclusive only to the specific drug that is licensed, leaving us the rights to commercializeand develop products with other drugs for the same indications using our proprietary foam technology while also allowing the licensee to apply the newproducts to any indication with its specific drug. The prospective products under these various agreements are currently in pre-clinical, Phase II, Phase III andcommercial stages. In September 2015, Bayer Healthcare began selling Finacea® Foam (azelaic acid) 15% in the U.S. Finacea Foam is a prescription topical drug which wasdeveloped by collaboration between Bayer and Foamix. It is the first prescription product developed using our proprietary technology that has beenapproved by the FDA for sale in the U.S. Bayer listed in the Orange Book several patents that were licensed from Foamix in connection with the developmentof Finacea Foam. According to our license agreement with Bayer, we are entitled to receive royalties and certain contingent payments upon thecommercialization of Finacea Foam. In 2016 we were entitled to $3.0 million from Bayer in royalties and $2.5 million in contingent payments related toachievement of certain revenue targets, on account of its sales of Finacea. Our total revenues from such agreements from our inception to December 31, 2016 were approximately $24.5 million. Additional Research and Development In addition to FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatmentof impetigo and FDX104 for managing severe chemotherapy-induced rashes, and aside from the licensed products resulting from our development andlicense agreements with various pharmaceutical companies, we are developing a series of product candidates for a wide variety of indications to which weown worldwide rights and which are all based on formulations and adaptations of our patented, versatile foam platforms. We intend to selectively proceed to clinical trials with these formulations under the FDA's 505(b)(2) regulatory pathway according to our identification ofunmet needs and potential market opportunities. Intellectual Property Our intellectual property and proprietary technology are essential to the development, manufacture, and sale of FMX101, FMX102, FMX103 andFDX104 and our future pipeline products. We seek to protect our intellectual property, core technologies and other know-how, through a combination ofpatents, trademarks, trade secrets, non-disclosure and confidentiality agreements, licenses, assignments of invention and other contractual arrangements withour employees, consultants, partners, suppliers, customers and others. Additionally, we rely on our research and development program, clinical trials, know-how and marketing and distribution programs to advance our products. We submit applications directly or under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unifiedprocedure for filing a single initial patent application to seek patent protection for an invention simultaneously in any one of the designated member states.Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phaseapplications. We also submit applications for a single European patent application covering member states. If granted, the European patent must be validated in eachnational member state in which the patent is to continue and becomes a bundle of individual national patents. Our most important patents are several U.S. patents relating to our lead product candidates, FMX101, FMX102, FMX103 and FDX104, which areexpected to remain in effect until 2030. These patents relate to a composition of matter comprising a claim to a formulation of a tetracycline antibiotic, whichcan include minocycline or doxycycline and therefore may be less protective than patents that claim a new drug. We also have patent applications claimingcompositions of matter, which relate to FMX101, FMX102, FMX103 and FDX104, pending in each of the following international markets: Australia, Brazil,Canada, China, the European Union, India, Israel and Mexico. 36Our other patents granted in the U.S. have claims relating to certain formulations of our foam platforms and other technology, including emulsion foams,hydrophobic foams, hydroalcoholic and aqueous foams. As of December 31, 2016, we had a patent portfolio of 149 granted patents in certain countries worldwide, including 50 granted patents in the U.S.Additionally, as of December 31, 2016, we had over 80 pending patent applications worldwide, of which over 45 are pending in the U.S., describing andclaiming our various foam based platforms and other technology. Our other pending applications relate to various foam platforms such as emulsion foam,hydrophobic foam, hydro-alcoholic foam and water-free foams, as well as specialty foams (such as potent solvent foams) and our recently-developed 'metereddose dispenser' for controllable dosing. Competition The medical and pharmaceutical industries in which we operate are intensely competitive and subject to significant technological change and changes inpractice. While we believe that our innovative technology, knowledge, experience and resources provide us with competitive advantages, we may facecompetition from many different sources with respect to FMX101, FMX103 and our other pipeline products or any product candidates that we may seek todevelop or commercialize in the future. Possible competitors may include pharmaceutical companies, academic and medical institutions, governmentalagencies and public and private research institutions. These prospective competitors have the ability to effectively discover, develop, test and obtainregulatory approvals for products that compete with ours, as well as the ability to effectively commercialize, market and promote approved products,including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. At the end of 2014 we became aware that an active pharmaceutical ingredient and drug product intermediate manufacturer, Hovione, had submitted anIND for Phase I and II clinical trials of a new topical gel suspension containing minocycline for the treatment of inflammatory skin disease, including acneand rosacea. Hovione is a privately-held company and we do not know if they have commenced a clinical trial for such a new topical minocycline product.During 2015 we became aware that another company, BioPharmX Corporation (NYSE MKT: BPMX), is developing a topical hydrophilic gel containingminocycline for treatment of acne, known as BPX-01, for which BioPharmX has announced Phase IIa clinical trial results. If ultimately approved andlaunched in the US, these products would become direct competitors to FMX101 and FMX103, if commercialized. Further, we are developing certain topical products with several licensees combining our proprietary technology with a drug selected by the licensee.While the licenses we grant are exclusive with respect to the specific drug which is licensed, our agreements with these licensees allow them to commercializethe licensed developed products for any topical dermatological application, not just for the specific indication for which each product was originallyintended. If any such licensed product proves to be effective for moderate-to severe acne, impetigo, rosacea, chemotherapy-induced rash, or any otherindication that we are pursuing with FMX101, FMX103 or our other product candidates, we may face competition from these licensees, as they are not boundby non-compete restrictions. Although we believe that FMX101, FMX103 and our other product candidates can outperform the licensed products in thespecific indications our product candidates are targeting, such licensed products may nevertheless pose a competitive challenge, as they will have the benefitof our foam technology coupled with the licensees' greater resources, experience and brand recognition, extensive marketing channels and other capabilities,and possibly the advantage of entering the market before us. In addition to products that are currently available, other products may be introduced to treat acne, rosacea, impetigo and other skin disorders during thetime that we engage in necessary development. Accordingly, if one of our pipeline products is approved, our main challenge in the market would be toconvince dermatologists, pediatricians or other physicians seeking alternatives to oral or other existing treatments to use our product instead. While we arestill in the preliminary stages, based on our studies, we believe that our pipeline products could be more effective than the current non-topical alternativesand exhibit significantly less adverse side effects. Government Regulation Our business is subject to extensive government regulation. Regulation by governmental authorities in the U.S. and other jurisdictions is a significantfactor in the development, manufacture and marketing of our foam delivered treatments and in our ongoing research and development activities. Product approval process in the U.S. Review and Approval of Drugs In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act and implementing regulations and other laws, including the PublicHealth Service Act. Drugs require the submission of a new drug application, or NDA, and approval by the FDA prior to being marketed in the U.S. The processof obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires theexpenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product developmentprocess, approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions and enforcement actions brought bythe FDA, the Department of Justice or other governmental entities. Possible sanctions may include the FDA's refusal to approve pending NDAs, withdrawal ofan approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production ordistribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. 37The process required by the FDA prior to marketing and distributing a drug in the U.S. generally involves the following: ·completion of laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice, or GLP, or otherapplicable regulations; ·submission to the FDA of an application for an IND designation, which must become effective before human clinical trials may begin; ·approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; ·performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, to establish the safety andefficacy of the proposed drug for its intended use; ·preparation and submission to the FDA of an NDA or supplemental NDA; ·satisfactory completion of an FDA advisory committee review, if applicable; ·satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product or components thereof areproduced, to assess compliance with current good manufacturing processes, or cGMP, and to assure that the facilities, methods and controls areadequate to preserve the drug's identity, strength, quality and purity; and ·payment of user fees and FDA review and approval of the NDA. Preclinical studies Preclinical studies include laboratory evaluation, as well as animal studies to assess the potential safety and efficacy of the product candidate. Preclinicalsafety tests must be conducted in compliance with the FDA's GLP regulations. The results of the preclinical tests, together with manufacturing informationand analytical data, are submitted to the FDA as part of an IND which must become effective before clinical trials may be commenced. Clinical trials in support of an NDA Clinical trials involve the administration of an investigational product to human subjects under the supervision of qualified investigators in accordancewith GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before theirparticipation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the trial, theparameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocolamendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before thattime the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDAmust resolve any outstanding concerns before the clinical trial can begin. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before itcommences at that institution, and the IRB must conduct continuing review and reapprove the trial at least annually. The IRB must review and approve,among other things, the trial protocol and informed consent information to be provided to trial subjects. An IRB must operate in compliance with FDAregulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for publicdissemination on their ClinicalTrials.gov website. Clinical trials are typically conducted in three sequential phases, which may overlap or be combined: ·Phase I: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosagetolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimaldosage. ·Phase II: The drug is administered to a limited patient population to identify possible short-term adverse effects and safety risks, to preliminarilyevaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. ·Phase III: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlledclinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefitprofile of the product, and to provide adequate information for the labeling of the product. 38Submission of an NDA to the FDA The results of the preclinical studies and clinical trials, together with other detailed information, including information on the manufacture, control andcomposition of the product, are submitted to the FDA as part of an NDA requesting approval to market the product candidate for a proposed indication. Underthe Prescription Drug User Fee Act, as amended, applicants are required to pay fees to the FDA for reviewing an NDA. These user fees, as well as the annualfees required for commercial manufacturing establishments and for approved products, can be substantial. The NDA review fee alone can exceed $2.3 million,subject to certain limited deferrals, waivers and reductions that may be available. Each NDA submitted to the FDA for approval is typically reviewed foradministrative completeness and reviewability within 45 to 60 days following submission of the application. If found complete, the FDA will "file" the NDA,thus triggering a full review of the application. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time ofsubmission. The FDA's established goal is to review 90% of NDA applications and original efficacy supplements given 'Priority' status within 6 months, and 90% ofapplications and original efficacy supplements given 'Standard' status within 10 months, whereupon a review decision is to be made. The FDA, however, maynot approve a drug within these established goals, and its review goals are subject to change from time to time. Further, the outcome of the review, even ifgenerally favorable, may not be an actual approval but rather an "action letter" that describes additional work that must be completed before the applicationcan be approved. Before approving an NDA, the FDA inspects the facilities at which the product is manufactured or facilities that are significantly involved in the productdevelopment and distribution process, and will not approve the product unless cGMP compliance is satisfactory. The FDA may deny approval of an NDA ifapplicable statutory or regulatory criteria are not satisfied, or may require additional testing or information, which can delay the approval process. FDAapproval of any application may include many delays or may never be granted. If a product is approved, the approval will impose limitations on theindicated uses for which the product may be marketed, may require that warning statements be included in the product labeling, may require that additionalstudies or trials be conducted following approval as a condition of the approval, may impose restrictions and conditions on product distribution, prescribingor dispensing in the form of a risk management plan, or impose other limitations. Once a product is approved, marketing the product for other indicated uses or making certain manufacturing or other changes requires FDA review andapproval of a supplement NDA or a new NDA, which may require additional clinical data and review fees. In addition, further post-marketing testing andsurveillance to monitor the safety or efficacy of a product may be required. Also, product approvals may be withdrawn if compliance with regulatorystandards is not maintained or if safety or manufacturing problems occur following initial marketing. In addition, new government requirements may beestablished that could delay or prevent regulatory approval of our product candidate under development. 505(b)(2) NDAs As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit anNDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA. Section 505(b)(2) was enacted as part of the Hatch-WaxmanAmendments and permits the filing of an NDA where at least some of the information required for approval comes from studies or trials not conducted by orfor the applicant. If the 505(b)(2) applicant can establish that reliance on FDA's previous findings of safety and effectiveness is scientifically appropriate, itmay eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additionalstudies or measurements, including clinical trials, to support the change from the approved reference, or "listed" drug. The FDA may then approve the newproduct candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the505(b)(2) applicant. To the extent that a Section 505(b)(2) NDA relies on clinical trials conducted for a previously approved drug product or the FDA's prior findings of safetyand effectiveness for a previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications in its Section 505(b)(2)application with respect to any patents for the previously approved product on which the applicant's application relies that are listed in the FDA's Publicationof Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the 'Orange Book'. Specifically, the applicant must certify foreach listed patent that, in relevant part, (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has notexpired, but will expire on a particular date and approval is not sought until after patent expiration; or (iv) the listed patent is invalid, unenforceable or willnot be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product's listed patent or that such patent is invalid or unenforceable isknown as a Paragraph IV certification. If the applicant does not challenge one or more listed patents through a Paragraph IV certification, the FDA will notapprove the Section 505(b)(2) NDA application until all the listed patents claiming the referenced product have expired. Further, the FDA will also notapprove, as applicable, a Section 505(b)(2) NDA application until any non-patent exclusivity, such as, for example, five-year exclusivity for obtainingapproval of a new chemical entity, three-year exclusivity for an approval based on new clinical trials, or pediatric exclusivity, listed in the Orange Book forthe referenced product, has expired. 39If the Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IVcertification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2)NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section 505(b)(2)applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certificationautomatically prevents the FDA from approving the Section 505(b)(2) NDA until the earliest to occur of 30 months beginning on the date the patent holderreceives notice, expiration of the patent, settlement of the lawsuit, or until a court deems the patent unenforceable, invalid or not infringed. Even if a patentinfringement claim is not brought within the 45-day period, a patent infringement claim may be brought under traditional patent law, but it does not invokethe 30-month stay. Moreover, in cases where a Section 505(b)(2) application containing a Paragraph IV certification is submitted after the fourth year of a previouslyapproved drug's five-year exclusivity period and the patent holder brings suit within 45 days of notice of certification, the 30-month period is automaticallyextended to prevent approval of the Section 505(b)(2) application until the date that is seven and one-half years after approval of the previously approvedreference product. The court also has the ability to shorten or lengthen either the 30 month or the seven and one-half year period if either party is found not tobe reasonably cooperating in expediting the litigation. In addition to patent protections applicable to a listed drug, a Section 505(b)(2) application may be subject to periods of statutory market exclusivityafforded to an approved new drug. Statutory market exclusivity provides the holder of an approved NDA limited protection from new competition in themarketplace for the innovation represented by its approved drug product, and precludes approval of certain 505(b)(2) applications for prescribed periods oftime. Exclusivity is available for new chemical entities, as well as for significant changes in already approved drug products, such as a new use. FDA mayrefuse to approve a Section 505(b)(2) application to the extent it is subject to the market exclusivity. Notwithstanding the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years, some pharmaceutical companies andothers have objected to the FDA's interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA's interpretationis successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) NDA that we submit. Post-approval requirements Any drug products for which we receive FDA approval will be subject to continuing regulation by the FDA. Certain requirements include, among otherthings, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information onan annual basis or more frequently for specific events, product sampling and distribution requirements, complying with certain electronic records andsignature requirements and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, amongothers, standards for direct-to-consumer advertising, prohibitions against promoting drugs for uses or patient populations that are not described in the drug'sapproved labeling, known as "off-label use," and other promotional activities, such as those considered to be false or misleading. Failure to comply with FDArequirements can have negative consequences, including the immediate discontinuation of noncomplying materials, adverse publicity, enforcement lettersfrom the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Such enforcement may also lead to scrutinyand enforcement by other government and regulatory bodies. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not encourage, market or promote such off-label uses. Asa result, "off-label promotion" has formed the basis for litigation under the Federal False Claims Act, violations of which are subject to significant civil finesand penalties. In addition, manufacturers of prescription products are required to disclose annually to the Center for Medicaid and Medicare any paymentsmade to physicians and teaching hospitals in the U.S. under the federal Physician Payment Sunshine Act. Reportable payments may be direct or indirect, incash or kind, for any reason, and are required to be disclosed even if the payments are not related to the approved product. Failure to fully disclose or not intime reporting could lead to penalties up to $1.15 million per year. The manufacturing of any of our products will be required to comply with applicable FDA manufacturing requirements contained in the FDA's cGMPregulations. The FDA's cGMP regulations require, among other things, quality control and quality assurance, as well as the corresponding maintenance ofcomprehensive records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are alsorequired to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. Theseentities are further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws.Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer or holder of an approvedNDA, as well as lead to potential market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured that qualitystandards can be met, and continuing oversight of manufacturing by the FDA under a "consent decree," which frequently includes the imposition of costs andcontinuing inspections over a period of many years, as well as possible withdrawal of the product from the market. In addition, changes to the manufacturingprocess generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications andadditional labeling claims, are also subject to further FDA review and approval. 40The FDA also may require post-marketing testing, or Phase IV testing, as well as risk minimization action plans and surveillance to monitor the effects ofan approved product or place conditions on an approval that could otherwise restrict the distribution or use of our products. Pediatric trials and exclusivity Even when not pursuing a pediatric indication, under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that areadequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosingand administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safetyand Innovation Act, or the FDASIA, in 2012, sponsors must also submit pediatric trial plans prior to the assessment data. Those plans must contain an outlineof the proposed pediatric trials the applicant plans to conduct, including trial objectives and design, any deferral or waiver requests, and other informationrequired by regulation. The applicant, the FDA, and the FDA's internal review committee must then review the information submitted, consult with eachother, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of theproduct for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requestsand requests for extension of deferrals are contained in the FDASIA. Separately, in the event the FDA makes a written request for pediatric data relating to a drug product, an NDA sponsor who submits such data may beentitled to pediatric exclusivity. Pediatric exclusivity is another type of non-patent marketing exclusivity in the U.S. and, if granted, provides for theattachment of an additional 6 months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphanexclusivity. Patent term restoration and extension A patent claiming a new drug product may be eligible for a limited patent term extension under the Drug Price Competition and Patent Term RestorationAct of 1984, commonly referred to as the "Hatch-Waxman Act," which permits a patent restoration of up to five years for patent term lost during productdevelopment and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and thesubmission date of an NDA, plus the time between the submission date of a NDA and the ultimate approval date. Patent term restoration cannot be used toextend the remaining term of a patent past a total of 14 years from the product's approval date. Only one patent applicable to an approved drug product iseligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that coversmultiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews andapproves the application for any patent term extension or restoration in consultation with the FDA. Since the active pharmaceutical ingredients of FMX101,FMX102, FMX103 and FDX104 are already known and marketed in tablet form, these products may not be eligible for the said patent term extension, ifapplicable. Orphan drug designation Orphan drug designation in the U.S. is designed to encourage sponsors to develop drugs intended for rare diseases or conditions. In the U.S., a rare diseaseor condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the U.S. or that affects more than 200,000 individuals in theU.S. and for which there is no reasonable expectation that the cost of developing and making available the drug for the disease or condition will be recoveredfrom sales of the drug in the U.S. Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the drug's marketing approval, ifgranted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market theproduct. A drug becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development, or OOPD, at the FDA basedon acceptable confidential requests made under the regulatory provisions. The drug must then go through the new drug approval process like any other drug.Orphan drug designations are decided solely by the OOPD staff, but the OOPD occasionally will request opinions from the Center for Drug Evaluation andResearch, especially when dealing with issues such as the appropriateness of the requested indication or the scientific rationale described by the sponsor. A sponsor may request orphan drug designation of a previously unapproved drug or new orphan indication for an already marketed drug. In addition, asponsor of a drug that is otherwise the same drug as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent drugfor the same rare disease or condition if it can present a plausible hypothesis that its drug may be clinically superior to the first drug. More than one sponsormay receive orphan drug designation for the same drug for the same rare disease or condition, but each sponsor seeking orphan drug designation must file acomplete request for designation. 41The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the drughas been designated. The FDA could approve a second application for the same drug for a different use or a second application for a clinically superiorversion of the drug for the same use. The FDA cannot, however, approve the same drug made by another manufacturer for the same indication during themarket exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities. Review and approval of drug products outside the U.S. In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales anddistribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by thecomparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies fromcountry to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials,product licensing, pricing and reimbursement vary greatly from country to country. Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized, decentralized or mutual recognitionprocedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. Thedecentralized procedure includes selecting one "reference member state," or RMS, and submitting to more than one member state at the same time. The RMSNational Competent Authority conducts a detailed review and prepares an assessment report, to which concerned member states provide comment. Themutual recognition procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketingauthorization may submit an application to the remaining member states post-initial approval. Within 90 days of receiving the applications and assessmentreport, each member state must decide whether to recognize the approval. Pharmaceutical coverage, pricing and reimbursement Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the U.S.and other markets, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability ofreimbursement from third-party payers. Third-party payers include government health administrative authorities, managed care providers, private healthinsurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process forsetting the price or reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on anapproved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, inaddition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of FMX101, in addition to the costs required to obtain the FDA approvals. Additionally, FMX101 may not be considered medically necessaryor cost-effective. A payer's decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequatethird-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in productdevelopment. In March 2010, the President of the U.S. signed one of the most significant healthcare reform measures in decades. The healthcare reform law substantiallychanges the way healthcare will be financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. Thecomprehensive $940 billion dollar overhaul is expected to extend coverage to approximately 36 million previously uninsured Americans. The healthcarereform law contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud andabuse, which will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment forperformance initiatives and improvements to the physician quality reporting system and feedback program. Additionally, the healthcare reform law: ·increases the minimum level of rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%; and ·imposes a non-deductible annual fee on pharmaceutical manufacturers or importers who sell "branded prescription drugs" to specified federalgovernment programs There have been proposed in Congress a number of legislative initiatives regarding healthcare, including possible repeal of the healthcare reform law. Atthis time, it remains unclear whether there will be any changes made to the healthcare reform law, whether to certain provisions or its entirety. 42In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may bemarketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies or trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the European Union provides options for its member states torestrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products forhuman use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls onthe profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, butmonitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result,increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exertcompetitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may notallow favorable reimbursement and pricing arrangements. Healthcare laws and regulations Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of drug products that are grantedmarketing approval. Arrangements with healthcare providers, third-party payers and other customers are subject to broadly applicable fraud and abuse andother healthcare laws and regulations. Such restrictions under applicable federal and state healthcare laws and regulations, include the following: ·the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving orproviding remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order orrecommendation of, any good or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare; ·the federal False Claims Act imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities forknowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statementto avoid, decrease or conceal an obligation to pay money to the federal government; ·the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme todefraud any healthcare benefit program or making false statements relating to healthcare matters; ·HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposesobligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiablehealth information; ·the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materiallyfalse statement in connection with the delivery of or payment for healthcare benefits, items or services; ·the federal transparency requirements under the Health Care Reform Law require manufacturers of drugs, devices and medical supplies to report to theDepartment of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals andphysician ownership and investment interests; and ·analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements andclaims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevantcompliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments tophysicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information insome circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Manufacturing, Supply and Production We do not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own manufacturingoperations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, active ingredients andfinished products for our preclinical research and clinical trials, including the Phase III clinical trials for FMX101, FMX103 and our additional productcandidates, as applicable. We have contractual relationships for the manufacture of clinical supplies of FMX101 and FMX103, and for commercial supplies ifthese products are approved. If FMX101, FMX103 or any of our other product candidates are approved by any regulatory agency, we intend to enter intoadditional agreements with one or more third-party contract manufacturers as secondary manufacturers for the commercial production of these products. We,and our contract manufacturers, are developing the validation processes, methods, tests and or controls suitable for commercial scale manufacturing of ourvarious product candidates and for defining their properties. Changes in manufacturing scale or the manufacturer may require changes to processes, methods,tests and or controls, which may take time to develop, validate and implement. 43Development stage and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that complywith the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal andexternal resources to manage our manufacturing contractors. The relevant manufacturers of our drug products for our current preclinical and clinical trialshave advised us that they are compliant with both Good Laboratory Practices, or GLP, and current Good Manufacturing Practices, or cGMP. Our product candidates, if approved, may not be producible in sufficient commercial quantities, in compliance with regulatory requirements or at anacceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture of anypharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the processes, methods and equipment are compliantwith cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and foreign regulatory authorities, and conduct extensive audits of vendors,contract laboratories and suppliers. We use, and we intend to continue to use, leading providers of manufacturing services to the global pharmaceutical industry, to scale-up and validate arobust manufacturing process to support commercialization and distribution of our products if approved by the FDA. Marketing, Sales and Distribution Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure. Extensive planning and market research hasbeen conducted on our current product portfolio. Additionally, continuous efforts are deployed to identify unmet needs in the dermatology market, assestheir commercial potential and advise on the prioritization of the development of our future product candidates accordingly. We have formed a U.S.subsidiary, Foamix Pharmaceuticals Inc., with five key executives to support our clinical development, regulatory affairs, CMC / drug development, andcommercialization efforts in the U.S. We are also evaluating the optimal price range for FMX101 and FMX103, that will reflect their benefits relative to alternative treatments while remainingaffordable to potential customers and reimbursable by governments and third-party payers. In the event that we receive regulatory approvals for FMX101 and FMX103 in markets outside of the U.S., we intend, where appropriate, to pursuecommercialization relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equippedto market or sell our products through their well-developed sales, marketing and distribution organizations in such countries. In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development, marketing anddistribution of any products we develop. Environmental, Health and Safety Matters We are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among otherthings, (i) the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; and (ii) chemical, air, water and groundcontamination, air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure to properlydispose of chemicals, waste materials and sewage. Our operations at our Rehovot research and development facility use chemicals and produce wastematerials and sewage. Our activities require permits from various governmental authorities including, local municipal authorities, the Ministry ofEnvironmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the Ministry of Health, local authorities and themunicipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations. These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail tocomply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation ofpermits and licenses necessary to continue our business activities. In addition, we may be required to pay damages or civil judgments in respect of third-partyclaims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture or dispose of),property damage or contribution claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs,regardless of comparative fault. We may be identified as a responsible party under such laws. Such developments could have a material adverse effect on ourbusiness, financial condition and results of operations. In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In the event of any changes or new lawsor regulations, we could be subject to new compliance measures or to penalties for activities which were previously permitted. For instance, Israeliregulations were promulgated in 2011 relating to the discharge of industrial sewage into the sewer system. These regulations establish new and potentiallysignificant fines for discharging forbidden or irregular sewage into the sewage system. 44The operations of our subcontractors and suppliers are also subject to various Israeli and foreign laws and regulations relating to environmental, healthand safety matters, and their failure to comply with such laws and regulations could have a material adverse effect on our business and reputation, result in aninterruption or delay in the development or manufacture of our product candidates, or increase the costs for the development or manufacture of our productcandidates. Legal Proceedings From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. Weare not currently involved in any legal proceedings. We may become involved in material legal proceedings in the future. 4.C.Organizational structure We were formed as a company in the State of Israel on January 19, 2003. Our corporate structure consists of Foamix Pharmaceuticals Ltd. and Foamix Pharmaceuticals Inc., our wholly-owned U.S. subsidiary, which wasincorporated on May 6, 2014, under the laws of the State of Delaware, and which is intended to serve as our marketing and sales arm in the U.S. 4.D.Property, plants and equipment Our facilities in Israel, which house our headquarters and our research and developments laboratories, are located at two sites in the Weizmann SciencePark in Rehovot, Israel. Under a Lease Agreement with Gav Yam Lands Ltd., we are leasing approximately 2,199 square meters until December 31, 2020.Under a Lease Agreement with Shrada Ltd. we are leasing approximately 550 square meters until February 28, 2017. Our executive offices in the U.S. arelocated in Bridgewater, New Jersey. The lease agreement was signed in September 2014, expires on August 31, 2017 and consists of approximately 770square meters of space. We believe that our current office space in Israel is sufficient to meet our anticipated needs for the foreseeable future and is suitable forthe conduct of our business. We may need to secure larger office space to support the internal growth of our U.S. organization. ITEM 4A.UNRESOLVED STAFF COMMENTS None. 45ITEM 5.OPERATING AND FINANCIAL REVIEW AND PROSPECTS The following discussion and analysis of our financial condition and results of operations should be read in conjunction with "Item 3.A. KeyInformation—Selected Financial Data" above and our financial statements and related notes that appear elsewhere in this annual report. In addition tohistorical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual resultscould differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include thosediscussed below and elsewhere in this annual report, particularly in the sections titled "Risk Factors" and "Special Note Regarding Forward-LookingStatements." 5.A.Results of Operations The following table summarizes our results of operations for the years ended December 31, 2016, 2015 and 2014: Year ended December 31, 2016 2015 2014 (in thousands of US$) Revenues $5,527 $849 $5,414 Cost of revenues(1) 59 70 527 Gross profit 5,468 779 4,887 Operating expenses Research and development(1) 25,897 10,680 3,557 Selling, general and administrative(1) 9,221 7,029 2,964 Total operating expenses 35,118 17,709 6,521 Operating loss 29,650 16,930 1,634 Finance expenses (income), net (701) (452) 9,844 Income tax 387 39 6 Net loss $29,336 $16,517 $11,484 (1)Includes share-based compensation expenses as follows: Year ended December 31, 2016 2015 2014 (in thousands of US$) Cost of revenues $3 $2 $15 Research and development 1,135 588 80 Selling, general and administrative 1,774 1,187 102 Total share-based compensation $2,912 $1,777 $197 Revenues To date, we have not generated any revenues from sales of FMX101 or any of our other product candidates. We do not expect to commercially launchFMX101 or other product candidates or generate any revenues from sales of any of our product candidates before 2018, after completing their developmentand clinical testing and obtaining approvals for their marketing in the U.S. Our ability to generate revenues from sales will depend on the successfulcommercialization of FMX101 and our other product candidates. As of December 31, 2016, we had generated cumulative revenues of approximately $24.5 million under development and license agreements, of whichapproximately $18.2 million were development service payments, approximately $3.1 million were contingent payments and $3.2 million were royaltypayments. Our total revenues for the years ended December 31, 2016, 2015 and 2014 were $5.5 million, $849,000 and $5.4 million, respectively. We maybecome entitled to additional contingent payments, subject to achievement of the applicable clinical results by our licensees. In light of the current phase ofdevelopment under these agreements, we do not expect to receive significant payments in the near term, if at all. We are also entitled to additional royaltiesfrom net sales or net profits generated by other products to be developed under these agreements, if they are successfully commercialized. In thosedevelopment and license agreements in which royalties are based on net sales, their rate ranges from 3% to 8.5%, and in the agreement in which royalties arebased on net profits, their rate is 6%. Pursuant to a collaboration agreement with Bayer HealthCare AG, we are entitled to receive royalty payments with respect to Finacea®, a prescriptionfoam product that we developed in collaboration with Bayer. As of December 31, 2016, we were entitled to receive royalty payments in an amount of $3.2million, and an additional contingent payment in the amount of $2.5 million for the achievement of certain revenue targets. 46Cost of revenues Cost of revenues includes costs and expenses we incur in supplying services to our licensees under our development and license agreements with them.These services include design and development of product prototypes, performance of in-vitro studies and other lab tests, compiling project reports andrecommendations and carrying out other tasks related to such efforts. Our services to licensees do not include development work beyond the prototype stage,clinical trials or pursuit of regulatory approval, which are the responsibility and at the expense of each licensee. Accordingly, our cost of revenues includes payroll and other payments on behalf of the employees and consultants assigned to these projects; laboratoryservices related to the studies we perform on behalf of the licensees; rent and office maintenance costs related to the use of our facilities and infrastructure,utilities and other overhead services in connection with the projects performed for the licensees. Our total cost of revenues for the twelve months ended December 31, 2016, 2015 and 2014 were $59,000, $70,000 and $527,000, respectively. We do notexpect substantial changes in cost of revenue unless and until we obtain regulatory approval for our lead product candidates and begin serial production ofsuch products, whether internally or through third party manufacturers, at which point we expect our cost of revenues to grow along with the growth of oursales and inventory needs. Cost of revenues as a percentage of revenues for the twelve months ended December 31, 2016, 2015 and 2014 were 1.1%, 8.2%, and 9.7%, respectively.The decrease in cost of revenues is primarily due to the decrease in new development projects and the increase in royalty and contingent payments which donot bear related cost of revenue. Operating Expenses Research and development expenses Research and development activities are, and will continue to be, central to our business. Product candidates in later stages of clinical developmentgenerally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stageclinical trials. We expect research and development costs to increase significantly for the foreseeable future as our pipeline products progress into clinicaltrials. However, we do not believe that it is possible at this time to accurately project total program-specific expenses to reach commercialization. There arenumerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatoryrequirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial andregulatory factors beyond our control will affect our clinical development programs and plans. Our research and development expenses relate primarily to the development of FMX101. From 2007 until December 31, 2016, we cumulatively spentapproximately $47.1 million on research and development of FMX101 and our other product candidates. Our total research and development expenses forthe years ended December 31, 2016, 2015 and 2014 were approximately $25.9, $10.7 and $3.6 million, respectively. We charge all research and developmentexpenses to operations as they are incurred. We expect research and development expenses to increase in the near term due to the ongoing and beginning ofPhase III clinical trials for FMX101 and FMX103. The successful development of FMX101, FMX103 and additional product candidates is highly uncertain. As such, at this time, we cannot reasonablyestimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of our technology foradditional indications. This uncertainty is due to numerous risks and variables associated with developing products, including the uncertainty of: ·the scope, rate of progress and expense of our research and development activities; ·preclinical results; ·clinical trial results; ·the terms and timing of regulatory approvals; ·our ability to file, prosecute, obtain, maintain, defend and enforce patents and other intellectual property rights and the expense of filing, prosecuting,obtaining, maintaining, defending and enforcing patents and other intellectual property rights; ·the ability to market, commercialize and achieve market acceptance for FMX101 or any other product candidate that we may develop in the future;and ·our ability to identify, evaluate, acquire or in-license intellectual property, if needed, to facilitate the commercialization of our products andtechnologies. A change in the outcome of any of these variables with respect to the development of FMX101, FMX103 or our other product candidates could result in asignificant change in the costs and timing associated with their development. For example, if the FDA or foreign regulatory authority were to require us toconduct preclinical studies and clinical trials beyond those which we currently anticipate for the completion of clinical development of our productcandidates, or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financialresources and time on the completion of the clinical development. 47Research and development expenses consist primarily of: ·employee-related expenses, including salaries, benefits and related expenses, including share based compensation expenses; ·expenses incurred under agreements with third parties, including subcontractors, suppliers and consultants that conduct regulatory activities, clinicaltrials and preclinical studies; ·expenses incurred to acquire, develop and manufacture clinical trial materials; ·facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and otheroperating costs; and ·costs associated with preclinical and clinical activities and regulatory operations. We have managed to finance our research and development operations and expenses without the aid of government grants, other than a loan in theamount of approximately $450,000 received from the Israel-U.S. Bi-national Industrial Research and Development Foundation, or BIRD, in 2008.Accordingly, we are not subject to the provisions of the Law for Encouragement of Research and Development in Industry, 5744-1984, nor to any directivesissued by the Israeli Office of the Chief Scientist. Selling, general and administrative expenses Our selling, general and administrative expenses consist principally of: ·employee-related expenses, including salaries, benefits and related expenses, including share based compensation expenses; ·costs associated with market research and business development activities in preparation for future marketing and sales, including activities intendedto select the most promising product candidates for further development and commercialization; ·legal and professional fees for auditors and other consulting expenses not related to research and development activities or to market research orbusiness development activities; ·cost of offices, communication and office expenses; ·information technology expenses; ·depreciation of tangible fixed assets related to our general and administrative activities or to our market research and business development activities;and ·costs associated with filing, prosecuting, obtaining and maintaining patents and other intellectual property. As part of our growth strategy, we have begun building up our dedicated U.S. marketing and business development team and infrastructure, and we intendto further increase such U.S. infrastructure, as well as expand our marketing effort to new markets. We therefore expect selling and marketing expenses toincrease in absolute terms as a percentage of our revenues. Our total selling, general and administrative expenses for the years ended December 31, 2016,2015 and 2014 were approximately $9.2, $7.0 and $3.0 million, respectively. Financial income Financial income consists primarily of gains from interest earned from our bank deposits and financial income on our marketable securities. Taxes on income During 2014 and 2015 the standard corporate tax rate in Israel was 26.5%, and during 2016 it was 25%. We have yet to generate taxable income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totalingapproximately $50.1 million as of December 31, 2016. We anticipate that we will be able to carry forward these tax losses to future tax years. Accordingly, wedo not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We provided a full valuationallowance with respect to the deferred tax assets related to these carry forward losses. During 2016, 2015 and 2014 we incurred tax expenses of $387,000, $39,000 and $6,000, respectively, in our US subsidiary, Foamix Pharmaceuticals Inc. 48Comparison of the Year ended December 31, 2016 to the Year Ended December 31, 2015 Revenues Our total revenues increased by $4.7 million, or 553%, from $849,000 in the year ended December 31, 2015 to $5.5 million in the year ended December31, 2016. The increase is mainly due to the increase of $2.7 million in royalty payments from Bayer HealthCare AG for the sales of Finacea® Foam, andadditional contingent payments totaling $2.5 million, due to Bayer's achievement of certain sale targets during 2016. Cost of revenues Our cost of revenues for the years ended December 31, 2016 and 2015 were $59,000 and $70,000, respectively. The $11,000 decrease in cost of revenuesresulted primarily from a decrease in the development projects. Cost of revenues as a percentage of revenues for the years ended December 31, 2016 and 2015was 1.1% and 8.2%, respectively. The decrease in the cost of revenues as a percentage of revenues was primarily due to the increase in royalty and contingentpayments, to which no cost of revenue is related. Research and development expenses Our research and development expenses for the year ended December 31, 2016 were $25.9 million, representing an increase of $15.2 million, or 142%,compared to $10.7 million for the year ended December 31, 2015. The increase in research and development expenses resulted primarily from an increase of$12.8 million in costs relating to the FMX101 and FMX103 clinical trials and an increase of $2.2 million in payroll and payroll related expenses due to anincrease in the number of R&D employees. Selling, general and administrative expenses Our general and administrative expenses for the year ended December 31, 2016 were $9.2 million, representing an increase of $2.2 million, or 31%, comparedto $7.0 million for the year ended December 31, 2015. The increase in selling, general and administrative expenses resulted primarily from an increase of $1.3million in payroll and other payroll-related expenses mainly due to an increase in headcount; an increase of $417,000 in market research expenses; anincrease of $225,000 in travel expenses; and an increase of $201,000 in expenses related to the Company's board of directors. Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2016, was $29.6 million, compared to an operating loss of $16.9 millionfor the year ended December 31, 2015, an increase of $12.7 million, or 75%. Finance income In the year ended December 31, 2016, our financial income included mostly gains from marketable securities and interest earned on our bank deposits,partially offset by expenses on the loan from the BIRD foundation fully repaid during the second quarter of 2016. In the year ended December 31, 2015 ourfinancial income included mostly gains from marketable securities and interest earned on our bank deposits. The finance expenses (income) by cash and non-cash components are as follows: Year ended December 31, 2016 2015 (in thousands of US$) Other expenses $17 $23 Finance expenses on BIRD loan 243 * Total expenses 260 23 Less: Interest on bank deposits (536) (289)Gain from marketable securities, net (401) (180)Non-cash foreign exchange profit, net (24) (6)Total income (961) (475)Finance income, net $(701) $(452) * Less than $1,000 Taxes on income During 2015 and 2016, we have not generated taxable income in Israel. However, we had incurred tax expenses in our US subsidiary, FoamixPharmaceuticals, Inc, in the amount of $39,000 and $387,000 for the years 2015 and 2016 respectively. Net Loss As a result of the foregoing our loss for the year ended December 31, 2016 was $29.3 million, compared to $16.5 million for the year ended December 31,2015, an increase of $12.8 million, or 78%. 49Comparison of the Year ended December 31, 2015 to the Year Ended December 31, 2014 Revenues Our total revenues decreased by $4.6 million, or 84.3%, from $5.4 million in the year ended December 31, 2014, to $849,000 in the year ended December 31,2015, due to completion of certain development projects for our licensees that generated development fees during 2014, and resulted in products that hadbegun clinical trial phases or commercialization at the end of 2015, and thus did not generate substantial fees during that year. Cost of revenues Our cost of revenues for each of the years ended December 31, 2015 and 2014 consisted of the following items: Year ended December 31, 2015 2014 Cost of revenues (in thousands of US$) Payroll and related expenses $27 $385 Testing, professional and laboratory services 4 72 Rent and office maintenance 31 37 Other 8 33 Total $70 $527 Our cost of revenues for the years ended December 31, 2015 and 2014 were $70,000 and $527,000, respectively. The $457,000 decrease in cost ofrevenues resulted primarily from a decrease in the development projects. Cost of revenues as a percentage of revenues for the years ended December 31, 2015and 2014 were 8.2% and 9.7%, respectively. The decrease in cost of revenues as a percentage of revenues resulted primarily from the fact that royaltypayments received in 2015 had no cost related to them. Research and development expenses Our research and development expenses for the year ended December 31, 2015 were $10.7 million, representing an increase of $7.1 million, or 100%,compared to $3.6 million for the year ended December 31, 2014. The increase is primarily due to an increase of $4.0 million in costs relating to thepreparation and ongoing FMX101 and FMX103 clinical trials and expenses with respect to the FDX104 clinical trial, an increase of $649,000 in advisoryand consulting expenses and an increase of $2.3 million in payroll and related expenses due to an increase in the number of R&D employees. Selling, general and administrative expenses Our general and administrative expenses totaled $7.0 million for the year ended December 31, 2015, an increase of $4.1 million, or 37.1%, compared to$3.0 million for the year ended December 31, 2014. The increase resulted primarily from an increase of $2.2 million in payroll and related expenses, anincrease of $196,000 in investor relations expenses, an increase of $529,000 in expenses related to directors' compensation, an increase of $255,000 in rentand office maintenance and an increase of $195,000 in expenses related to advisors and other professional fees. Operating loss As a result of the foregoing, our operating loss for the year ended December 31, 2015 was $16.9 million, as compared to an operating loss of $1.6 millionfor the year ended December 31, 2014, an increase of $15.3 million, or 836%. Finance expenses Finance expenses, net, includes cash and non-cash components. The cash component of finance expenses, net, consists of bank fees and realized gain orloss on marketable securities. The non-cash components of our finance expenses, net, consist of (i) finance expenses on convertible loans and warrants, (ii)linkage of the BIRD foundation loan to the U.S. CPI, and (iii) gain or loss from foreign currency exchange differentials. Our finance expenses by cash andnon-cash components are as follows: Year ended December 31, 2015 2014 (in thousands of US$) Non-cash—finance expenses on convertible loans and warrants $- $9,915 Other expenses 23 15 Total expenses 23 9,930 Less: Interest on bank deposits (289) - Gain from sale of marketable securities (180) (11)Other income - (28)Non-cash foreign exchange profit, net (6) (47)Finance expenses, net $(452) $9,844 50Finance expenses, net, decreased by $10.3 million, or 104.6%, from $9.8 million in the year ended December 31, 2014, to $(452,000) (meaning a positivefinancial income of $452,000) in the year ended December 31, 2015. The decrease was primarily due to the fact that in 2014 we had significant non-cashfinance expenses on convertible loans and warrants, that were converted into shares during that year and were no longer outstanding in 2015, while in 2015we had financial income from investment securities and interest earned on our bank deposits following our initial public offering in the third quarter of 2014. Taxes on income During 2014 and 2015, we have not generated taxable income in Israel. However, during 2014 we incurred a tax expense in the amount of $6,000 in ourUS subsidiary, Foamix Pharmaceuticals, Inc., and in 2015 we incurred a tax expense of $39,000. We do not foresee any material tax liabilities, in Israel or theUS, in the near future. Net Loss As a result of the foregoing, our loss for the year ended December 31, 2015 was $16.5 million, compared to $11.5 million for the year ended December 31,2014, an increase of $5.0 million, or 43.8%. The increase in net loss is due primarily to the decrease in our revenues in 2015, which was compounded by theincrease in our research and development expenses and selling, general and administrative expenses and partially offset by a decrease in our net financeexpenses in such year compared to 2014, as described above. For information regarding the impact of foreign currency fluctuations on the company see "Item 11 – Quantitative and Qualitative Disclosures AboutMarket Risk –– Foreign Currency Exchange Risk." 5.B.Liquidity and capital resources Liquidity Since our inception, we have incurred losses from operations and negative cash flows from our operations. For the twelve months ended December 31,2016, we incurred a net loss of $29.3 million, which included $27.4 million used for operating activity. For the year ended December 31, 2015 we incurred anet loss of $16.5 million, which included $12.5 million used for operating activity. As of December 31, 2016 and December 31, 2015, we had a workingcapital surplus of $111.7 million and $53.1 million, respectively, and an accumulated deficit of $75.6 million and $46.2 million, respectively. Our principalsource of liquidity as of December 31, 2016 consisted of cash, cash equivalents, restricted cash, bank deposits and marketable securities of $131.0 million. In the second quarter of 2014, we completed a private placement of preferred A shares and warrants with a group of new investors and several of ourexisting shareholders in two phases, on May 13, 2014 and June 3, 2014, raising a total of $8.2 million, net of issuance costs, in consideration of 1,036,431preferred shares and 1,061,469 warrants to purchase preferred shares. In September 2014, we completed our initial public offering in which we sold 6,700,000 ordinary shares for $6.00 per share raising total net proceeds,after expenses, of approximately $35.7 million. In October 2014 the underwriters exercised their option to purchase an additional 968,200 ordinary shares ata price of $6.00 per share. The proceeds from the exercise of the option, net of underwriters' commission, were approximately $5.4 million, bringing the totalnet proceeds from the initial public offering, after expenses, to approximately $41.1 million. In April 2015, we completed a follow-on offering in which we sold 7,419,353 ordinary shares, including the exercise of underwrites option, for $9.30 pershare, raising total net proceeds, after expenses, of approximately $64.2 million. On October 21, 2015, we filed with the Securities and Exchange Commission (the SEC) a "shelf" registration statement on a Form F-3 for the registrationof our ordinary shares that we may, from time to time, offer and sell in one or more offerings with an aggregate offering price of up to $150 million. OnSeptember 12, 2016 we filed with the SEC an amendment to the shelf registration statement on a Form F-3/A, which became effective on September 23, 2016. On September 30, 2016, we completed another follow-on offering under our amended shelf registration statement, in which we sold 5,700,000 ordinaryshares for $9.50 per share, raising net proceeds, after expenses and underwriter commissions, of approximately $50.4 million. An additional 300,000 ordinaryshares were sold by certain selling shareholders. In October 2016 the underwriters partially exercised the option granted to them in the underwritingagreement and purchased an additional 411,959 ordinary shares at a price of $9.50 per share. The proceeds from the exercise of the option, net of expensesand underwriter commissions, were approximately $3.7 million, bringing the total net proceeds from the offering to approximately $54.1 million. 51We anticipate that we will be able to fund our operating expenses and capital expenditure requirements throughout the Phase III clinical trials and NDAfilings for our lead product candidates, FMX101 and FMX103, which we expect to complete by 2018 and 2019, respectively. Foamix Pharmaceuticals Inc., our wholly-owned subsidiary, was incorporated on May 6, 2014 under the laws of the State of Delaware, with the intent toserve as our marketing and sales arm in the U.S. As a result, we do not expect our subsidiary to distribute any dividends, or extend any loans or advances to usin the foreseeable future. Capital resources Overview To date, we have financed our operations through private and public placements of our ordinary shares, convertible loans and through fees, costreimbursements and royalties received from our licensees. From inception through December 31, 2016, we have received net cash proceeds of approximately $187.6 million from the sale of ordinary shares,preferred shares, exercise of options and warrants and from convertible loans. Cash flows The following table summarizes our statement of cash flows for the years ended December 31, 2016, December 31, 2015 and December 31, 2014: Year ended December 31, 2016 2015 2014 (in thousands of US$) Net cash used in: Operating activities $(27,370) $(12,498) $(714)Investing activities (15,018) (78,516) (7,349)Financing activities $55,031 $66,801 $49,339 Net cash used in operating activities The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and measurements and changes in components ofworking capital. Adjustments to net income for non-cash items mainly include depreciation and amortization, finance expenses on convertible loans andwarrants and share-based compensation. Net cash used in operating activities was $27.4 million in the twelve months ended December 31, 2016, compared to $12.5 of net cash used in operatingactivities in the twelve months ended December 31, 2015 and compared to $714,000 of net cash used in operating activities in the twelve months endedDecember 31, 2014. The increase was attributable primarily to the increase in company activity mostly related to clinical trials and payroll expenses. Net cash used in investing activities The use of cash in investing activities has been primarily related to purchase of marketable securities and investment in bank deposits. Net cash used ininvesting activities was $15.0 million in the twelve months ended December 31, 2016, compared to $78.5 million in the twelve months ended December 31,2015 and compared to $7.3 million in the twelve months ended December 31, 2014. The decrease in investing activities between 2016 and 2015, wasattributable primarily to increase in proceeds from sale and maturity of marketable securities and bank deposits, and the decrease in cash invested comparedto 2015. The increase in investing activities between 2015 and 2014, was attributable primarily to investment of the cash raised in our 2015 follow-onoffering, in bank deposits and marketable securities. Net cash provided by financing activities Net cash provided by financing activities was $55.0 million in the twelve months ended December 31, 2016, a decrease of $11.8 million from $66.8million in the twelve months ended December 31, 2015. The decrease was attributable primarily to a larger amount of capital raised in the 2015 financinground compared to the 2016 financing round. Net cash provided by financing activities was $66.8 million in the twelve months ended December 31, 2015, an increase of $17.5 million from $49.3million in the twelve months ended December 31, 2014. The increase was attributable primarily to our follow-on offering in April 2015 and the exercise ofwarrants and options. 52Cash and funding sources The table below summarizes our main sources of financing for the years ended December 31, 2016 and 2015: Proceeds from ourpublic offerings(1) Proceeds fromissuance of ordinaryshares(1) Paymentsfrom licensees Total (in thousands of US$) Year ended December 31, 2016 $54,132 $1,407 $2,575 $58,114 Year ended December 31, 2015 $64,202 $2,629 $1,063 $67,894 Year ended December 31, 2014 $41,092 $8,157(2) $4,052 $53,301 (1)Net of issuance costs.(2)Issuance of preferred shares converted to ordinary shares. Our sources of financing in the year ended December 31, 2016 totaled $58.1 million and consisted primarily of $54.1 million of net proceeds from our2016 follow-on public offering. Our sources of financing in the year ended December 31, 2015 totaled $67.9 million and consisted primarily of $64.2 million proceeds from our 2015follow-on public offering. We have no ongoing material financial commitments (such as lines of credit) that may affect our liquidity over the next five years. Funding requirements We believe, based on our current business plan, that our existing cash, cash equivalents and marketable securities will enable us to fund our operatingexpenses and capital expenditure requirements throughout the Phase III clinical trials for our lead product candidate, FMX101, which we expect to completeby 2017. The full development and NDA submissions for FMX103 and any future pipeline products will require us to raise additional funds. We have basedthis estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our present and future funding requirements will depend on many factors, including, among other things: ·the progress, timing and completion of preclinical testing and clinical trials for FMX101, FMX103 or any future pipeline product; ·selling, marketing and patent-related activities undertaken in connection with the anticipated commercialization of FMX101 and any other productcandidates and costs involved in the development of an effective sales and marketing organization; ·the time and costs involved in obtaining regulatory approval for FMX101 and our other pipeline products and any delays we may encounter as a resultof evolving regulatory requirements or adverse results with respect to any of these products; ·the number of potential new products we identify and decide to develop; ·the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims orinfringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectualproperty rights; and ·the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of FMX101 and any other pipelineproduct that is commercialized. For more information as to the risks associated with our future funding needs, see "Item 3.D. Risk Factors—We will require substantial additionalfinancing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduceor terminate our product development, other operations or commercialization efforts." Our capital expenditures for 2016, 2015 and 2014 amounted to $424,000, $500,000, and $219,000, respectively. During 2016, these expenditures wereprimarily related to the purchase of laboratory equipment, computers, software and leasehold improvements. 5.C.Research and Development, Patents and Licenses, etc. See "Item 4.B. Business Overview—Who we are—Development and license agreements" and "Item 4.B. Business Overview—Who we are—IntellectualProperty." 5.D.Trend Information. We are currently in the development stage and we expect to remain in that stage for the upcoming year, and therefore trends relating to production, sales,inventory, backlog and selling prices are not applicable. 535.E.Off-Balance Sheet Arrangements We currently do not have any, and during the periods presented we did not have any, off-balance sheet arrangements. 5.FContractual Obligations Our significant non-cancelable contractual obligations as of December 31, 2016 are summarized in the following table. Payments due by period Total less than 1 year 1-3 years (in thousands of US$) Operating lease obligations(1) $2,164 $498 $1,666 Bank borrowings(2) $20 $20 - ___________________________________________(1)Operating lease obligations consist of lease of the Company's facilities.(2)Current maturities of long term bank borrowings ITEM 6.DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 6.A.Directors and Senior Management The following table sets forth information relating to our executive officers and directors as of December 31, 2016. Unless otherwise stated, the address forour directors and executive officers is c/o Foamix Pharmaceuticals Ltd., 2 Holzman St., Weizmann Science Park, Rehovot 7670402, Israel. NameAgePositionExecutive Officers Dov Tamarkin, Ph.D.61Chief Executive Officer and DirectorMeir Eini62Chief Innovation OfficerDavid Domzalski50President, Foamix Pharmaceuticals Inc. (U.S. Subsidiary)Ilan Hadar, M.B.A.47Chief Financial OfficerYohan Hazot34Chief Technology OfficerDavid Schuz62Executive Vice President, Intellectual PropertyMitchell Shirvan, Ph.D., M.B.A.63Senior Vice President, Research and DevelopmentAlvin Howard62Vice President, Regulatory Affairs (U.S. Subsidiary)Herman Ellman, M.D.69Vice President, Clinical Affairs (U.S. Subsidiary)Russell Elliott, D.Phil.51VP Drug Development (U.S. Subsidiary)Iain A. Stuart, Ph.D.44Vice President, Clinical Development (U.S. Subsidiary)Non-Employee Directors Stanley Hirsch, D.Phil.58Director, Chairman of the Board of DirectorsRex Bright76Director, Chairman of the Compensation CommitteeDarrell Rigel, M.D.66DirectorStanley Stern59Director, Chairman of the Audit CommitteeAnna Kazanchyan, Ph.D.49DirectorAaron Schwartz, Ph.D.75DirectorDalia Megiddo, Ph.D., M.B.A.64Director Our executive officers Dov Tamarkin, Ph.D. has been serving as our Chief Executive Officer and as our director since January 2003. Prior to that, Dr. Tamarkin served as VicePresident of R&D at Portman Pharmaceuticals, Inc., a biotech research and development company and as Senior R&D Manager at Teva PharmaceuticalIndustries Ltd., a public Israeli pharmaceutical company. Dr. Tamarkin holds a Ph.D. in chemistry from The Hebrew University of Jerusalem. Meir Eini served as chairman of our board of directors from January 2003 through May 2016. Mr. Eini simultaneously served as our Chief OperationsOfficer from January 2003, and since 2014 he has been serving as the Company's Chief Innovation Officer. Since stepping down from his positon as chairmanof the board, Mr. Eini continues to serves as a non-voting observer to the board, a capacity in which he is entitled to attend meetings and receive all noticesand other correspondence and communications sent by us to the directors. Mr. Eini has 27 years of experience in healthcare and marketing and is anexperienced entrepreneur. Between 2000 and 2003, Mr. Eini founded and served as the Chief Executive Officer of Flexiprobe Ltd., the developer of a medicaldevice for women's health. Prior to that, Mr. Eini was the Founder and President of Clilco Ltd., a company engaged in the development andcommercialization of non-prescription pharmaceuticals, and was the Founder of Thixo Ltd., an oilgel food technology company. 54David Domzalski has been serving as the President of our U.S. subsidiary, Foamix Pharmaceuticals, Inc., since April 2014. Mr. Domzalski has 24 years ofindustrial experience, previously holding positions as Vice President Sales and Marketing at LEO Pharma Inc. from 2009 to 2013, Senior Vice President andGeneral Manager at Azur Pharma from 2008 to 2009, and Vice President Sales and Marketing at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds aB.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania. Ilan Hadar has been serving as our Chief Financial Officer since February 2014. Mr. Hadar has extensive experience in executive financial positions,previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager, Accounting and Reporting at theIsraeli subsidiary of HP from 2007 to 2011, and prior to that as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a B.A. in businessadministration and economics and an MBA from The Hebrew University of Jerusalem. Yohan Hazot has been serving as our Chief Technology Officer since December 2014. Mr. Hazot has been with the Company since April 2007, and hasheld several positions in the field of drug development and intellectual property, with his previous position being a Director of Pharmaceutical Development.Mr. Hazot holds an MSc in Biochemistry & Biotechnology from the National Institute of Applied Sciences, Lyon, France and is the inventor of severalpatents in the field of Pharmaceutical Chemistry. David Schuz has been serving as our Executive Vice President since 2010 and as our Senior Vice President for intellectual property since 2006. Mr. Schuzhas 22 years of experience in the field of intellectual property in relation to the pharmaceuticals and biotechnology industries, previously holding variousintellectual property and legal positions at Biotechnology General Israel Ltd. and Savient Pharmaceuticals, Inc. between 1996 and 2006, including VicePresident from 2003. Mr. Schuz holds an LL.M. from the London School Economics; a Certificate in Patent Law, Queen Mary London University; an M. Phil.(Biochemistry), and a Diploma of Pharmacology, both from Cambridge University; and a B.Sc. Hons. (Chemistry) from Manchester University. Mitchell Shirvan, Ph.D. has been serving as our Senior Vice President of Research and Development since March 2014. Dr. Shirvan has over 21 years ofexperience in the pharmaceuticals and biotechnology industry, previously holding positions of Chief Executive Officer at Macrocure Ltd. from 2008 to 2012and as Senior Director, Strategic Business Planning and Senior Manager, Research and Development at Teva Pharmaceutical Industries between 1992 and2008. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jerusalem, and an MBA from the University of Bradford. Alvin Howard has been serving as Vice President of Regulatory Affairs of our U.S. subsidiary, Foamix Pharmaceuticals, Inc., since April 2014. Mr.Howard has over 31 years of industry experience, previously holding positions as Senior Vice President of Regulatory Affairs in Warner Chilcott from 2005to 2013, Vice President of Regulatory Affairs at Roberts Pharmaceuticals from 1998 to 2000 and various positions at Solvay Pharmaceuticals from 1990 to1998. Mr. Howard holds a B.Sc. in chemistry from Stillman College, Tuscaloosa, Alabama. Herman Ellman, M.D. has been serving as Vice President of Clinical Affairs of our U.S. subsidiary, Foamix Pharmaceuticals, Inc., since April 2014. Dr.Ellman has over 26 years of experience in the pharmaceutical industry, previously holding positions as Senior Vice President for Clinical Development atWarner Chilcott from 2000 to 2013 and Medical Director at Berlex Laboratories from 1995 to 2000. Dr. Ellman holds a M.D. from the State University ofNew York, Downstate Medical Center and Boards in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. Russell Elliott, D.Phil. has served as Vice President of Drug Development of our U.S. subsidiary, Foamix Pharmaceuticals, Inc. since May 2016. Dr. Elliotthas over 25 years of experience in the pharmaceutical industry, previously holding the position of Vice President Product Development at Stiefel. Prior tothis, Dr. Elliott served as Vice President and Head of Center of Excellence for topical formulations at GSK. Dr. Elliott holds a D. Phil from the OxfordUniversity in the U.K., Iain Stuart, Ph.D. has served as Vice President of Clinical Development of our U.S. subsidiary, Foamix Pharmaceuticals, Inc. since October 2016. Dr.Stuart has over 18 years of clinical development scientific affairs experience in multiple therapeutic classes with the last 8 years being focused exclusively indermatology. Prior to joining Foamix, Dr. Stuart served as Vice President of Medical Strategy and Scientific Affairs at LEO Pharma. Prior to this, Dr. Stuartserved as Director, Clinical Operations – The Americas, also at LEO Pharma. Dr. Stuart holds a Ph.D. from Glasgow Caledonian University in Scotland. Our directors Stanley Hirsch, D.Phil. has been serving as our director since February 2005 and as chairman of the board since May 2016. Dr. Hirsch has 30 years ofexperience in executive positions, including director of business development for a privately held group of healthcare companies. He has also served asgeneral manager of two diagnostics development companies. Dr. Hirsch has been CEO at FuturaGene Ltd., and its predecessor company CBD TechnologiesLtd., since 1989, and has also held the position of General Manager of Portman Pharmaceutical Industries. Since the acquisition of FuturaGene Plc by SuzanoPulp and Paper, a major Brazilian industrial public corporation in July 2010, he also holds the equivalent position of a vice president at Suzano, reporting tothe CEO at Suzano. Dr. Hirsch holds a D. Phil in Cell Biology and Immunology from Oxford University, England. 55Rex Bright has been serving as our director since our initial public offering that was completed in September 2014. Mr. Bright has held CEO positions inthe health care industry for the past 21 years. Mr. Bright was the co-founder and CEO of SkinMedica, a specialty pharmaceutical business that was lateracquired by Allergan. Mr. Bright has worked in executive positions for Johnson & Johnson and GlaxoSmithKline. Mr. Bright holds a B.A. in BusinessAdministration and Marketing from Drury College, Springfield, Missouri. Aaron Schwartz, Ph.D. has been serving as our director since May, 2015. Dr. Schwartz served in a number of positions at Teva Pharmaceutical IndustriesLtd. from 1975 through 2011. After serving 7 years as the head of the pharmaceutical division of Teva in Israel, Dr. Schwartz created the Copaxone divisionof Teva in 1992 and led it for 9 years. His most recent position was Vice President, Head of Teva Innovative Ventures - TIV, which he held from 2008 to2011. Dr. Schwartz is currently chairman of the board for several life science companies. Dr. Schwartz received a Ph.D. in organic chemistry from theWeizmann Institute, an M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Herecently received a second Ph.D. from the Hebrew University of Jerusalem in history and philosophy of science. Anna Kazanchyan, M.D. has been serving as our director since December 2014. Dr. Kazanchyan is a biotechnology executive with more than 16 years ofexperience at Wall Street firms, biopharmaceutical companies and as an entrepreneur. Dr. Kazanchyan is the founder and Managing Partner of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceuticalcompanies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, she has been a strategic advisor to CEOs ofbiopharmaceutical companies (start-ups to global companies) and has advised companies on matters related to business development, regulatory strategy,marketing and commercial/competitive landscape. Previously, Dr. Kazanchyan was Senior Biotechnology Analyst at Wachovia Securities, and was a memberof the biotechnology equity research teams at Goldman Sachs and Citigroup. She received an M.D. from Harvard Medical School and a B.A. in biology,summa cum laude, from Clark University. Darrell Rigel, M.D. has been serving as our director since our initial public offering that was completed in September 2014. Dr. Rigel is a ClinicalProfessor of Dermatology at the New York University Medical School, an Adjunct Clinical Professor of Dermatology at the Mount Sinai School of Medicine,as well as being an Attending at the Tisch and Bellevue Hospitals in New York. Dr. Rigel holds an SB in Management Information Sciences and an SM inManagement Information Science from the Massachusetts Institute of Technology and an M.D. from the George Washington University School of Medicine. Stanley Stern has been serving as our director since our initial public offering that was completed in September 2014. Mr. Stern has 32 years ofexperience as an investment banker, working primarily for Oppenheimer & Co, in a number of positions including head of investment banking. He alsoworked for STI Ventures, Salomon Brothers and C.E. Unterberg. In 2013, Mr. Stern founded Alnitak Capital Partners which provides strategic advice andconducts merchant banking activities. Mr. Stern holds a B.A. in Economics and Accounting from City University of New York, Queens College, and anM.B.A. from Harvard University. He currently serves as chairman of Audiocodes (AUDC) and Sodastream (SODA) and also serves as a director of OrmatTechnologies and Ekso Bionics. He previously served as a director of Given Imaging and Fundtech. Dalia Megiddo, M.D. has been serving as our director since May 2016. Dr. Megiddo co-founded a number of pharma companies, including Alcobra Ltd.(Nasdaq: ADHD), Bioblast-Pharma Ltd. (Nasdaq: ORPN) and Chiasma Ltd. (Nasdaq: CHMA). She currently serves as Managing Partner of Expedio Ventures,and previously ran other life science investment funds, including Jerusalem Global Ventures and 7-Health. Dr. Megiddo serves as a director of Bioblast-Pharma Ltd. She formerly served as a director of Alcobra Ltd., AngioScore Inc., Chiasma (Israel) Ltd., Chiasma Inc., Given Imaging Ltd. (Nasdaq: GIVN) andElron Electronic Industries Ltd. (Nasdaq: ELRN). Dr. Megiddo holds an M.D. in Medicine from Hebrew University, Jerusalem, and is a licensed specialist infamily medicine. She also holds an M.B.A. degree from the Kellogg Recanati International School of Business (Tel Aviv University and North WesternUniversity).Observers to the board of directors Chaim Chizic, who served as a director of the Company until June 2015, currently serves as a non-voting observer to our board of director. In suchcapacity Mr. Chizic may attend meetings of the board and is entitled to receive all notices and other correspondence and communications sent by us tomembers of our board of directors. In addition, he receives compensation equal to the compensation we pay our directors. Meir Eini -- see above disclosure regarding Mr. Eini's role as an observer to the board in "Item 6.A. Directors and Senior Management—Our executiveofficers—Meir Eini". 56Arrangements concerning election of directors; family relationships We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among ourexecutive officers and directors. 6.B.Compensation Compensation of executive officers and directors The following table summarized the compensation awarded to, earned by, or paid to each of our five most highly compensated directors and executiveofficers during the twelve months ended on December 31, 2016 (in thousands of U.S. dollars): Name Position Salary(1) Bonus Value of EquityAwards Granted(2) OtherCompensation(3) Total (in thousands of US$) Dr. Dov Tamarkin CEO $385 $352 $239 $207 $1,183 David Domzalski President of FoamixU.S. 370 225 446 - 1,041 Meir Eini Chief InnovationOfficer 300 165 203 158 826 Ilan Hadar CFO 240 173 318 81 812 Alvin Howard VP Regulatory AffairsU.S. $307 $98 $179 $- $584 (1)Salary paid in Israeli Shekels is shown in the table in U.S. dollars based on the average exchange rate of 2016.(2)The value of options and RSUs shown in this column is the expense recorded in our financial statements for the period ended December 31, 2016,with respect to all options and RSUs granted to such executive officer.(3)The amounts reported in the All Other Compensation consist of social benefits, medical coverage expenses and car allowance. The aggregate compensation paid and equity-based compensation and other payments expensed by us to all of our directors and executive officers withrespect to the year ended December 31, 2016 was $7.2 million. This amount does not include business travel, professional and business association dues andexpenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry. As of December 31, 2016, options and Restricted Stock Units, or RSUs, for a total of 2,013,913 ordinary shares granted to our directors and executiveofficers were outstanding under our 2009 and 2015 Plans. The weighted average exercise price of options as of December 31, 2016, was $5.74 per share. 6.C.Board practices Board of directors Under the Israeli Companies Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers andmay take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-daymanagement and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at thediscretion of, our board of directors, subject to the employment agreement that we have entered into with him. All other executive officers are also appointedby our board of directors, and are subject to the terms of any applicable employment agreements that we may enter into with them. Under our amended and restated articles of association, our board of directors must consist of at least five and not more than nine directors. The IsraeliCompanies Law and our amended and restated articles of association provide that directors are elected annually at the general meeting of our shareholders bya vote of the holders of a majority of the voting power represented present and voting, in person or by proxy, at that meeting. We have only one class ofdirectors. In August 2016, our board of directors resolved, in accordance with the Israeli Companies Regulations (Concessions for Companies Whose Shares areListed for Trading on a Stock Exchange Abroad), 5760-2000, or the Concession Regulations, as amended on April 17, 2016, to "opt out" from certainrequirements of the Israeli Companies Law, 5759-1999, or the Companies Law, with regard to (i) the appointment of external directors; (ii) certain restrictionson the engagement of external directors and their relatives and affiliates following the end of their tenure, and (iii) the composition and quorum of the auditcommittee and compensation committee. Under the Concession Regulations, these concessions will continue to be available to the Company so long as: (i)its shares are traded on a U.S. stock exchange, including the NASDAQ Global Market; (ii) it does not have a "controlling shareholder" (as such term is definedunder the Companies Law), and (iii) it complies with the majority board independence requirements and audit committee and compensation committeerequirements under U.S. laws applicable to U.S. domestic issuers. External directors who were appointed prior to the date on which our board decided to optout of the requirement to maintain such function may continue to hold their office until the earlier of the expiry of their original 3-year term or the secondannual shareholder meeting held after such decision was taken. Our board of directors has determined that seven of our directors (namely – all directors apart from Dr. Dov Tamarkin) are independent under the NASDAQStock Market rules. 57In accordance with the exemption available to foreign private issuers, we do not follow the requirements of the NASDAQ rules with regard to the processof nominating directors, and instead, follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized torecommend to our shareholders director nominees for election. Under the Israeli Companies Law and our amended and restated articles of association, nominees for directors may also be proposed by any shareholderholding at least one percent (1%) of our outstanding voting power. However, any such shareholder may propose a nominee only if a written notice of suchshareholder's intent to propose a nominee has been given to our Secretary (or, if we have no such Secretary, our Chief Executive Officer). Any such noticemust include certain information, including, among other things, a description of all arrangements between the nominating shareholder and the proposeddirector nominee and any other person pursuant to which the nomination is to be made by the nominating shareholder, the consent of the proposed directornominee to serve as our director if elected and a declaration signed by the nominee declaring that there is no limitation under the Israeli Companies Lawpreventing his or her election, and that all of the information that is required under the Israeli Companies Law to be provided to us in connection with suchelection has been provided. In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, fora term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors may befilled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of ourshareholders in which the other directors then in office are proposed to be replaced or reappointed. Under the Israeli Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting andfinancial expertise. In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the typeand size of the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors of ourcompany who are required to have accounting and financial expertise is one. Chairman of the board In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of itsmembers to serve as chairman of the board of directors. Our board of directors has appointed Dr. Stanley Hirsch to serve as chairman of the board of directors. Board Committees Audit committee Israeli Companies Law requirements Under the Israeli Companies Law, we are required to have an audit committee. However, following the decision of our board of directors to opt out of thevarious restrictions concerning the composition of the audit committee under the Israeli Companies Law, the composition of our audit committee and thenomination of members to such committee are now governed by the regulations of the U.S. Securities Exchange Commission, or SEC, and the NASDAQStock Market rules, as set out below. NASDAQ listing requirements and SEC regulations Under the NASDAQ Stock Market rules and SEC regulations, we are required to maintain an audit committee consisting of at least three independentdirectors, each of whom is financially literate and one of whom has accounting or related financial management expertise. In order for a director to be designated as "independent" under the NASDAQ Stock Market rules and SEC regulations, he or she must not have a materialrelationship with the company that would impair his or her independence, such as a commercial, consulting, legal, accounting or familial relationships,among others. However, ownership of a significant amount of shares or affiliation with a major shareholder should not, in and of itself, preclude the boardfrom determining that a director is independent, nor is the board precluded from appointing its chairman as a member of the audit committee or as chairmanof the committee. In order for a director to be designated as "financially literate" under the NASDAQ Stock Market rules and SEC regulations, he or she are required to havesufficient understanding of the language of accounting and corporate finance to act as effective overseers of the integrity of a company's financial reportingprocess and its financial statements, including the selection and oversight of the performance of the external and internal auditors. In order for a director to qualify as an "audit committee financial expert" under SEC regulations he or she must have education and experience as chieffinancial officer, chief accounting officer, controller, public accountant or auditor, or experience in one or more positions that involve the performance ofsimilar functions or in actively supervising such positions. If no audit committee member qualifies, the company must state why its audit committee lacks afinancial expert. 58Our audit committee consists of Stanley Stern (Chairman), Rex Bright and Darrell Rigel. Each of the members of our audit committee is eligible to beclassed as an independent director in accordance with SEC regulations and satisfies the independent director requirements under the NASDAQ Stock Marketrules. All designated members of our audit committee meet the requirements for financial literacy under the applicable rules of the NASDAQ Stock Marketand SEC regulations. However, we do not currently have an audit committee financial expert as such term is defined by the SEC. Nevertheless, our board ofdirectors has determined in its business judgment that our existing committee members have the ability to oversee our financial statements based on theirextensive business backgrounds and that Stanley Stern has "financial sophistication" under the NASDAQ Stock Market rules. Audit committee roles Our board of directors has adopted an audit committee charter that sets forth the responsibilities of the audit committee consistent with the rules andregulations of the SEC and the NASDAQ Stock Market rules, as well as the requirements for such committee under the Israeli Companies Law, including thefollowing: ·oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement ofour independent registered public accounting firm to the board of directors in accordance with Israeli law; ·recommending the engagement or termination our internal auditor; and ·recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our boardof directors. Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting,auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants andreviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees theaudit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent ofmanagement. Under the Israeli Companies Law, our audit committee is responsible for: i.determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditoror the independent auditor, and making recommendations to the board of directors to improve such practices; ii.determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest andwhether such transaction is extraordinary or material under the Israeli Companies Law) (see our Registration Statement on Form F-1 as filed underthe Securities Act with the SEC on August 13, 2014, under "Management—Approval of Related Party Transactions under Israeli Law—FiduciaryDuties of Directors and Executive Officers"); iii.establishing the approval process (including, potentially, the approval of the audit committee) for certain transactions with a controlling shareholderor in which a controlling shareholder has a personal interest; iv.where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board ofdirectors and proposing amendments thereto v.examining our internal audit controls and internal auditor's performance, including whether the internal auditor has sufficient resources and tools tofulfill his responsibilities; vi.examining the scope of our auditor's work and compensation and submitting a recommendation with respect thereto to our board of directors orshareholders, depending on which of them is considering the appointment of our auditor; and vii.establishing procedures for the handling of employees' complaints as to the management of our business and the protection to be provided to suchemployees. Our audit committee may not approve any actions requiring its approval (see our Registration Statement on Form F-1 as filed under the Securities Act withthe SEC on August 13, 2014, under "Management—Approval of Related Party Transactions under Israeli Law—Fiduciary Duties of Directors and ExecutiveOfficers"), unless at the time of the approval a majority of the committee's members are present, which majority consists of independent directors. Agreements with executive officers; consulting and directorship services provided by directors We have entered into written employment agreements with all of our executive officers. These agreements contain standard provisions for a company inour industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receivebenefits upon the termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) duringthe required notice period for termination of their employment, which varies for each individual. 59Compensation committee and compensation policy Following the Concession Regulations and the decision of our board of directors to opt out of the requirements concerning the appointment of acompensation committee under the Israeli Companies Law, the company is only required to comply with the requirements regarding such appointment underthe NASDAQ Stock Market rules. Accordingly, we have established and continue to maintain a compensation committee, the members of which are currentlyRex Bright (Chairman), Darrel Rigel, Stanley Stern and Anna Kazanchyan. Each member of our compensation committee is independent under the NASDAQStock Market rules. The duties of the compensation committee include the recommendation to the company's board of directors of a policy regarding the terms of engagementof office holders, to which we refer as a compensation policy. That policy must be adopted by the company's board of directors, after considering therecommendations of the compensation committee, and will need to be brought for approval by the company's shareholders, referred to herein as the SpecialMajority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the shares presentand voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the shares held by allshareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement; or (ii) the total number of shares ofnon-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangementdoes not exceed 2% of the company's aggregate voting rights. The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, includingexculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensationpolicy must relate to certain factors, including advancement of the company's objectives, the company's business plan and its long-term strategy, and creationof appropriate incentives for office holders. It must also consider, among other things, the company's risk management, size and the nature of its operations.The compensation policy must furthermore consider the following additional factors: ·the knowledge, skills, expertise and accomplishments of the relevant office holder; ·the office holder's roles and responsibilities and prior compensation agreements with him or her; ·the relationship between the terms offered and the average compensation of the other employees of the company, including those employed throughmanpower companies ·the impact of disparities in salary upon work relationships in the company; ·the possibility of reducing variable compensation at the discretion of the board of directors; ·the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and ·as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company'sperformance during that period of service, the person's contribution towards the company's achievement of its goals and the maximization of its profits,and the circumstances under which the person is leaving the company. The compensation policy must also include the following principles: ·the link between variable compensation and long-term performance and measurable criteria; ·the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; ·the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon whichsuch compensation was based was inaccurate and was required to be restated in the company's financial statements; ·the minimum holding or vesting period for variable, equity-based compensation; and ·maximum limits for severance compensation The compensation committee is responsible for (i) recommending the compensation policy to a company's board of directors for its approval (andsubsequent approval by its shareholders) and (ii) duties related to the compensation policy and to the compensation of a company's office holders as well asfunctions previously fulfilled by a company's audit committee with respect to matters related to approval of the terms of engagement of office holders,including: ·recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval ofeither a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years); ·recommending to the board of directors periodic updates to the compensation policy; ·assessing implementation of the compensation policy; and 60·determining whether the compensation terms of the chief executive officer of the company need not be brought to approval of the shareholders Our compensation committee, board of directors and shareholders approved our compensation policy. Compensation committee roles Our board of directors has adopted a compensation committee charter setting forth the responsibilities of the compensation committee, which include: ·the responsibilities set forth in the compensation policy; ·reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and ·reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. Internal auditor Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the auditcommittee. An internal auditor may not be: ·a person (or a relative of a person) who holds more than 5% of the company's outstanding shares or voting rights; ·a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; ·an office holder (including a director) of the company (or a relative thereof); or ·a member of the company's independent accounting firm, or anyone on its behalf. The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures. The auditcommittee is required to oversee the activities and to assess the performance of the internal auditor as well as to review the internal auditor's work plan. Wehave appointed an internal auditor. Exculpation, Insurance and Indemnification of Directors and Officers Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company mayexculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty ofcare but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association includesuch a provision. A company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders. Under the Israeli Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for actsperformed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles ofassociation include a provision authorizing such indemnification: ·financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator's award approved by acourt. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must belimited to events which, in the opinion of the board of directors, can be foreseen based on the company's activities when the undertaking to indemnifyis given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertakingshall detail the abovementioned foreseen events and amount or criteria; ·reasonable litigation expenses, including attorneys' fees, incurred by the office holder (1) as a result of an investigation or proceeding institutedagainst him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such officeholder as a result of such investigation or proceeding, and (ii) no financial liability was imposed upon him or her as a substitute for the criminalproceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense thatdoes not require proof of criminal intent; and (2) in connection with a monetary sanction; and ·reasonable litigation expenses, including attorneys' fees, incurred by the office holder or imposed by a court in proceedings instituted against him orher by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a resultof a conviction for an offense that does not require proof of criminal intent. 61Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as anoffice holder, if and to the extent provided in the company's articles of association: ·a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the actwould not harm the company; ·a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and ·a financial liability imposed on the office holder in favor of a third party. Under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: ·a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the officeholder acted in good faith and had a reasonable basis to believe that the act would not harm the company; ·a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; ·an act or omission committed with intent to derive illegal personal benefit; or ·a fine or forfeit levied against the office holder. Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by thecompensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to bepermitted by the Israeli Companies Law. We have obtained directors and officers liability insurance for the benefit of our office holders and have increased such coverage to $25 million perannum. We intend to maintain such increased coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. Inaddition, we have entered into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us asa result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated articles ofassociation and Israeli Law. 6.D.Employees As of December 31, 2016, we had 68 employees, 57 are based in Israel and 11 are based in the U.S. The distribution of our full-time employees according tomain areas of activity is set forth in the following table: Employees Area of Activity: Research and development 50 Selling, general and administrative 18 Total 68 Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees,determination of severance pay, annual leave, sick days, advance notice of termination, payments to the National Insurance Institute, and other conditions ofemployment and include equal opportunity and anti-discrimination laws. While none of our employees is party to any collective bargaining agreements,certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau ofEconomic Organizations (including the Industrialists' Associations) are applicable to our employees in Israel by order of the Israeli Ministry of the Economy.These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents, recuperation pay and travel expenses. Wegenerally provide our employees with benefits and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good. 626.E.Share ownership The following table provides information with respect to our securities beneficially owned by our directors and executive officers who hold more than 1%of our outstanding shares, as of December 31, 2016: * Less than one percent Name Type ofSecurity Number ofSecurities Options/WarrantsExercise Price ($) Options/WarrantsExercise Date Percent ofSharesOutstanding Dr. Dov Tamarkin(1) Shares 2,750,689 - - 7.6% Warrants 2,094 $5.04 April 9, 2018 Options 24,000 5.88 December 29, 2024 Options 45,000 6.77 December 28, 2024 Options 100,000 6.34 March 1, 2026 RSUs 9,000 - - Meir Eini(2) Shares 2,896,781 - - 8.0% Warrants 20,860 $5.04 April 9, 2018 Options 48,000 5.88 December 29, 2024 Options 36,000 6.77 December 28, 2024 Options 35,000 7.09 August 9, 2026 RSUs 9,000 - - RSUs 20,000 - - David Domzalski - * Ilan Hadar - * Alvin Howard - * * Less than one percent (1)Dr. Dov Tamarkin ("Tamarkin"), our co-founder, Chief Executive Officer and director owns our securities indirectly through Tamarkin MedicalInnovation, Ltd. an Israeli company owned and controlled by Tamarkin. (2)Meir Eini ("Eini"), our co-founder and Chief Innovative Officer owns our securities indirectly through Meir Eini Holdings Ltd., an Israeli companyowned and controlled by Eini. Other directors and officers beneficially own securities that represent less than 1% of our share capital. 2009 Israeli Share Option Plan In July 2009, we adopted our 2009 Israeli Share Option Plan, or the 2009 Plan. The 2009 Plan provides for the grant of options to our and our subsidiaries'directors, employees, officers, consultants and service providers, among others. The 2009 Plan is administered by our board of directors or a committee designated by our board of directors, which determines, subject to Israeli law, thegrantees of options, the terms of the options, including exercise or purchase prices, vesting schedules, acceleration of vesting, the type of option and the othermatters necessary or desirable for, or incidental to the administration of the 2009 Plan. The 2009 Plan provides for the issuance of options under various taxregimes including, without limitation, pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance (New Version) 1961, or the Ordinance. Anyoptions that expire or are canceled for any reason prior to their exercise or relinquishment in full may once again be granted pursuant to options under the2009 Plan. If our outstanding shares are changed or exchanged at any time by declaration of a share dividend, share split, combination or exchange of shares,recapitalization or any similar event, then the number, class and kind of shares subject to the 2009 Plan, the options granted under the 2009 Plan and theapplicable exercise prices will be proportionally adjusted. Section 102 of the Ordinance allows employees, directors and officers, who are not controlling shareholders and who are Israeli residents, to receivefavorable tax treatment for compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment involvingthe issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or sharesdirectly to the grantee. Section 102(b)(2) of the Ordinance, which provides the most favorable tax treatment for grantees, permits the issuance to a trustee under the "capital gainstrack." In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section 102 ofthe Ordinance, as well as the shares issued upon exercise of such options and other shares received following any realization of rights with respect to suchoptions, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust for the benefitof the relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of theissuance and deposit of the options with the trustee. However, under this track, we are not allowed to deduct an expense with respect to the issuance of theoptions or shares. The 2009 Plan provides that options granted to our employees, directors and officers who are not controlling shareholders and who are considered Israeliresidents may qualify for special tax treatment under the "capital gains track" provisions of Section 102(b)(2) of the Ordinance. Our Israeli non-employeeservice providers and controlling shareholders may only be granted options under Section 3(i) of the Ordinance, which does not provide for similar taxbenefits. Options granted under the 2009 Plan are subject to vesting schedules and vest over a four-year period commencing on the date of grant, such that 20% ofthe granted options are fully vested as of the date of the grant and thereafter 5% of the granted options vest upon the lapse of each three-month period.Options generally expire 10 years from approval of their approval. Under the 2009 Plan, in the event of termination of employment or services for reasons ofdisability or death, the grantee, or in the case of death, his or her legal successor, may exercise options that have vested prior to termination within a period of12 months after the date of termination. If a grantee's employment or service is terminated for cause, as defined in the 2009 Plan, all of the grantee's vestedand unvested options expire or forfeited on the date of termination. If a grantee's employment or service is terminated without cause, the grantee may exercisehis or her vested options within 90 days after the date of termination. Any expired, forfeited or unvested options are returned to the pool for reissuance. 63The 2009 Plan provides that in the event of a merger or consolidation of our company, or a sale of all, or substantially all, of our assets, the unexercisedoptions outstanding may be assumed, or substituted for an appropriate number of shares of each class of shares or other securities as were distributed to ourshareholders in connection with such transaction and the exercise price will be appropriately adjusted. If not so assumed or substituted, all non-vested andnon-exercised options will expire upon the closing of the transaction. Our board of directors or its designated committee, as applicable, may provide in theoption agreement that if the acquirer does not agree to assume or substitute the options, vesting of the options shall be accelerated so that any unvestedoption or any portion thereof will vest generally 10 days prior to the closing of the transaction. In the event that such consideration received in thetransaction is not solely in the form of ordinary shares of another company, the board of directors or the designated committee, as applicable, may, with theapproval of the acquirer, provide that in lieu of the assumption or substitution of the options, the options will be substituted by another type of asset orproperty, including cash. If we are voluntarily liquidated or dissolved, option holders will have 10 days to exercise any then-vested options upon receivingnotification from us of the liquidation or dissolution. The board may amend, alter, suspend or terminate the 2009 Plan at any time. However no amendment, alteration, suspension or termination may impairthe rights of any option holder under the 2009 Plan unless agreed upon in writing by us and the affected option holder. Since the adoption of the 2015 Plan (see below), the Company stopped granting options under the 2009 Plan. 2015 Israeli Share Incentive Plan In May 2015, we adopted our 2015 Israeli Share Incentive Plan, or the 2015 Plan. The 2015 Plan provides for the grant of options to our and oursubsidiaries' directors, employees, officers, consultants and service providers, among others. As of the adoption of the 2015 Plan, all new grants of optionsand RSUs are made pursuant to the 2015 Plan. The 2015 Plan is administered by our board of directors or a committee designated by our board of directors, which determines, subject to Israeli or US law(as applicable), the grantees of options or RSUs (collectively – Awards), the terms of the Awards including exercise prices (with regard to options), vestingschedules, acceleration of vesting, the type of Award and the other matters necessary or desirable for, or incidental to the administration of the 2015 Plan. The 2015 Plan also authorizes our board of directors or a committee designated by our board of directors to allow net exercise of options. The 2015 Planprovides for the issuance of Awards under various tax regimes including, without limitation, pursuant to Sections 102 and 3(i) of the Ordinance. Any Awardsthat expire or are canceled for any reason prior to their exercise or relinquishment in full may once again be granted under the 2015 Plan. If our outstandingshares are changed or exchanged at any time by declaration of a share dividend, share split, combination or exchange of shares, recapitalization or any similarevent, then the number, class and kind of shares subject to the 2015 Plan, the Awards granted under the 2015 Plan and the applicable exercise prices will beproportionally adjusted. The 2015 Plan provides that Awards granted to our employees, directors and officers who are not controlling shareholders and who are considered Israeliresidents may qualify for special tax treatment under the "capital gains track" provisions of Section 102(b)(2) of the Ordinance. Our Israeli non-employeeservice providers and controlling shareholders (if any) may only be granted options under Section 3(i) of the Ordinance, which does not provide for similartax benefits. Awards granted under the 2015 Plan are subject to vesting schedules and generally expire 10 years from approval of the Award. The vesting periods orvesting conditions (e.g. performance-based vesting) may be set by our board of directors or a committee designated by our board of directors. Under the 2015Plan, in the event of termination of employment or services for reasons of disability or death, the grantee, or in the case of death, his or her legal successor,may exercise options that have vested prior to termination within a period of 12 months after the date of termination. If a grantee's employment or service isterminated for cause, as defined in the 2015 Plan, all of the grantee's vested and unvested Awards expire on the date of termination. If a grantee's employmentor service is terminated without cause, the grantee may exercise his or her vested Awards within 90 days after the date of termination. Any expired orunvested Awards are returned to the pool for reissuance. The 2015 Plan provides that in the event of a merger or consolidation of our company, or a sale of all, or substantially all, of our assets, the unexercisedAwards outstanding may be assumed, or substituted for an appropriate number of shares of each class of shares or other securities as were distributed to ourshareholders in connection with such transaction and the exercise price will be appropriately adjusted. If not so assumed or substituted, all non-vested andnon-exercised Awards will expire upon the closing of the transaction. Our board of directors or its designated committee, as applicable, may provide in theAward agreement that if the acquirer does not agree to assume or substitute the options, vesting of any or all of such Awards shall be accelerated so that anyunvested Award or any portion thereof will vest generally 10 days prior to the closing of the transaction. In the event that such consideration received in thetransaction is not solely in the form of ordinary shares of another company, the board of directors or the designated committee, as applicable, may, with theapproval of the acquirer, provide that in lieu of the assumption or substitution of the Awards, the Awards will be substituted by another type of asset orproperty, including cash. If we are voluntarily liquidated or dissolved, Award holders will have 10 days to exercise any then-vested Awards upon receivingnotification from us of the liquidation or dissolution. 64The board may amend, alter, suspend or terminate the 2015 Plan at any time. However no amendment, alteration, suspension or termination may impairthe rights of any option holder under the 2015 Plan unless agreed upon in writing by us and the affected option holder. As of December 31, 2016, there were 184,733 RSUs and 2,514,142 options outstanding under the 2009 and 2015 Plans. The weighted average exerciseprice of these options was $5.7. Out of awards granted, 90,117 RSUs and 69,444 options were exercised. As of December 31, 2016, 845,858 Awards remainavailable for grant under the 2015 Plan. In November, 2016 the board of directors approved an increase of 900,000 ordinary shares, to a total of 1,745,858 awards remain available for grant underthe 2015 Plan. The shares were registered in January 2017. ITEM 7.MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 7.A.Major Shareholders The following table sets forth information regarding the beneficial ownership by each person or entity known to beneficially own more than 5% of ourordinary shares and of our directors and officers as of December 31, 2016, or a different date, if so provided in the table below or footnotes thereof. According to our transfer agent, as of December 31, 2016, there were 9 record holders of our ordinary shares, among whom two (including Cede & Co.) areU.S. holders who beneficially own in the aggregate 37,167,791 of our ordinary shares. None of our shareholders has different voting rights from othershareholders. We are not owned or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement thatmay, at a subsequent date, result in a change of control of our company. Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect toall shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each beneficialowner's address is: c/o 2 Holzman St., Weizmann Science Park, Rehovot 7670402, Israel Name Number and Percentage ofOrdinary Shares Number Percent 5% or Greater Shareholders (other than directors and executive officers) Baker Bros. Advisors (GP) LLC (1) 2,046,967 6.6%Great Point Partners, LLC (2) 2,769,425 7.5%Directors and Executive Officers Dr. Dov Tamarkin(3) 2,750,689 7.6%Meir Eini(4) 2,896,781 8.0%Dr. Stanley Hirsch(5) * - David Schuz(6) * - Dr. Mitchell Shirvan(7) * - Ilan Hadar(8) * - David Domzalski(9) * - Alvin Howard(10) * - Dr. Herman Ellman(11) * - Rex Bright(12) * - Dr. Darrell Rigel(13) * - Stanley Stern(14) * - Dr. Anna Kazanchyan(15) * - Yohan Hazot(16) * - Dr. Aaron Schwartz(17) * - All Directors and Executive Officers as a Group(18) 6,567,063 17.3%*Less than 1%(1)Based on information contained in Schedule 13G filed with the SEC on February 16, 2016 jointly by Baker Bros. Advisors LP, a limited partnershiporganized under the laws of the State of Delaware (the "Adviser"), Baker Bros Advisors (GP) LLC, a limited liability company organized under the lawsof the State of Delaware (the "Adviser GP"), Felix J. Baker, a U.S. citizen and Julian C. Baker, a U.S. citizen (in this footnote, collectively with theAdviser and the Adviser GP, the "Reporting Persons"). Pursuant to that Schedule 13G, 165,124 ordinary shares are held directly by 667 L.P. and1,881,843 ordinary shares are held by Baker Brothers Life Sciences, L.P. (collectively, the "Funds"). Pursuant to an amended and restated managementagreements among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser alldiscretion and authority with respect to the investment and voting power of the securities held by the Funds, and the Adviser has complete andunlimited discretion and authority with respect to the Funds' investments and voting power over investments. The business address of each of theReporting Persons is c/o Baker Bros. Advisors LP, 667 Madison Avenue, 21st Floor, New York, NY 10065. 65(2)Based on information contained in Schedule 13G filed with the SEC on October 11, 2016 jointly by Great Point Partners LLC, a limited liabilitycompany organized under the laws of the State of Delaware ("Great Point"), Dr. Jeffery R. Jay, M.D., a U.S. citizen ("Dr. Jay"), and Mr. David Kroin, a U.S.citizen ("Mr. Kroin", and collectively with Dr. Jay and Great Point, in this footnote, the "Reporting Persons"). Pursuant to that Schedule 13G (i)Biomedical Value Fund, L.P. ("BVF") is the record owner of 727,127 ordinary shares (the "BVF Shares"). Great Point is the investment manager of BVF. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment powerwith respect to the BVF Shares, (ii) Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record owner of 1,047,995 ordinary shares (the "BOVFShares"). Great Point is the investment manager of BOVF, and each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as specialmanaging member of Great Point, has voting and investment power with respect to the BOVF Shares, (iii) GEF-SMA, LP ("GEF-SMA") is the recordowner of 812,519 shares of ordinary shares (the "GEF-SMA Shares"). Great Point is the investment manager of GEF-SMA and each of Dr. Jay, as seniormanaging member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-SMA Shares, and (iv) Class D Series of GEF-PS, L.P. ("GEF-PS") is the record owner of 181,784 shares of ordinary shares (the "GEF-PS Shares"). GreatPoint is the investment manager of GEF-PS and each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing memberof Great Point, has voting and investment power with respect to the GEF-PS Shares. The business address of each of the Reporting Persons is 165 MasonStreet, 3rd Floor, Greenwich, CT 06830. (3)Tamarkin Medical Innovation Ltd., is an Israeli company controlled by Dr. Dov Tamarkin, our co-founder, Chief Executive Officer and director.Consists of (i) 2,749,564 ordinary shares; (ii) 2,094 ordinary shares issuable upon exercise of outstanding warrants at a price of $5.04 per share (iii)24,000 ordinary shares issuable upon exercise of outstanding options at a price of $5.88 per share; (iv) 45,000 ordinary shares issuable upon exercise ofoutstanding options at a price of $6.77 per share and (v) 100,000 ordinary shares issuable upon exercise of outstanding options at a price of $6.34 pershare and (vi) 1,125 ordinary shares issued upon vesting of outstanding RSUs. The address of Tamarkin Medical Innovation Ltd. is 537 Har Hila St.,Modiin-Maccabim-Reut 7179901, Israel. (4)Meir Eini Holdings Ltd., is an Israeli company controlled by Meir Eini, our co-founder and Chief Innovation Officer. Consists of (i) 2,895,656 ordinaryshares (ii) 20,860 ordinary shares issuable upon exercise of outstanding warrants at a price of $5.04 per share (iii) 48,000 ordinary shares issuable uponexercise of outstanding options at a price of $5.88 per share and (iv) 36,000 ordinary shares issuable upon exercise of outstanding options at a price of$6.77 per share, and (v) 35,000 ordinary shares issuable upon exercise of outstanding options at a price of $7.09 per share, and (vi) 1,125 ordinary sharesissued upon vesting of outstanding RSUs. The address of Meir Eini Holdings Ltd. is 2 Hashaked St., Ness-Ziona 7408711, Israel. (5)Consists of (i) 6,448 ordinary shares (ii) 6,224 ordinary shares issuable upon exercise of outstanding warrants at a price of $5.04 per share; and (iii)197,500 ordinary shares issuable to ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch, upon exerciseof outstanding options at a price of $0.62 per share, and (iv) 27,000 ordinary shares issuable upon vesting of outstanding options at a price of $5.88 pershare. (6)Consists of (i) 3,936 ordinary shares (ii) 64,188 ordinary shares issuable upon exercise of outstanding options at a price of $1.92 per share (iii) 9,000ordinary shares issuable upon exercise of outstanding options at a price of $6.77 per share, and (iv) 3,499 ordinary shares issuable upon exercise ofoutstanding options at a price of $7.13 per share, and (v) 7,500 ordinary shares issuable upon exercise of outstanding options at a price of $6.34 pershare, and (vi) 564 ordinary shares issued upon vesting of outstanding RSUs. (7)Consists of (i) 3,936 ordinary shares (ii) 2,187 ordinary shares issuable upon exercise of outstanding options at a price of $1.92 per share, and (iii)15,681 ordinary shares issuable upon exercise of outstanding options at a price of $5.46 per share and (iv) 9,000 ordinary shares issuable upon exerciseof outstanding options at a price of $6.77 per share, and (v) 5,834 ordinary shares issuable upon exercise of outstanding options at a price of $7.13 pershare, and (vi) 7,500 ordinary shares issuable upon exercise of outstanding options at a price of $6.34 per share, and (vii) 564 ordinary shares issuedupon vesting of outstanding RSUs. (8)Consists of (i) 3,936 ordinary shares (ii) 6,406 ordinary shares issuable upon exercise of outstanding options at a price of $1.92 per share, and (iii)15,681 ordinary shares issuable upon exercise of outstanding options at a price of $5.46 per share and (iv) 9,000 ordinary shares issuable upon exerciseof outstanding options at a price of $6.77 per share, and (v) 63,126 ordinary shares issuable upon exercise of outstanding options at a price of $7.13 pershare, and (vi) 15,000 ordinary shares issuable upon exercise of outstanding options at a price of $6.34 per share, and (vii) 1,189 ordinary shares issuedupon vesting of outstanding RSUs. (9)Consists of (i) 14,949 ordinary shares (ii) 9,375 ordinary shares issuable upon exercise of outstanding options at a price of $7.98 per share, and (iii)74,003 ordinary shares issuable upon exercise of outstanding options at a price of $7.14 per share and (iv) 15,000 ordinary shares issuable upon exerciseof outstanding options at a price of $6.04 per share, and (v) 625 ordinary shares issued upon vesting of outstanding RSUs. (10)Consists of (i) 10,015 ordinary shares (ii) 6,250 ordinary shares issuable upon exercise of outstanding options at a price of $7.98 per share, and (iii)14,271 ordinary shares issuable upon exercise of outstanding options at a price of $7.14 per share, and (iv) 7,500 ordinary shares issuable upon exerciseof outstanding options at a price of $6.04 per share. (11)Consists of (i) 10,015 ordinary shares (ii) 3,125 ordinary shares issuable upon exercise of outstanding options at a price of $7.98 per share, and (iii)6,676 ordinary shares issuable upon exercise of outstanding options at a price of $7.14 per share, and (iv) 3,750 ordinary shares issuable upon exerciseof outstanding options at a price of $6.04 per share. (12)Consists of 18,000 ordinary shares issuable upon exercise of outstanding options at a price of $5.88 per share. (13)Consists of 18,000 ordinary shares issuable upon exercise of outstanding options at a price of $5.88 per share. (14)Consists of 18,000 ordinary shares issuable upon exercise of outstanding options at a price of $5.88 per share. (15)Consists (i) 16,000 ordinary shares issuable upon exercise of outstanding options at a price of $5.88 per share, and (ii) 1,000 ordinary shares issuableupon exercise of outstanding options at a price of $10.80 per share (16)Consists of (i) 3,936 ordinary shares (ii) 10,813 ordinary shares issuable upon exercise of outstanding options at a price of $1.92 per share, and (iii)18,000 ordinary shares issuable upon exercise of outstanding options at a price of $6.77 per share and (iv) 9,000 ordinary shares issuable upon exerciseof outstanding options at a price of $6.77 per share, and (v) 13,373 ordinary shares issuable upon exercise of outstanding options at a price of $7.13 pershare, and (vi) 15,000 ordinary shares issuable upon exercise of outstanding options at a price of $6.34 per share, and (vii) 564 ordinary shares issuedupon vesting of outstanding RSUs. (17)Consists of 8,000 ordinary shares issuable upon exercise of outstanding options at a price of $11.87 per share. (18)Consists of 16 persons. 66 Shelf registration statement On October 21, 2015, we filed with the SEC a "shelf" registration statement on a Form F-3 for the registration of our ordinary shares that we may, fromtime to time, offer and sell in one or more offerings with an aggregate offering price of up to $150 million. On September 12, 2016, we filed with the SEC anamendment to the shelf registration statement on a Form F-3/A, which became effective on September 23, 2016. On September 30, 2016, we completed afollow-on offering in which we sold a total of 6,111,959 ordinary shares (including shares that were sold following the exercise of the option granted to theunderwriters) for $9.50 per share, and certain selling shareholders sold 300,000 of their ordinary shares at the same price per share. 7.B.Related Party Transactions For compensation to our directors and officers, see "Item 6.B. Compensation." Agreements and Arrangements with, and Compensation of, Directors and Executive Officers Employment agreements We have entered into written employment agreements with each of our executive officers. These agreements contain customary provisions andrepresentations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by the executive officers. However, theenforceability of the non-competition provisions may be limited under applicable law. The agreements are terminable by us at will, subject to prior notice,which varies for each individual. Our executive officers will not receive benefits upon termination of their respective employment with us, other thanpayment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment. However, all ofour executive officers will be entitled to accelerated vesting of their stock options and RSUs in the event of termination without cause, so that all optionsscheduled to vest after the date of termination will become fully vested upon the effective date of termination. We have also entered into employment agreements with each of Dr. Dov Tamarkin and Meir Eini, which contain provisions similar to those included inthe agreements entered into with our other executive officers, as set out above. However, these agreements allow each of Dr. Tamarkin and Mr. Eini to changetheir mode of employment and provide us with their management services through companies wholly owned and controlled by them rather than as our directemployees, provided that each of them undertakes to personally perform the management services and carry out the roles and responsibilities of theirrespective offices on behalf of these companies, as well as hold us harmless and indemnify us for any claim for additional compensation under an employer-employee relationship. Consulting and option agreements As of December 31, 2016, our agreement with ZEAS Technology and Science Management Ltd., a company beneficially owned by Dr. Stanley Hirsch,the chairman of our board of directors, remained in effect. The agreement required ZEAS to provide us with various business consulting services through Dr.Hirsch, in consideration for the grant of options under our 2009 Plan, in the number and on the terms set out in the section above titled "Item 7.A. MajorShareholders— (7)." On January 25, 2017, the agreement was terminated by the mutual written consent of both parties. Indemnification agreements Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extentpermitted by the Israeli Companies Law. We have entered into indemnification agreements with each of our directors and executive officers, undertaking toindemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from a public offering of our shares, to the extentthat such liabilities are not covered by insurance. We have also obtained Directors and Officers insurance for each of our executive officers and directors. Forfurther information, see "Item 6.C. Board Practices—Exculpation, Insurance and Indemnification of Directors and Officers." 7.C.Interests of Experts and Counsel Not applicable. ITEM 8.FINANCIAL INFORMATION 8.A.Consolidated Statements and Other Financial Information See "Item 18 – Financial Statements." 67Legal proceedings From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. Weare not currently involved in any legal proceedings. We may become involved in material legal proceedings in the future. Dividends We have never declared or paid cash dividends to our shareholders and we do not intend to pay cash dividends in the foreseeable future. We intend toreinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of ourboard of directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions,capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our board of directors maydeem relevant. The Israeli Companies Law imposes further restrictions on our ability to declare and pay dividends. See Registration Statement on Form F-1 as filed underthe Securities Act with the SEC on August 13, 2014, under "Description of Share Capital—Dividend and Liquidation Rights" for additional information. Payment of dividends may be subject to Israeli withholding taxes. See "Item 10.E. Taxation" for additional information. 8.B.Significant changes Except as disclosed elsewhere in this annual report, there have been no other significant changes since December 31, 2016. ITEM 9.THE OFFER AND LISTING 9.A.4Offer and Listing Details Our ordinary shares have been listed on the NASDAQ Global Market under the symbol "FOMX" since September 17, 2014. Prior to that date, there was nopublic trading market for our ordinary shares. Our initial public offering was priced at $6.00 per share. The following table sets forth for the periods indicatedthe high and low sales prices per ordinary share as reported on the NASDAQ Global Market: Low High Annual Information: 2016 $5.48 $11.26 2015 6.25 14.00 Quarterly Information: Fourth Quarter 2016 7.12 11.26 Third Quarter 2016 6.16 10.40 Second Quarter 2016 5.70 7.67 First Quarter 2016 5.48 8.45 Fourth Quarter 2015 6.25 9.50 Monthly Information: September 2016 $8.05 $10.40 October 2016 7.78 9.65 November 2016 7.12 9.42 December 2016 8.97 11.26 January 2017 9.58 11.27 February 2017 (through February 20) 9.85 11.11 9.B.Plan of Distribution Not applicable. 9.C.Market for Ordinary Shares Our Ordinary Shares have been quoted on the NASDAQ Global Market since September 17, 2014 under the symbol "FOMX." 9.D.Selling Shareholders Not applicable. 9.E.Dilution Not applicable. 9.F.Expenses of the Issue Not applicable. 68ITEM 10.ADDITIONAL INFORMATION 10.A.Share Capital Not applicable. 10.B.Memorandum and Articles of Association The information called for by this item has been reported previously in our Registration Statement on Form F-1 as filed under the Securities Act with theSEC on September 3, 2014 and has not changed since, and therefore is incorporated by reference to that Registration Statement. 10.C.Material Contracts We are currently in the development stage and therefore we have not entered into any agreements, other than in the ordinary course of our business, thatwe deem material. 10.D.Exchange Controls There are currently no Israeli currency control restrictions on the import or export of capital or the remittances of dividends on our ordinary shares,proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, orhave been, in a state of war with Israel. 10.E.Taxation The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership and disposition of ourordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences thatmay arise under the laws of any state, local, foreign or other taxing jurisdiction. Israeli Tax Considerations and Government Programs The following is a brief summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli taxconsequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss certain tax benefits, including under the Lawfor Encouragement of Capital Investments, 5719-1959, to which we may become eligible in the future if we establish a manufacturing facility for ourproducts in Israel. This summary also does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or herpersonal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents ofIsrael or traders in securities who are subject to special tax regimes not covered in this discussion. Because parts of this discussion are based on new taxlegislation that has not yet been subject to judicial or administrative interpretation, the appropriate tax authorities or the courts may not accept the viewsexpressed in this discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicialor administrative interpretations of Israeli law, which change could affect the tax consequences described below. General Corporate Tax Structure in Israel In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate in 2016and thereafter, from 26.5% to 25%.In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year),2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision settingthe corporate tax rate in 2017 at 24%. As a result, the corporate tax rate will be 24% in 2017 and 23% in 2018 and thereafter. Taxation of our Shareholders Capital gains taxes applicable to non-Israeli resident shareholders A non-Israeli resident who derives capital gains from the sale of our shares that were purchased after the shares were listed for trading on the NASDAQ isexempt from Israeli tax so long as such gains were not attributable to a permanent establishment that the non-resident maintains in Israel. In the case of ashareholder that is a corporation, in order for it to qualify as a non-Israeli resident for these purposes, it must be incorporated in, as well as managed andcontrolled from, a jurisdiction other than the State of Israel, and persons who are Israeli residents may not either: (i) have a controlling interest (directly orindirectly, alone or together with another, or together with another Israeli resident) exceeding 25% in one or more of the means of control in such corporationor (ii) be the beneficiaries of, or entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly. 69Taxation of non-Israeli shareholders on receipt of dividends Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unlessrelief is provided in a treaty between Israel and the shareholder's country of residence (subject to the receipt of a valid certificate from the Israel TaxAuthority, allowing for such reduced withholding tax rate). With respect to a person who is considered a substantial shareholder at the time of receiving thedividend or at any time during the preceding 12 months, subject to the terms of an applicable tax treaty, the applicable withholding tax rate is 30%.Notwithstanding all of the above, an additional 3% tax might be applicable to individual shareholders if certain conditions are met. A person is considered tobe a substantial shareholder if it holds, directly or indirectly, alone or together with another affiliated party, 10% or more of a company's means of control,which include, among other things, voting rights, the right to receive profits of the company, the right to receive proceeds upon liquidation and the right toappoint a director. Under the U.S.-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S.resident (for purposes of the U.S.-Israel Tax Treaty) is 25%. However, with regard to dividends paid to a U.S. resident corporation which held 10% or more ofour outstanding voting rights throughout the tax year in which the dividend was distributed and which maintained its shareholdings at or above suchthreshold during the entire previous tax year, the maximum rate of withholding tax is generally 12.5%, provided that no more than 25% of our gross incomefor such preceding year consists of certain types of dividends and interest. U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in theamount of the taxes withheld, subject to detailed limitations under U.S. laws applicable to foreign tax credits. A non-Israeli resident who receives dividends from which the full amount of tax was withheld according to sections 161, 164, or 170 of the Israeli TaxOrdinance is generally exempt from the obligation to file tax returns in Israel with respect to such income. In the event we declare a dividend, we may not designate the income that we may distribute in a way that will reduce shareholders' tax liability. U.S. Federal Income Tax Consequences The following is a description of the U.S. federal income tax consequences of the ownership and disposition of our ordinary shares. This description doesnot address tax considerations applicable to holders that may be subject to special tax rules, including, without limitation: ·banks, financial institutions or insurance companies; ·real estate investment trusts, regulated investment companies or grantor trusts; ·dealers or traders in securities, commodities or currencies; ·tax-exempt entities or organizations, including an "individual retirement account" or "Roth IRA" as defined in Section 408 or 408A of the U.S. InternalRevenue Code, or the Code, respectively; ·certain former citizens or long-term residents of the U.S.; ·persons that received our shares as compensation for the performance of services; ·persons that will hold our shares as part of a "hedging," "integrated" or "conversion" transaction or as a position in a "straddle" for U.S. federal incometax purposes; ·partnerships (including entities classified as partnerships for U.S. federal income tax purposes) or other pass-through entities, or holders that will holdour shares through such an entity; ·S corporations; ·holders that acquire ordinary shares as a result of holding or owning our preferred shares; ·U.S. Holders (as defined below) whose "functional currency" is not the U.S. Dollar; or holders that own or have owned directly or indirectly 10.0% ormore of the voting power or value of our shares. Moreover, this description does not address the U.S. federal estate, gift or alternative minimum tax consequences, or any state, local or foreign taxconsequences, of the ownership and disposition of our ordinary shares. This description is based on the Code existing, proposed and temporary U.S. Treasury Regulations and judicial and administrative interpretations thereof,in each case as in effect and available on the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affectthe tax consequences described below. The U.S. Internal Revenue Service, or the IRS, may take a different position concerning the tax consequences of theownership and disposition of our ordinary shares and such a position may be sustained. Holders should consult their own tax advisers concerning the U.S.federal, state, local and foreign tax consequences of purchasing, owning and disposing of our ordinary shares in their particular circumstances. 70For purposes of this description, a "U.S. Holder" is a beneficial owner of our ordinary shares that, for U.S. federal income tax purposes, is: ·a citizen or resident of the U.S.; ·a corporation (or other entity treated as a corporation) created or organized in or under the laws of the U.S. or any state thereof, including the District ofColumbia; ·an estate the income of which is subject to U.S. federal income taxation regardless of its source; or a trust if such trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or if (1) a court within the U.S. is able to exerciseprimary supervision over its administration and (2) one or more U.S. persons have the authority to control all of the substantial decisions of such trust. A "Non-U.S. Holder" is a beneficial owner of our ordinary shares that is neither a U.S. Holder nor a partnership (or other entity treated as a partnership forU.S. federal income tax purposes). If a partnership (or any other entity treated as a partnership for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner insuch partnership will generally depend on the status of the partner and the activities of the partnership. Such a partner or partnership should consult its taxadvisor as to the particular U.S. federal income tax consequences of owning and disposing of our ordinary shares in its particular circumstance. Unless otherwise indicated, this discussion assumes that the Company is not, and will not become, a "passive foreign investment company," or a PFIC, forU.S. federal income tax purposes. See "Item 10.E. Taxation—U.S. Federal Income Tax Consequences—Passive Foreign Investment Company Considerations"below. You should consult your tax advisor with respect to the U.S. federal, state, local and foreign tax consequences of owning and disposing of our ordinaryshares. Distributions The gross amount of any distribution made to you with respect to our ordinary shares before reduction for any Israeli taxes withheld therefrom willgenerally be includible in your income as dividend income to the extent such distribution is paid out of our current or accumulated earnings and profits asdetermined under U.S. federal income tax principles. However, this will not apply to certain distributions, if any, of our ordinary shares that are distributedpro rata to all our shareholders. To the extent that the amount of any distribution by us exceeds our current and accumulated earnings and profits asdetermined under U.S. federal income tax principles, it will be treated first as a tax-free return of your adjusted tax basis in our ordinary shares and thereafteras either long-term or short-term capital gain depending upon whether you have our ordinary shares for more than one year as of the time such distribution isreceived. We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles. Therefore you should expect that theentire amount of any distribution will generally be reported as ordinary dividend income to you. Non-corporate U.S. Holders may qualify for the lower ratesof taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than oneyear), provided that certain conditions are met, including certain holding period requirements and the absence of certain risk reduction transactions.Moreover, such lower rate of taxation shall not apply if the Company is a PFIC for the taxable year in which it pays a dividend, or was a PFIC for thepreceding taxable year. Such dividends will not be eligible for the dividends received deduction generally allowed to corporate holders. Subject to certain conditions and limitations, Israeli tax withheld on dividends may be deducted from your taxable income or credited against your U.S.federal income tax liability. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For thispurpose, dividends that we distribute generally should generally constitute "passive category income," or, in the case of certain U.S. Holders, "generalcategory income." A foreign tax credit for foreign taxes imposed on distributions may be denied if you do not satisfy certain minimum holding periodrequirements. The rules relating to the determination of the foreign tax credit are complex, and you should consult your tax advisor to determine whether andto what extent you will be entitled to this credit. Subject to certain exceptions, dividends paid to you with respect to our ordinary shares will be treated asforeign source income, which may be relevant in calculating your foreign tax credit limitation. However, for periods in which we are a "United Stated-ownedforeign corporation," a portion of dividends paid by us may be treated as U.S. source solely for purposes of the foreign tax credit. We would be treated as aU.S. owned foreign corporation if 50% or more of the total value or total voting power of our stock is owned, directly, indirectly or by attribution, by U.S.persons. To the extent any portion of our dividends is treated as U.S. source income pursuant to this rule, the ability of a holder to claim a foreign tax creditfor any Israeli withholding taxes payable in respect of our dividends may be limited. U.S. Holders should consult their own tax advisors about the effect of,and any exception available to, the special sourcing rule described in this paragraph. Dividends paid in NIS will be included in income in a U.S. dollar amount calculated by reference to the prevailing spot market exchange rate in effect onthe day the dividends are received by you, regardless of whether the NIS are converted into U.S. dollars at that time. Any foreign currency gain or loss a U.S.Holder realizes on a subsequent conversion of NIS into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in NIS are convertedinto U.S. dollars on the day they are received, a U.S. Holder generally should not be required to recognize foreign currency gain or loss in respect of thedividend income. 71Sale, exchange or other disposition of ordinary shares You will generally recognize gain or loss on the sale, exchange or other disposition of our ordinary shares equal to the difference between the amountrealized on such sale, exchange or other disposition and your adjusted tax basis in our ordinary shares, and such gain or loss will be capital gain or loss. IfIsraeli tax is imposed on the sale, exchange or other disposition of our ordinary shares, your amount realized will include the gross amount of the proceeds ofthe deposits before deduction of the Israeli tax. The adjusted tax basis in an ordinary share will generally be equal to the cost of such ordinary share. If youare a non-corporate holder, capital gain from the sale, exchange or other disposition of ordinary shares is generally eligible for a preferential rate of taxationapplicable to capital gains, if your holding period for such ordinary shares exceeds one year. The deductibility of capital losses for U.S. federal income taxpurposes is subject to limitations under the Code. Any such gain or loss that a holder recognizes will generally be treated as U.S. source income or loss for foreign tax credit limitation purposes. Becausegain from the sale or other disposition of our ordinary shares will be so treated as U.S. source income; and you may use foreign tax credits to offset only theportion of U.S. federal income tax liability that is attributed to foreign source income; you may be unable to claim a foreign tax credit with respect to theIsraeli tax, if any, on gains. You should consult your tax advisor as to whether the Israeli tax on gains may be creditable against your U.S. federal income taxon foreign-source income from other sources. A Non-U.S. Holder, will generally not be subject to U.S. federal income or withholding tax on any gain realized on the sale or exchange of such ordinaryshares unless: ·such gain is effectively connected with your conduct of a trade or business in the U.S. (or, if required by an applicable income tax treaty, the gain isattributable to a permanent establishment or fixed base that such holder maintains in the U.S.); or ·you are an individual and have been present in the U.S. for 183 days or more in the taxable year of such sale or exchange and certain other conditionsare met. Passive foreign investment company considerations If we were to be classified as a PFIC in any taxable year, a U.S. Holder would be subject to special rules generally intended to reduce or eliminate anybenefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of itsearnings on a current basis. A non-U.S. corporation will be classified as a PFIC for federal income tax purposes in any taxable year in which, after applying certain look-through ruleswith respect to the income and assets of subsidiaries, either: ·at least 75% of its gross income is "passive income"; or ·at least 50% of the average quarterly value of its total gross assets (which may be determined in part by the market value of our ordinary shares, whichis subject to change) is attributable to assets that produce "passive income" or are held for the production of passive income. Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess ofgains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of fundsraised in offerings of our ordinary shares. If a non-U.S. corporation owns at least 25% by value of the stock of another corporation, the non-U.S. corporation istreated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate shareof the other corporation's income. For publicly traded corporations, the PFIC asset test described above is applied using the fair market value of the non-U.S.corporation's assets. For purposes of a the PFIC asset test, a publicly traded non-U.S. corporation may treat the aggregate fair market value of its assets asbeing equal to the sum of the aggregate value of its outstanding stock, or Market Capitalization, and the total amount of its liabilities. We intend to take theposition that the excess of a non-U.S. corporation's Market Capitalization plus liabilities over the book value of all of its assets may generally be treated as anon-passive asset to the extent attributable to the non-passive activities of such corporation. If we are classified as a PFIC in any year with respect to which aU.S. Holder owns our ordinary shares, we will generally continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during whichthe U.S. Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above. Based on certain estimates of our gross income and gross assets and the nature of our business, we believe that we were not classified as a PFIC for thetaxable year ended December 31, 2016, and do not anticipate being classified as a PFIC for the taxable year ending December 31, 2017. However, becausePFIC status is based on our income, assets and activities for the entire taxable year and our Market Capitalization, it is not possible to determine whether wewill be characterized as a PFIC for the 2016 taxable year until after the close of the year. Moreover, we must determine our PFIC status annually based on testswhich are factual in nature, and our status in future years will depend on our income, assets, activities and our Market Capitalization in those years. We maybe considered a PFIC for any taxable year. 72If we were a PFIC, then unless you make one of the elections described below, a special tax regime will apply to both (i) any "excess distribution" by us toyou (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorterof the three preceding years or your holding period for our ordinary shares) and (ii) any gain realized on the sale or other disposition of the ordinary shares.Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution orgain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holdingperiod at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, whichwould be subject to tax, at the your regular ordinary income rate for the current year and would not be subject to the interest change discussed below), and (c)the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition,dividend distributions made to you will not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under"Distributions." Certain elections may be available that would result in an alternative treatment (such as mark-to-market treatment) of our ordinary shares. If a U.S. Holder makes the mark-to-market election, then, in lieu of being subject to the tax and interest charge rules discussed above, the U.S. Holder willgenerally recognize as ordinary income any excess of the fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis,and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the end of thetaxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes theelection, such holder's tax basis in the ordinary shares will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or otherdisposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to theextent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our ordinary shares are "regularly traded" on a "qualified exchange." Our ordinaryshares will be treated as "regularly traded" in any calendar year in which more than a de minimis quantity of the ordinary shares, are traded on a qualifiedexchange on at least 15 days during each calendar quarter. The NASDAQ Global Market is a qualified exchange for this purpose. Because a mark-to-marketelection cannot be made for any lower-tier PFICs that we may own, a U.S. Holder may continue to be subject to the tax and interest charge rules discussedabove with respect to such holder's indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income taxpurposes, including stock in any of the Company's subsidiaries that are treated as PFICs. If a U.S. Holder makes a mark-to market election, it will be effectivefor the taxable year for which the election is made and all subsequent taxable years unless our ordinary shares are no longer regularly traded on a qualifiedexchange or the IRS consents to the revocation of the election. We do not intend to provide the information necessary for U.S. Holders to make qualified electing fund elections if we are classified as a PFIC. U.S.Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternativetreatments would be in their particular circumstances. If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section would apply to indirect distributions and gainsdeemed to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. If a U.S. Holder owns ordinary shares during any year in which we are a PFIC, such holder will generally be required to file an IRS Form 8621 (InformationReturn by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally with the U.S. Holder'sfederal income tax return for that year. You should consult your tax advisors regarding whether we are a PFIC and the potential application of the PFIC rules. Medicare tax Certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their "net investment income," which may includeall or a portion of their dividend income and net gains from the disposition of ordinary shares. Each U.S. Holder that is an individual, estate or trust is urgedto consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares. Foreign asset reporting Certain Holders who are individuals are required to report information relating to an interest in our ordinary shares, subject to certain exceptions(including an exception for shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign FinancialAssets) with their federal income tax return. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, withrespect to their ownership and disposition of our ordinary shares. 73The above description is not intended to constitute a complete analysis of all tax consequences relating to ownership and disposition of our ordinaryshares. You should consult your tax advisor concerning the tax consequences of your particular situation. 10.F.Dividends and Paying Agents Not applicable. 10.G.Statement by Experts Not applicable. 10.H.Documents on Display We are subject to certain of the information reporting requirements of the Exchange Act, or the Exchange Act. As a foreign private issuer, we are exemptfrom the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principalshareholders are exempt from the reporting and "short-swing" profit recovery provisions contained in Section 16 of the Exchange Act, with respect to theirpurchase and sale of our shares. In addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S.companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC, within four months after the end of eachfiscal year, an annual report on Form 20-F containing financial statements audited by an independent accounting firm. We publish unaudited interimfinancial information after the end of each quarter. We furnish this quarterly financial information to the SEC under cover of a Form 6-K. You may read and copy any document we file with the SEC at its public reference facilities at 100 F Street, NE, Washington, D.C. 20549. You may alsoobtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, NE, Washington, D.C. 20549. TheSEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically withthe SEC. The address of this website is http://www.sec.gov. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the publicreference facilities. 10.I.Subsidiary Information Not applicable. ITEM 11.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK In the ordinary course of our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.Market risk is the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that mayadversely impact our financial position, results of operations or cash flows. Foreign currency exchange risk The U.S. dollar is our functional and reporting currency. Although a substantial portion of our expenses (mainly salaries and related costs) aredenominated in Israeli shekels, accounting for 21%, 32% and 73% of our expenses in the years ended December 31, 2016, 2015 and 2014, respectively,almost all our revenues were generated under agreements denominated in U.S. dollars and our proceeds from our public offerings, share issuance andconvertible loan agreements, which are the main source of our financing, are denominated in U.S. dollars. Furthermore, while we anticipate that a portion ofour expenses, principally salaries and related personnel expenses in Israel, will continue to be denominated in shekels, we expect to incur an increasingamount of expenses in U.S. dollars as we expand our operations in the U.S. We also have expenses, although to a much lesser extent, in other non-dollarcurrencies, in particular the Euro. Moreover, for the next few years we expect that the substantial majority of our revenues, if any, will be denominated in U.S.dollars from the sale of FMX101 and potentially other product candidates in the U.S. Having the substantial majority of our revenues denominated in U.S.dollars while having a substantial portion of our expenses denominated in Israeli shekels and other non-U.S. currencies exposes us to risk, associated withexchange rate fluctuations vis-à-vis the U.S. dollar. See "Item 3.D. Risk Factors—Exchange rate fluctuations between the U.S. dollar and the Israeli shekelmay negatively affect our earnings." A devaluation of the shekel in relation to the U.S. dollar has the effect of reducing the U.S. dollar amount of our expenses or payables that are payable inshekels, unless those expenses or payables are linked to the U.S. dollar. Conversely, any appreciation of the shekel in relation to the U.S. dollar has the effectof increasing the U.S. dollar value of our unlinked shekel expenses, which would have a negative impact on our profit margins. In 2016, the value of theshekel appreciated in relation to the U.S. dollar by -1.5%, the effect of which was compounded by deflation in Israel at a rate of approximately -0.2%. In2016, the value of the shekel depreciated in relation to the U.S. dollar by approximately 0.3%, the effect of which was set-off by deflation in Israel at the rateof approximately -1.0%. Because exchange rates between the U.S. dollar and the shekel (as well as between the U.S. dollar and other currencies) fluctuate continuously, suchfluctuations have an impact on our results and period-to-period comparisons of our results. The effects of foreign currency re-measurements are reported inour statements of operations. 74 Shekel against the U.S. dollar (%) 2015 (0.3)%2016 1.5%The following table presents information about the changes in the exchange rates of the shekel against the U.S. dollar: We will continue to monitor exposure to currency fluctuations. Since February 2015 we engage in currency hedging activities in order to reduce ourexposure to currency fluctuations. Instruments that are used to hedge future risks may include foreign currency forward, swap contracts and options. Theseinstruments may be used to selectively manage risks, but we may not be fully protected against material foreign currency fluctuations. Inflation-related risks We do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will increase if inflationin Israel exceeds the devaluation of the shekel against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel. As of December 31, 2016, we do not have any market risk sensitive instruments. ITEM 12.DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 12.A-D.2. Not applicable. 12D.3-4. The Company does not have any outstanding American Depositary Shares or American Depositary Receipts. 75PART TWO ITEM 13.DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES None. ITEM 14.MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS None. ITEM 15.CONTROLS AND PROCEDURES (a)Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosurecontrols and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act and regulations promulgated thereunder) as ofDecember 31, 2016, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controlsand procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filingsunder the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financialofficers, as appropriate to allow timely decisions regarding required disclosure. (b)Management's Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financialreporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervisionof, the company's executive and financial officers and effected by the company's board of directors, management and other personnel, to provide reasonableassurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes and includes those policies andprocedures that: ·Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of thecompany; ·Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generallyaccepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations ofmanagement and directors of the company; and ·Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use of disposition of the company's assets thatcould have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation ofeffectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliancewith the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting, as of December 31, 2016. In making this assessment, ourmanagement used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-IntegratedFramework (2013). Based on our assessment, management believes that as of December 31, 2016 our internal control over financial reporting is effective based on thiscriteria. (c)Attestation Report of the Registered Public Accounting Firm See statement in Section B above. As an "emerging growth company," as defined in the JOBS Act, we may take advantage of certain temporaryexemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements ofSection 404 of SOX (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to incur additional expenses anddevote increased management effort toward ensuring compliance with them. (d)Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)that occurred during the period covered by this annual report that have materially affected, or that are reasonably likely to materially affect, our internalcontrol over financial reporting. 76 ITEM 16A.Audit Committee Financial Expert We do not currently have an audit committee financial expert as such term is defined by the SEC. However, our board of directors has determined in itsbusiness judgment that our existing committee members have the ability to oversee our financial statements based on their extensive business backgroundsand that Stanley Stern has "financial sophistication" under the NASDAQ Stock Market rules. For Mr. Stern's qualifications please refer to "Item 6.A. Directorsand Senior Management." ITEM 16B.CODE OF ETHICS Code of Business Conduct and Ethics We have adopted a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, ChiefFinancial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a "code of ethics" as defined in Item 16Bof Form 20-F promulgated by the SEC. The full text of the Code of Business Conduct and Ethics will be on our website at www.foamixpharma.com.Information contained on, or that can be accessed through, our website does not constitute a part of this report and is not incorporated by reference herein. Ifwe make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code ofethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16Bof Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer,principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form 20-F, we are required todisclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B. ITEM 16C.PRINCIPAL ACCOUNTANT FEES AND SERVICES Kesselman & Kesselman (a member firm of Pricewaterhouse Coopers International Limited, or PwC), has served as our principal independent registeredpublic accounting firm for each of the two years ended December 31, 2016 and 2015. The following table provides information regarding fees paid by us to PwC for all services, for the years ended December 31, 2016 and 2015: Year EndedDecember 31, 2016 2015 Audit fees (1) $182 $193 Tax fees(2) - 9 Total fees $182 $202 ______________________________(1)Includes professional services rendered in connection with the audit of our annual financial statements, the review of our interim financial statements,fees for the 2016 and 2015 follow-on offerings and shelf registration statements.(2)Tax consulting services.Pre-Approval of Auditors' Compensation Our audit committee is responsible for pre-approving audit and non-audit services provided to us by our independent registered public accounting firm.All of the non-audit services provided to us by the independent auditors in following the formation of our audit committee were pre-approved by the auditcommittee. ITEM 16D.EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES None. ITEM 16E.PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS None. ITEM 16F.CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT None. ITEM 16G.CORPORATE GOVERNANCE Home Country Practice Exemptions Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the NASDAQGlobal Market, are considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israelilaw relating to such matters as external directors, the audit committee and an internal auditor. This is the case even if the shares of such companies are notlisted on the Tel Aviv Stock Exchange and are listed exclusively on a non-Israeli stock exchange, although such companies are allowed to opt-out of severalof these corporate governance requirements under certain conditions. These requirements are in addition to the corporate governance requirements imposedby the NASDAQ Stock Market rules and other applicable provisions of U.S. securities laws to which we are subject as a foreign private issuer. Under theNASDAQ Stock Market rules, a foreign private issuer, such as us, may generally follow its home country rules of corporate governance in lieu of thecomparable requirements of the NASDAQ Stock Market rules, except for certain matters including (among others) the composition and responsibilities of theaudit committee and the independence of its members within the meaning of the rules and regulations of the SEC. 77We rely on this "home country practice exemption" with respect to, among others, the following requirements: ·Reporting requirements. We are a foreign private issuer and are not subject to the same requirements that are imposed upon U.S. domestic issuers bythe SEC. Under the Exchange Act, we will be subject to reporting obligations that, in certain respects, are less detailed and less frequent than those ofU.S. domestic reporting companies. For example, we will not be required to issue quarterly reports, proxy statements that comply with the requirementsapplicable to U.S. domestic reporting companies, or individual executive compensation information that is as detailed as that required of U.S.domestic reporting companies. We will also have four months after the end of each fiscal year to file our annual reports with the SEC and will not berequired to file current reports as frequently or promptly as U.S. domestic reporting companies. Furthermore, our officers, directors and principalshareholders will be exempt from the requirements to report equity holdings contained in Section 16 of the Exchange Act. ·Requirement to have a majority of independent directors. Under the rules of the NASDAQ, a U.S. domestic listed company generally must have amajority of independent directors on its board. Under the Israeli Companies Law and the regulations promulgated thereunder, we may opt-out ofcertain Israeli requirements related to the obligation to appoint external directors, within the meaning of the Companies Law, as we have done. See"Item 6.C. Board Practices—Board of Directors." ·Nomination of directors. With the exception directors elected by our board of directors due to vacancy, our directors are elected by an annual meetingof our shareholders to hold office until the next annual meeting following one year from his or her election. See "—Board Practices—Board ofDirectors." The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board ofdirectors itself, in accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. Nominations neednot be made by a nominating committee of our board of directors consisting solely of independent directors or otherwise, as required under theNASDAQ Stock Market rules. ·Compensation of officers. Israeli law and our amended and restated articles of association do not require that the independent members of our Board ofDirectors (or a compensation committee composed solely of independent members of our Board of Directors) determine an executive officer'scompensation, as is generally required under the Listing Rules of the NASDAQ Stock Market with respect to the Chief Executive Officer and all otherexecutive officers. Rather, compensation of officers requires approval first by the company's compensation committee, then by the company's board ofdirectors. If such compensation arrangement is inconsistent with the company's stated compensation policy, or if the office holder is the chiefexecutive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval forCompensation. Compensation is either consistent with our office holder compensation policy or, in special circumstances in deviation therefrom,taking into account certain considerations stated in the Israeli Companies Law. For additional information see "Item 6.B. Compensation." ·Quorum. As permitted under the Israeli Companies Law pursuant to our amended and restated articles of association, the quorum required for anordinary meeting of shareholders consists of at least two shareholders present in person, by proxy or by other voting instrument in accordance with theIsraeli Companies Law, who hold at least 25% of the voting power of our shares (and in an adjourned meeting, with some exceptions, at least twoshareholders), instead of 33⅓% of the issued share capital required under the NASDAQ Stock Market rules. ·Shareholder approval. We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the IsraeliCompanies Law, rather than seeking approval for corporation actions in accordance with NASDAQ Listing Rule 5635. In particular, under thisNASDAQ rule, shareholder approval is generally required for: (i) an acquisition of shares or assets of another company that involves the issuance of20% or more of the acquirer's shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company orthe consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption or amendment of equity compensationarrangements; and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of alisted company via a private placement (including via sales by directors, officers or 5% shareholders) if such equity is issued (or sold) at below thegreater of the book or market value of shares. By contrast, under the Israeli Companies Law, shareholder approval is required for, among other things:(a) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any otherposition that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required,(b) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval described in theRegistration Statement on Form F-1 as filed under the Securities Act with the SEC on August 13, 2014, under "Management—Approval of RelatedParty Transactions Under Israeli Law—Disclosure of Personal Interests of a Controlling Shareholder and Approval of Certain Transactions," and (c)terms of employment or other engagement of the controlling shareholder of the Company or such controlling shareholder's relative, which require thespecial approval described Registration Statement on Form F-1 as filed under the Securities Act with the SEC on August 13, 2014, under "Management—Approval of Related Party Transactions Under Israeli Law— Disclosure of personal interests of a controlling shareholder and approval oftransactions." In addition, under the Israeli Companies Law, a merger requires approval of the shareholders of each of the merging companies. 78Among the matters for which we do not seek shareholder approval, in reliance on Israeli law and contrary to NASDAQ Rule 5635, is the materialincrease of the number of shares reserved for grant to our employees, officers and service providers under our share incentive plans, and registered byour filings on Form S-8. We otherwise generally intend comply with the rules generally applicable to U.S. domestic companies listed on the NASDAQ Global Market. We may inthe future decide to use the foreign private issuer opt-out with respect to some or all of the other NASDAQ Stock Market rules. Fiduciary Duties of Directors and Executive Officers The Israeli Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under "Item 6.A. Directors,Senior Management and Employees—Directors and Senior Management" is an office holder under the Israeli Companies Law. An office holder's fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of carewith which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an office holderact in good faith and in the best interests of the company. The duty of care includes a duty to use reasonable means to obtain: ·information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and ·all other important information pertaining to any such action. The duty of loyalty includes a duty to: ·refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; ·refrain from any activity that is competitive with the company; ·refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and ·disclose to the company any information or documents relating to the company's affairs which the office holder received as a result of his or herposition as an office holder. Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware ofand all related material information or documents concerning any existing or proposed transaction with the company. An interested office holder's disclosuremust be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. A personal interestincludes an interest of any person in an action or transaction of a company, including a personal interest of such person's related party or of a corporate bodyin which such person or a related party of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appointat least one director or the general manager, but excluding a personal interest stemming from one's ownership of shares in the company. A personal interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of theoffice holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest in thematter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in atransaction that is not considered an extraordinary transaction. 79Under the Israeli Companies Law, an extraordinary transaction is defined as any of the following: ·a transaction other than in the ordinary course of business; ·a transaction that is not on market terms; or ·a transaction that may have a material impact on a company's profitability, assets or liabilities. If it is determined that an office holder has a personal interest in a transaction, approval by the board of directors is required for the transaction, unless thecompany's articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her personal interest in atransaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of his or her duty of loyalty. However,a company may not approve a transaction or action that is not in the company's interest or that is not performed by the office holder in good faith. An extraordinary transaction in which an office holder has a personal interest requires approval first by the company's audit committee and subsequentlyby the board of directors. The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director requires approval first by the company'scompensation committee, then by the company's board of directors. If such compensation arrangement or an undertaking to indemnify or insure isinconsistent with the company's stated compensation policy, or if the office holder is the chief executive officer (apart from a number of specific exceptions),then such arrangement is further subject to a Special Majority Approval for Compensation. Arrangements regarding the compensation, indemnification orinsurance of a director require the approval of the compensation committee, board of directors and shareholders by ordinary majority, in that order, and undercertain circumstances, a Special Majority Approval for Compensation. Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not bepresent at such a meeting or vote on that matter unless the chairman of the relevant committee or board of directors (as applicable) determines that he or sheshould be present in order to present the transaction that is subject to approval. If a majority of the members of the audit committee or the board of directors(as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or the board ofdirectors (as applicable) on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controllingshareholder of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes ashareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. Forthis purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (i) extraordinary transactionswith a controlling shareholder or in which a controlling shareholder has a personal interest, (ii) the engagement with a controlling shareholder or his or herrelative, directly or indirectly, for the provision of services to the company, (iii) the terms of engagement and compensation of a controlling shareholder orhis or her relative who is not an office holder or (iv) the employment of a controlling shareholder or his or her relative by the company, other than as an officeholder. In addition, the shareholder approval requires one of the following, which we refer to as a Special Majority: ·at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at themeeting approves the transaction, excluding abstentions; or ·the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meetingdo not exceed 2% of the voting rights in the company. To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every threeyears, unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the circumstancesrelated thereto. Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require theapproval of the compensation committee, board of directors and shareholders by a Special Majority and the terms thereof may not be inconsistent with thecompany's stated compensation policy. Pursuant to regulations promulgated under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or withdirectors, that would otherwise require approval of a company's shareholders may be exempt from shareholder approval upon certain determinations of theaudit committee and board of directors. Under these regulations, a shareholder holding at least 1% of the issued share capital of the company may require,within 14 days of the publication of such determinations, that despite such determinations by the audit committee and the board of directors, such transactionwill require shareholder approval under the same majority requirements that would otherwise apply to such transactions. 80Shareholder Duties Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and othershareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholderclass meetings with respect to the following matters: ·an amendment to the company's articles of association; ·an increase of the company's authorized share capital; ·a merger; or ·the approval of related party transactions and acts of office holders that require shareholder approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, certain shareholders have a duty of fairness toward the company. These shareholders include a controlling shareholder, a shareholder whoknows that he or she has the power to determine the outcome of a shareholder vote and a shareholder who has the power to appoint or to prevent theappointment of an office holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the duty offairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness. Anti-Takeover Measures under Israeli Law The Israeli Companies Law allow us to create and issue shares having rights different from those attached to our ordinary shares, including sharesproviding certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. Currently no preferred sharesauthorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, suchclass of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent ourshareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferredshares will require an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of thevoting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate andthe majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law. Acquisitions under Israeli Law Full tender offer A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company's issued and outstandingshare capital is required by the Israeli Companies Law to make a tender offer to all of the company's shareholders for the purchase of all of the issued andoutstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued andoutstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for thepurchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued andoutstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offeraccept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will alsobe accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicableclass of shares. Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted thetender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer wasfor less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in theterms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. If (i) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of theapplicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance ofthe tender offer, or (ii) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or ofthe applicable class), the acquirer may not acquire shares from shareholders who accepted the tender offer that will increase its holdings to more than 90% ofthe company's issued and outstanding share capital or of the applicable class. 81Special tender offer The Israeli Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as aresult of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there isalready another holder of at least 25% of the voting rights in the company. Similarly, the Israeli Companies Law provides that an acquisition of shares in apublic company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of thevoting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject tocertain exceptions. A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% ofthe voting power attached to the company's outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may beconsummated only if (i) the offeror acquired shares representing at least 5% of the voting power in the company and (ii) the number of shares tendered byshareholders who accept the offer exceeds the number of shares held by shareholders who object to the offer (excluding the purchaser, controllingshareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer). If aspecial tender offer is accepted, the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person orentity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for aperiod of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial specialtender offer. Merger The Israeli Companies Law permits merger transactions if approved by each party's board of directors and, unless certain requirements described under theIsraeli Companies Law are met, by a majority vote of each party's shareholders. In the case of the target company, approval of the merger further requires amajority vote of each class of its shares. For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of sharesrepresented at the meeting of shareholders that are held by parties other than the other party to the merger, or by any person (or group of persons acting inconcert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, voteagainst the merger. If, however, the merger involves a merger with a company's own controlling shareholder or if the controlling shareholder has a personalinterest in the merger, then the merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controllingshareholders (as described Registration Statement on Form F-1 as filed under the Securities Act with the SEC on August 13, 2014, under "Management—Approval of Related Party Transactions under Israeli Law—Fiduciary Duties of Directors and Executive Officers—Disclosure of Personal Interests ofControlling Shareholders and Approval of Certain Transactions"). If the transaction would have been approved by the shareholders of a merging company if it weren't for the need for separate approval of each class or theexclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of at least 25% of thevoting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable, taking into account the respectivevalues assigned to each of the parties to the merger and the consideration offered to the shareholders of the target company. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists areasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may furthergive instructions to secure the rights of creditors. In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger is filedwith the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. Borrowing Powers Pursuant to the Israeli Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take allactions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including thepower to borrow money for company purposes. ITEM 16H.MINE SAFETY DISCLOSURE Not applicable. 82 PART THREE ITEM 17.FINANCIAL STATEMENTS Not applicable. ITEM 18.FINANCIAL STATEMENTS The following consolidated financial statements, and the related notes thereto, and the Reports of Independent Public Accountants are filed as a part ofthis annual report. Page Report of Independent Registered Public Accounting FirmF-2 Consolidated Balance SheetsF-3 Consolidated Statements of OperationsF-5 Consolidated Statements of Comprehensive LossF-6 Statements of Changes in Shareholders’ EquityF-7 Consolidated Statements of Cash FlowsF-8 Notes to Consolidated Financial StatementsF-9 83ITEM 19. EXHIBITSEXHIBIT INDEXEXHIBITNUMBERDESCRIPTION OF DOCUMENT1.1Amended and Restated Articles of Association of the Company*4.12009 Israeli Share Option Plan*4.22015 Israeli Share Incentive Plan**4.3Summary English Translation of Lease Agreement, dated as of May 7, 2008, as amended, by and between the Registrant and Gav YamReal Estate Ltd**4.4Form of indemnification agreement by and between the Registrant and each of its directors and executive officers*4.5Employment Agreement, dated as of August 22, 2014, between the Registrant and Dr. Dov Tamarkin*4.6Employment Agreement, dated as of August 22, 2014, between the Registrant and Meir Eini*4.7Foamix Pharmaceuticals Ltd. Compensation Policy for Officers and Directors****12.1Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 193412.2Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 193413.1Certification of the Chief Executive Officer pursuant to 18 U.S.C. 135013.2Certification of the Chief Financial Officer pursuant to 18 U.S.C. 135015.1Consent of Kesselman & Kesselman, independent registered public accounting firm * Filed as an exhibit to Form F-1/A filed by the Company on September 3, 2014 (File No. 333-198123) and incorporated herein by reference. ** Filed as an exhibit to Form F-3 filed by the Company on October 21, 2015 (File No. 333-207546) and incorporated herein by reference. *** Filed as an exhibit to Form F-3/A filed by the Company on September 12, 2016 (File No. 333-207546) and incorporated herein by reference. **** Filed as an exhibit to Form 6-K/A filed by the Company on May 20, 2015. The following materials from our Annual Report on Form 20-F for the year ended December 31, 2016 formatted in XBRL (Extensible Business ReportingLanguage) are furnished herewith: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Comprehensive Loss, (iii) the ConsolidatedStatements of Changes in Shareholders' Equity, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to Consolidated Financial Statements,tagged as blocks of text and in detail. 84SIGNATURES Foamix Pharmaceuticals Ltd. hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized theundersigned to sign this annual report on its behalf. FOAMIX PHARMACEUTICALS LTD. By: /s/ Dov Tamarkin Dr. Dov Tamarkin Chief Executive Officer Date: February 21, 2017 85 FOAMIX PHARMACEUTICALS LTD. CONSOLIDATED FINANCIAL STATEMENTSAS OF DECEMBER 31, 2016  FOAMIX PHARMACEUTICALS LTD. CONSOLIDATED FINANCIAL STATEMENTSAS OF DECEMBER 31, 2016 INDEX Page Report of Independent Registered Public Accounting FirmF-2 Consolidated Balance SheetsF-3 Consolidated Statements of OperationsF-5 Consolidated Statements of Comprehensive LossF-6 Statements of Changes in Shareholders’ EquityF-7 Consolidated Statements of Cash FlowsF-8 Notes to Consolidated Financial StatementsF-9REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMTo the shareholders ofFOAMIX PHARMACEUTICALS LTD.We have audited the accompanying consolidated balance sheets of Foamix Pharmaceuticals Ltd. and its subsidiary as of December 31, 2016 and 2015 andthe related consolidated statements of operations, comprehensive loss, shareholders’ equity and cash flows for each of the three years in the period endedDecember 31, 2016. These financial statements are the responsibility of the Company's Board of Directors and management. Our responsibility is to expressan opinion on these financial statements based on our audits.We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require thatwe plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includesexamining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accountingprinciples used and significant estimates made by the Company's Board of Directors and management, as well as evaluating the overall financial statementpresentation. We believe that our audits provide a reasonable basis for our opinion.In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of theCompany and its subsidiary as of December 31, 2016 and 2015 and the results of their operations and their cash flows for each of the three years in the periodended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America. Tel-Aviv, Israel/s/ Kesselman & KesselmanFebruary 21, 2017Certified Public Accountants (lsr.) A member firm of PricewaterhouseCoopers International LimitedKesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel,P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/ilF - 2 FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED BALANCE SHEETS(U.S. dollars in thousands) December 31 2016 2015 A s s e t s CURRENT ASSETS: Cash and cash equivalents $31,190 $18,795 Restricted cash 250 - Short term bank deposits 38,351 13,107 Investment in marketable securities (Note 4) 43,275 23,693 Restricted investment in marketable securities (Note 4) 261 769 Accounts receivable: Trade 3,236 314 Other (Note 11) 438 471 TOTAL CURRENT ASSETS 117,001 57,149 NON-CURRENT ASSETS: Investment in marketable securities (Note 4) 17,532 32,285 Restricted investment in marketable securities (Note 4) 129 - Investment in long term bank deposits - 15,130 Property and equipment, net (Note 5) 938 646 Other 35 35 TOTAL NON-CURRENT ASSETS 18,634 48,096 TOTAL ASSETS $135,635 $105,245 The accompanying notes are an integral part of these financial statements.F - 3FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED BALANCE SHEETS(U.S. dollars in thousands) December 31 2016 2015 Liabilities and shareholders’ equity CURRENT LIABILITIES: Current maturities of bank borrowing (Note 8c) $20 $31 Accounts payable and accruals: Trade 2,267 1,353 Deferred revenues - 29 Other (Note 11) 2,984 2,169 Loan from the BIRD foundation (Note 8a) - 476 TOTAL CURRENT LIABILITIES 5,271 4,058 LONG-TERM LIABILITIES: Bank borrowing (Note 8c) - 20 Liability for employee severance benefits (Note 6) 379 365 TOTAL LONG-TERM LIABILITIES 379 385 TOTAL LIABILITIES 5,650 4,443 COMMITMENTS (Note 7) SHAREHOLDERS' EQUITY: Ordinary Shares, NIS 0.16 par value - authorized: 50,000,000 OrdinaryShares as of December 31, 2016 and December 31, 2015; issued andoutstanding: 37,167,791 and 30,639,134 Ordinary Shares as ofDecember 31, 2016 and December 31, 2015, respectively 1,561 1,284 Additional paid-in capital 204,052 145,878 Accumulated deficit (75,566) (46,230)Accumulated other comprehensive loss (62) (130)TOTAL SHAREHOLDERS' EQUITY 129,985 100,802 TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $135,635 $105,245 The accompanying notes are an integral part of these financial statements. F - 4 FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED STATEMENTS OF OPERATIONS (U.S. dollars in thousands, except per share data) Year ended December 31 2016 2015 2014 REVENUES (Note 11) $5,527 $849 $5,414 COST OF REVENUES 59 70 527 GROSS PROFIT 5,468 779 4,887 OPERATING EXPENSES: Research and development 25,897 10,680 3,557 Selling, general and administrative 9,221 7,029 2,964 TOTAL OPERATING EXPENSES 35,118 17,709 6,521 OPERATING LOSS 29,650 16,930 1,634 FINANCE EXPENSES (INCOME), net (Note 11) (701) (452) 9,844 LOSS BEFORE INCOME TAX 28,949 16,478 11,478 INCOME TAX (Note 10) 387 39 6 NET LOSS FOR THE YEAR $29,336 $16,517 $11,484 LOSS PER SHARE BASIC AND DILUTED $0.91 $0.58 $0.79 WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATIONOF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS 32,263 28,229 14,512 The accompanying notes are an integral part of these consolidated financial statements.F - 5FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (U.S. dollars in thousands) Year ended December 31 2016 2015 2014 NET LOSS OTHER COMPREHENSIVE LOSS (INCOME): $29,336 $16,517 $11,484 Net unrealized losses (gains) from marketable securities (65) 103 68 Gains (losses) on marketable securities reclassified into net loss 4 (57) 11 Net unrealized losses (gains) on derivative financial instruments (20) 5 - Gains on derivative financial instruments reclassified into net loss 13 - - TOTAL OTHER COMPREHENSIVE LOSS (INCOME) (68) 51 79 TOTAL COMPREHENSIVE LOSS $29,268 $16,568 $11,563 The accompanying notes are an integral part of these financial statements F - 6FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(U.S. dollars in thousands, except share data) Ordinaryshares Additionalpaid-in capital Accumulateddeficit Accumulatedothercomprehensiveloss Total Number of shares Amounts Amounts BALANCE AT JANUARY 1, 2014 11,408,490 $471 $14,176 $(18,229) $- $(3,582)CHANGES DURING 2014: Comprehensive loss - - - (11,484) (79) (11,563)Capital contribution (Note 8b) - - 686 - - 686 Conversion of preferred A sharesinto Ordinary Share (Note 9) 3,367,244 147 13,291 - - 13,438 Conversion of warrants frompreferred A warrants toOrdinary Share warrants (Note9d) - - 8,494 - - 8,494 Issuance of Ordinary Sharesthrough an initial publicoffering, net of $4.9 millionissuance costs (Note 9c) 7,668,200 336 40,756 - - 41,092 Share-based compensation (Note9f) - - 197 - - 197 BALANCE AT DECEMBER 31,2014 22,443,934 954 77,600 (29,713) (79) 48,762 CHANGES DURING 2015: Comprehensive loss - - - (16,517) (51) (16,568)Issuance of Ordinary Sharesthrough a public offering, netof $4.8 million issuance costs(Note 9c) 7,419,353 298 63,904 - - 64,202 Exercise of warrants (Note 9e) 546,322 23 2,262 - - 2,285 Exercise of options andrestricted share units(Note 9f) 229,525 9 335 - - 344 Share-based compensation (Note9f) - - 1,777 - - 1,777 BALANCE AT DECEMBER 31, 2015 30,639,134 1,284 145,878 (46,230) (130) 100,802 CHANGES DURING 2016: Comprehensive income (loss) - - - (29,336) 68 (29,268)Issuance of Ordinary Sharesthrough a public offering, netof $3.9 million issuance costs(Note 9c) 6,111,959 260 53,872 - - 54,132 Exercise of warrants (Note 9e) 257,137 10 1,285 - - 1,295 Exercise of options andrestricted share units(Note 9f) 159,561 7 105 - - 112 Share-based compensation (Note9f) - - 2,912 2,912 BALANCE AT DECEMBER 31, 2016 37,167,791 $1,561 $204,052 $(75,566) $(62) $129,985 The accompanying notes are an integral part of these financial statements F - 7 FOAMIX PHARMACEUTICALS LTD.CONSOLIDATED STATEMENTS OF CASH FLOWS(U.S. dollars in thousands) Year ended December 31 2016 2015 2014 CASH FLOWS FROM OPERATING ACTIVITIES: Net Loss $(29,336) $(16,517) $(11,484)Adjustments required to reconcile net loss to net cash used in operating activities: Depreciation and amortization 143 87 33 Loss from disposal of fixed assets 16 15 - Changes in marketable securities and bank deposits, net 91 57 550 Changes in accrued liability for employee severance benefits,net of retirement fund profit 14 35 81 Share-based compensation 2,912 1,777 197 Non-cash finance expenses (income), net (1) (8) 9,925 Changes in operating asset and liabilities: Decrease (increase) in trade and other receivable (2,889) 140 (338)Increase in other non-current assets - (1) (24)Increase in accounts payable and accruals 1,680 1,917 346 Net cash used in operating activities (27,370) (12,498) (714) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets (424) (500) (219)Investment in bank deposits (23,000) (28,000) - Investment in marketable securities (31,700) (72,518) (11,107)Proceeds from sale and maturity of marketable securities and bank deposits 40,106 22,502 3,977 Net cash used in investing activities (15,018) (78,516) (7,349) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of ordinary shares through public offerings, net of issuance costs 54,132 64,202 41,092 Proceeds from issuance of Preferred A shares and warrants, net of issuance costs - - 8,157 Proceeds from exercise of warrants 1,295 2,285 - Proceeds from exercise of options 112 344 - Payments in respect of BIRD loan (476) - - Bank borrowings - - 102 Payments in respect of bank borrowings (32) (30) (12)Net cash provided by financing activities 55,031 66,801 49,339 INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 12,643 (24,213) 41,276 EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTEDCASH 2 *- (15) CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD 18,795 43,008 1,747 CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD $31,440 $18,795 $43,008 Cash and cash equivalents $31,190 $18,795 $43,008 Restricted cash 250 - - TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN INSTATEMENT OF CASH FLOWS $31,440 $18,795 $43,008 SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOTINVOLVING CASH FLOWS - Cashless exercise of warrants - 4 - Conversion of convertible loans into Preferred A Shares and warrants - - 8,096 Conversion of Preferred A Shares into Ordinary Shares - - 13,438 Conversion of warrants from preferred A warrants to Ordinary Share warrants - - 8,494 Property and equipment purchases included in accounts payable and accruals 27 - - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for taxes 163 16 - Interest received 1,015 921 - Interest paid 239 - - * Represents an amount less than $1. The accompanying notes are an integral part of these financial statements. F - 8 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS(U.S. dollars in thousands, except share and per share amounts) NOTE 1 - NATURE OF OPERATIONSFoamix Pharmaceuticals Ltd. (hereinafter “Foamix”) is an Israeli company incorporated in 2003. Foamix’s shares are publicly traded on theNASDAQ under the symbol “FOMX”, since its initial public offering (“IPO”) in September, 2014. Foamix is a clinical-stage specialty pharmaceutical company operating in one segment - the development and commercialization of foam-basedformulations, using its proprietary technology, which includes its foam platforms. Foamix develops its own product candidates, mainly for thetreatment of moderate-to-severe acne, the treatment of moderate-to-severe papulo-pustular rosacea and other skin conditions. It also licenses itstechnology under development and licensing agreements to various pharmaceutical companies for development of certain products combiningFoamix's foam technology with the licensee’s proprietary drugs. In May 2014, Foamix incorporated a wholly-owned subsidiary in the United States of America - Foamix Pharmaceuticals Inc. ("the subsidiary").The subsidiary was incorporated to assist Foamix with regard to marketing, regulatory affairs and business development relating its products andtechnology. Since incorporation through December 31, 2016, Foamix and its subsidiary (hereinafter “the Company”) has incurred losses and negative cashflows from operations mainly attributable to its development efforts and has an accumulated deficit of $75,566. The Company has financed itsoperations mainly through private and public financing rounds, convertible loans, royalties and payments received under development andlicensing agreements. The Company's cash, cash equivalents, deposits and marketable securities as of December 31, 2016, will allow theCompany to fund its operating plan through at least the next 12 months. However, the Company expects to continue to incur significant researchand development and other expenses related to its ongoing operations and in order to continue its future operations, the Company will need toobtain additional funding until becoming profitable. If the Company is unable to obtain such funding it will need to curtail or cease operations. NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:a.Basis of presentationThe Company’s financial statements have been prepared in accordance with generally accepted accounting principles in the United Statesof America (“U.S. GAAP”). b.Use of estimates in the preparation of financial statementsThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affectthe reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements andthe reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicableto these financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation. F - 9 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):c.Functional currencyThe U.S. dollar (“dollar”) is the currency of the primary economic environment in which the operations of Foamix and the subsidiary areconducted. Almost all Company revenues and operational expenses are in dollars and the Company’s financing has been provided indollars. Accordingly, the functional currency of the Company is the dollar.Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies aretranslated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollartransactions and other items in the statements of operations (indicated below), the following exchange rates are used: (i) for transactions -exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such asdepreciation and amortization, etc.) - historical exchange rates. Currency transaction gains and losses are presented in financial income orexpenses, as appropriate. d.Principles of consolidationThe consolidated financial statements include the accounts of Foamix and its subsidiary. Intercompany balances and transactions havebeen eliminated upon consolidation.e.Cash and cash equivalents The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits withoriginal maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readilyconvertible to known amounts of cash. f.Bank depositsBank deposits with original maturity dates of more than three months but less than one year are included in short-term deposits. Bankdeposits with maturity of more than one year are considered long-term. The interest rates on the Company’s deposits range between 1.3%-1.6%. The fair value of bank deposits approximates the carrying value since they bear interest at rates close to the prevailing market rates.g.Marketable securitiesThe Company invests in debt and equity securities classified as available for sale in accordance with ASC 320, Investments - Debt andEquity Securities. Management determines the appropriate classification of its investments in securities at the time of purchase and reevaluates suchdeterminations at each balance sheet date. Classifications of debt securities in the balance sheet are determined based on the maturity dateof the securities.Unrealized gains of available for sale securities, net of taxes, are reflected in other comprehensive income (loss). Unrealized lossesconsidered to be temporary are reflected in other comprehensive income (loss); unrealized losses that are considered to be other-than-temporary are charged to income as an impairment charge. Realized gains and losses for both debt and equity securities are included infinancial expense (income), net. F - 10FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):For equity securities, the Company considers available evidence in evaluating potential impairments of its investments, including theduration and extent to which fair value is less than cost. For debt securities, an other-than-temporary impairment has occurred if theCompany does not expect to recover the entire amortized cost basis of the debt security. If the Company does not intend to sell theimpaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortizedcost basis, the amount of the other-than-temporary impairment recognized in earnings, recorded in financial expense, net, is limited to theportion attributed to credit loss. The remaining portion of the other-than-temporary impairment related to other factors is recognized inother comprehensive income or loss.h.DerivativesThe Company purchases foreign exchange derivative financial instruments (written and purchased currency options). The transactions aredesigned to hedge the Company’s currency exposure.The Company recognizes all derivatives as either assets or liabilities in the consolidated balance sheet at their fair value. Changes in thefair value of derivatives that are highly effective and designated as cash flow hedges are reported as a component of other comprehensiveincome or loss and reclassified into earnings in the same line-item associated with the forecasted transaction and in the same periodsduring which the hedged transaction impacts earnings.For derivatives that qualify for hedge accounting, the cash flows associated with these derivatives are reported in the consolidatedstatements of cash flows consistently with the classification of cash flows from the underlying hedged items that these derivatives arehedging.i.Property and equipment:1)Property and equipment are stated at cost, net of accumulated depreciation and amortization. 2)The Company’s property and equipment are depreciated by the straight-line method on the basis of their estimated useful life.Annual rates of depreciation are as follows: %Computers15-33 (mainly 33)Laboratory equipment7-20Office furniture and equipment7-15Vehicles15 Leasehold improvements are amortized by the straight-line method over the expected lease term, which is shorter than the estimateduseful life of the improvements. F - 11 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):j.Impairment of long-lived assetsThe Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum ofexpected future cash flows (undiscounted and without interest charges) of the assets is less than the carrying amount of such assets, animpairment loss would be recognized. The assets would be written down to their estimated fair values, calculated based on the presentvalue of expected future cash flows (discounted cash flows), or some other fair value measure.For the three years ended December 31, 2016, the Company did not recognize an impairment loss for its long-lived assets.k.Allowance for doubtful accountsThe Company performs ongoing credit evaluations to estimate the need for maintaining reserves for potential credit losses. An allowancefor doubtful accounts is recognized on a specific basis with respect to those amounts that the Company has determined to be doubtful ofcollection. No allowance for doubtful accounts was recorded in the years ended December 31, 2016, December 31, 2015 and December31, 2014.l.ContingenciesCertain conditions may exist as of the date of the financial statements, which may result in a loss to the Company but which will only beresolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities and suchassessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pendingagainst the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceivedmerits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to besought.Management applies the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of acontingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then theestimated liability is recorded as accrued expenses in the Company’s financial statements. If the assessment indicates that a potentialmaterial loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of thecontingent liability, together with an estimate of the range of possible loss if determinable and material are disclosed.Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case theguarantees are disclosed.m.Share-based compensationThe Company accounts for employees’ and directors’ share-based payment awards classified as equity awards using the grant-date fairvalue method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net ofestimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vestingschedule using the straight-line method based on the multiple-option award approach. F - 12 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 2−SIGNIFICANT ACCOUNTING POLICIES (continued):When options and restricted share units (hereinafter “RSUs”) are granted as consideration for services provided by consultants and othernon-employees, the grant is accounted for based on the fair value of the consideration received or the fair value of the awards issued,whichever is more reliably measurable. The fair value of the awards granted is measured on a final basis at the end of the related serviceperiod and is recognized over the related service period using the straight-line method. n.Revenue recognitionThe Company's revenues are derived from development and license agreements for development of products combining the Company'sfoam technology with a drug selected by the licensee.The significant deliverables in the agreements between the Company and its licensees are the obligation of the Company to providedevelopment services and the grant of an exclusive license to the specific product developed. These deliverables are combined into one single unit of accounting for revenue recognition purposes since: ·Each element does not have value on a stand-alone basis. ·In order to develop the combined formulation in the licensed product, the use of the Company’s propriety technology is required.Therefore, the Company is the only party capable of performing the level and type of development services required under theagreement. The Company’s development and license agreements entitle the Company to: ·Development payments, including upfront payments, cost reimbursements and payments contingent only upon passage of time(together - “Development Service Payments”). ·Payments contingent solely upon performance or achievement of clinical results by the Company’s licensees (“ContingentPayments”). ·Royalties, calculated as a percentage of sales of the developed products made by the Company's licensees.Revenues from Development Service Payments under development and license agreements are recognized as the services are provided.When the Company receives a portion of the Development Service Payment before performance of such services, these advances arerecorded as deferred revenues and recognized as revenues as services are performed.Contingent Payments are recognized when the licensee’s performance or achievement event occurs. Royalties are recognized when subsequent sales are made by the licensees. o.Research and development costsResearch and development expenses include costs directly attributable to the conduct of research and development programs, includingthe cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses, consumable equipmentand consulting fees. All costs associated with research and developments are expensed as incurred.F - 13 Year ended December 31 2016 2015 2014 Outstanding share options and RSUs 2,698,875 2,124,951 1,171,125 Warrants 1,807,800 2,064,937 2,716,956 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):p.Income taxes:1)Deferred taxesIncome taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets andliabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and aremeasured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely thannot that the deferred taxes will not be realized in the foreseeable future. Given the Company’s losses, the Company has provided afull valuation allowance with respect to its deferred tax assets.2)Uncertainty in income tax The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the taxposition for recognition by determining if the available evidence indicates that it is more likely than not that the position will besustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount thathas more than a 50% likelihood of being realized upon ultimate settlement. q.Loss per shareNet loss per share, basic and diluted, is computed on the basis of the net loss for the year divided by the weighted average number ofcommon shares outstanding during the year. Diluted net loss per share is based upon the weighted average number of common shares andof common shares equivalents outstanding when dilutive. Common share equivalents include outstanding stock options and warrantswhich are included under the treasury share method when dilutive.The following share options, RSUs and warrants were excluded from the calculation of diluted net loss per ordinary share because theireffect would have been anti-dilutive for the periods presented (share data):r.Fair value measurement Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderlytransaction between market participants at the measurement date. In order to increase consistency and comparability in fair valuemeasurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fairvalue into three broad levels, which are described as follows: Level 1:Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair valuehierarchy gives the highest priority to Level 1 inputs. Level 2:Observable prices that are based on inputs not quoted on active markets, but corroborated by market data or active marketdata of similar or identical assets or liabilities. F - 14 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued): Level 3:Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority toLevel 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use ofunobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. s.Concentration of credit risks Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cashequivalents, restricted cash, bank deposits, marketable securities and certain receivables. The Company deposits cash and cashequivalents with highly rated financial institutions and, as a matter of policy, limits the amounts of credit exposure to any single financialinstitution. In addition, all marketable securities carry a high rating or are government insured. The Company has not experienced anymaterial credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. t.Comprehensive lossComprehensive loss includes, in addition to net loss, unrealized holding gains and losses on available-for-sale securities and derivativeinstruments designated as cash flow hedge (net of related taxes where applicable).Reclassification adjustments for gain or loss of available for sales securities are included in finance expenses net in the statement ofincome.u.Newly issued and recently adopted accounting pronouncements: Accounting pronouncements adopted in 2016:1)In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230) Restricted Cash”. The new guidancerequires that the reconciliation of the beginning-of-period and end-of-period amounts shown in the statement of cash flows includerestricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balancesheet, companies will be required to reconcile the amounts presented on the statement of cash flows to the amounts on the balancesheet. Companies will also need to disclose information about the nature of the restrictions. The guidance is effective for annual aninterim reporting periods beginning after December 15, 2017, and early adoption is permitted. The Company has chosen to adopt thisguidance starting from the year ended December 31, 2016.Accounting pronouncements that are not yet effective and have not been early adopted by the Company:1)In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which impacts virtually allaspects of an entity’s revenue recognition. The core principle of Topic 606 is that revenue should be recognized to depict the transferof promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled inexchange for those goods or services. In July 2015, the FASB deferred the effective date of the standard by one year which results inthe new standard being effective for the Company at the beginning of its first quarter of fiscal year 2018. In addition, during March,April and May 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versusAgent Considerations (Reporting Revenue Gross versus Net), ASU 2016-10, Revenue from Contracts with Customers (Topic 606):Identifying Performance Obligations and Licensing and ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, respectively, which clarified the guidance on certain items such as reporting revenueas a principal versus agent, identifying performance obligations, accounting for intellectual property licenses, assessing collectabilityand presentation of sales taxes. The Company is currently evaluating the impact of this new standard, however it is not expected tohave a material impact on the Company’s consolidated financial statements.F - 15 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued): 2)In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments—Overall (Subtopic 825-10)." This standard makesseveral modifications to Subtopic 825-10 including the elimination of the available-for-sale classification of equity investments, andrequires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized innet income. It is effective for interim and annual periods beginning after December 15, 2017. The Company is currently evaluatingthe impact of the amended guidance on its consolidated financial statements.3)In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting,Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largelyunchanged. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, and interim periods withinthose fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leasesexisting at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company iscurrently evaluating the impact of this new standard on its consolidated financial statements.4)In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718). ASU No. 2016-09 identifiesareas for simplification involving several aspects of accounting for share-based payment transactions, including the income taxconsequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense withactual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. The amendments areeffective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Earlyadoption is permitted but all of the guidance must be adopted in the same period. The adoption of this standard is not expected tohave a material impact on the Company’s consolidated financial statements.5)In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments.” This ASU significantlychanges how entities will measure credit losses for most financial assets and certain other instruments that aren’t measured at fairvalue through net income. In issuing the standard, the FASB is responding to criticism that today’s guidance delays recognition ofcredit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to asthe current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortizedcost, and (2) certain off-balance sheet credit exposures. This includes, but is not limited to, loans, leases, held-to-maturity securities,loan commitments, and financial guarantees. The CECL model does not apply to available-for-sale (“AFS”) debt securities. For AFSdebt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that thelosses will be recognized as allowances rather than reductions in the amortized cost of the securities. As a result, entities willrecognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today.The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands thedisclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and leaselosses. In addition, entities will need to disclose the amortized cost balance for each class of financial asset by credit quality indicator,disaggregated by the year of origination. ASU No. 2016-13 is effective for interim and annual reporting periods beginning afterDecember 15, 2019; early adoption is permitted for interim and annual reporting periods beginning after F - 16 December 31, 2016 Level 1 Level 2 Total Marketable securities $957 $60,240 $61,197 Currency options designated as hedging instruments (current asset) - $2 $2 December 31, 2015 Level 1 Level 2 Total Marketable securities $1,977 $54,770 $56,747 Currency options designated as hedging instruments (current liability) - $(5) $(5) 2014 Warrants* Embeddedderivatives** Balance at beginning of year $- $1,529 Warrants issued during the year 2,129 - Changes in fair value during the year 6,365 680 Conversion of convertible loans - (2,209)Conversion of warrants from preferred A warrants into ordinary share warrants (8,494) - Balance at end of year $- $- FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (continued):December 15, 2018. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of thebeginning of the first reporting period in which the guidance is effective (i.e., modified retrospective approach). The Company iscurrently evaluating the impact of the adoption of this guidance on its consolidated financial statements.6)In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows Topic 230: Classification of Certain Cash Receipts andCash Payments.” ASU No. 2016-15 issued guidance to clarify how certain cash receipts and cash payments should be presented in thestatement of cash flows. ASU 2014-15 is effective for annual and interim reporting periods beginning on or after December 15, 2016,and early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’sconsolidated financial statements. NOTE 3 - FAIR VALUE MEASUREMENTS The Company’s assets and liabilities that are measured at fair value as of December 31, 2016, and December 31, 2015, are classified in the tablesbelow in one of the three categories described in note 2r above: The Company’s corporate debt securities are traded in markets that are not considered to be active, but are valued based on quoted market prices,broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Accordingly, these assets are categorizedas Level 2.The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 (the derivativeembedded in the convertible loans):F - 17 December 31 2016 2015 Israeli mutual funds $957 $1,977 Certificates of deposit 33,350 35,627 Municipal and agency bonds 26,890 19,143 Total $61,197 $56,747 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 3 - FAIR VALUE MEASURMENTS (continued):*On September 17, 2014, as part of the Company’s initial public offering all preferred A shares were converted into ordinary shares(see Note 9). As a result, all outstanding warrants to purchase Preferred A shares (see Note 9c) were transformed on that date (“theConversion Date”) in accordance with their original terms, to warrants to purchase ordinary shares. Based on relevant accountingprinciples, these warrants are considered equity instruments. Accordingly, on the Conversion Date, those warrants ceased to beaccounted for as a liability and were recorded as equity. The fair value of each of the warrants, on the Conversion Date, was determined by using the Black-Scholes model. The underlyingdata used for computing the fair value of the warrants were mainly as follows: $6 value of ordinary shares, 0% Dividend yield, 1.45%risk free interest rate, 65% expected volatility and 3.6 years expected term.**As the convertible loans have been automatically converted on May 12, 2014, the change in fair value of the embedded derivativerepresents the difference between the carrying amount of the embedded as of December 31, 2013 and their original amount whichhave been recorded within the finance expenses. See note 8b.Foreign exchange risk managementThe Company purchases and writes options in order to hedge the currency exposure on the Company’s cash flow. The currency hedged items aredenominated in New Israeli Shekel (NIS). The purchasing and writing of options is part of a comprehensive currency hedging strategy. Thesetransactions are at zero cost for periods of up to one year. The counterparty to the derivatives are major banks in Israel.During February 2015, the Company began purchasing and writing options in respect of salary, rent and other expenses dominated in NIS for aperiod of up to a year ahead. These transactions qualify for cash flow hedge accounting. As of December 31, 2016 the Company recorded incomein the amount of $13 in operating expenses relating to hedge transaction.As of December 31, 2016 the total hedged amount was NIS 13.5 million.As of December 31, 2016, the Company has a lien in the amount of $224 on the Company’s marketable securities and a lien in the amount $250on the Company’s checking account, in respect of bank guarantees granted in order to secure the hedging transactions.NOTE 4 - MARKETABLE SECURITIESMarketable securities as of December 31, 2016, and December 31, 2015, consist mainly of debt and equity securities. These securities areclassified as available-for-sale and are recorded at fair value. Changes in fair value, net of taxes (if applicable), are reflected in othercomprehensive loss. Realized gains and losses on sales of the securities, as well as premium or discount amortization, are included in theconsolidated statement of operations as finance income or expenses.The following table sets forth the Company’s marketable securities:F - 18 December 31, 2016 Fairvalue Cost orAmortized cost Grossunrealizedholding loss Grossunrealizedholding gains Israeli mutual funds $957 $952 $- $5 Certificates of deposit 33,350 33,408 68 10 Agency bonds 26,890 26,901 13 2 Total $61,197 $61,261 $81 $17 December 31, 2015 Fairvalue Cost orAmortized cost Grossunrealizedholding loss Grossunrealizedholding gains Israeli mutual funds $1,977 $1,978 $3 $2 Certificates of deposit 35,627 35,703 79 3 Municipal and agency bonds 19,143 19,191 49 1 Total $56,747 $56,872 $131 $6 Market value December 31 2016 2015 Due within one year $42,708 $22,485 1 to 2 years 14,513 27,046 2 to 3 years 3,019 5,239 Total $60,240 $54,770 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 4 - MARKETABLE SECURITIES (continued): At December 31, 2016 and 2015, the fair value, cost and gross unrealized holding gains of the securities owned by the Company were as follows: As of December 31, 2016, the unrealized losses attributed to the Company’s marketable securities were primarily due to credit spreads andinterest rate movements. The Company has considered factors regarding other than temporary impaired securities and determined that there areno securities with impairment that is other than temporary as of December 31, 2016, and December 31, 2015. During the year ended December 31, 2016 the Company received proceeds of $27,106 upon sale and maturity of marketable securities.As of December 31, 2016, and December 31, 2015, the Company’s debt securities had the following maturity dates:$390 and $769 of the Company’s marketable securities were restricted as of December 31, 2016, and December 31, 2015, respectively, due to alien in respect of bank guarantees granted to secure hedging transaction and the Company’s rent agreement. Refer to note 7 and note 3. F - 19 December 31 2016 2015 Cost: Leasehold improvements $229 $164 Computers and software 187 130 Laboratory equipment 896 768 Furniture 96 84 Vehicles* 198 175 1,606 1,321 Less: Accumulated depreciation and amortization 668 675 Property and Equipment, net $938 $646 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 5 - PROPERTY AND EQUIPMENT: * See note 8c relating to the lien on the Company’s vehicles.Depreciation and amortization expense totaled $143, $87 and $33 for the years ended December 31, 2016, December 31 2015, and December 31,2014, respectively.During the years ended December 31, 2016 and December 31, 2015, the Company disposed of fixed assets in the net amount of $16 and $15respectively. NOTE 6 - EMPLOYEE SEVERANCE BENEFITSThe Company's liability for severance pay for its Israeli employees is calculated pursuant to Israeli severance pay law based on the most recentsalary of the employee multiplied by the number of years of employment, as of the balance sheet date, less amounts funded in each employee’sseverance fund. Such liability is recorded on the Company’s balance sheet under “Liability for employee severance benefits” as if it werepayable at each balance sheet date on an undiscounted basis. The Company partially secures this liability by purchasing insurance policies orestablishing dedicated severance accounts within the relevant employees’ pension funds, and making monthly deposits under such policies orinto such accounts. The value of these policies is recorded as an asset in the Company's balance sheet.During 2014, all of the Israeli employees agreed to the terms of Section 14 of the Israeli Severance Pay Law, 1963, according to which alldeposits in the pension fund and/or with the insurance company, thereafter, exempt the Company from any additional obligation. These depositsare accounted as defined contribution payments and therefore not recorded on the Company’s balance sheet. Once the employees agreed to theterms of Section 14, all amounts funded on behalf of the employees were released to their full ownership. The liability for employee severancebenefits as of December 31, 2016, represents the Company's obligation that has not been secured by deposits to employee severance funds.The amount of severance payment expenses were $244, $193 and $157 for the years ended December 31, 2016, December 31, 2015 andDecember 31, 2014, respectively.During 2017, the Company expects to deposit approximately $334 with respect to employee’s severance benefits.F - 20FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 7 - COMMITMENTSLease agreementThe Company leases office space for its headquarters and research and development facilities in Israel and the United States of America underseveral lease agreements. The lease agreements for the facilities in Israel are linked to the Israeli CPI and expire between February 2017 andDecember 2020. The lease agreement in the United States is due to expire during August 2017.Rental expenses for the years ended December 31, 2016, December 31, 2015 and December 31, 2014, were $358, $352 and $172, respectively.Future minimum lease commitments under non-cancelable operating lease agreements are as follows: 2017 $498 2018 554 2019 and thereafter 1,112 Total $2,164 The Company has a lien in the amount of $166 on the Company’s marketable securities in respect of bank guarantees granted in order to securethe lease agreements. NOTE 8 - LOANS:a.Loan from the BIRD foundationDuring the second quarter of 2016, the Company repaid the loan received from the Israel United States Binational Industrial Research andDevelopment Foundation (the "BIRD foundation") upon the completion of a certain clinical development. The loan, received ininstalments between 2008 and 2011, was denominated in US dollars and linked to the US Consumer Price Index.b.Convertible loans:1)During the years 2011- 2013 the Company entered into two convertible loan agreements (“2011 loan agreement” and “2012 loanagreement”), with several of its existing shareholders and other lenders, to receive an aggregate amount of $5,096. The loans boreinterest ranging between 6% and 8%.2)During the first quarter of 2014, the Company reached an agreement with certain lenders of the 2011 convertible loans that were dueto mature during that period, according to which the maturity date of those loans was deferred by one year and the interest rate wasincreased to 12% for the duration of the deferral period (the “amendment”).The Company has concluded that the amendment to the terms of the 2011 convertible loans is not considered to be “substantiallydifferent” under ASC 470-50, as the difference between the present value of the original loan and the present value of the modifiedloan was approximately 3.7%. Accordingly, the amendment was accounted for prospectively as yield adjustment, based on therevised terms of the loans.F - 21FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 8 - LOANS (continued):3)Accounting treatment of the loans2011 Convertible Loans: The automatic conversion feature in the loans has been bifurcated and accounted for as an embeddedderivative, measured initially and subsequently at fair value with changes in fair value recorded as finance expenses. The bifurcatedembedded derivative was presented in the Company's balance sheet on a combined basis with the related host contract. The loanswere measured at amortized costs using the effective interest rate method.2012 Convertible Loans: The automatic conversion feature in the loans was bifurcated and accounted for as an embedded derivativemeasured initially and subsequently at fair value with changes in fair value recorded as finance expenses. The bifurcated embeddedderivative is presented in the Company's balance sheet on a combined basis with the related host contract.The Company allocated the proceeds from its issuance of a unit consisting of 2012 convertible loans along with ordinary sharesbetween the convertible loans and the ordinary shares based on their relative fair values at the issuance date of the unit. Then, theCompany recorded the embedded derivative feature based on its fair value at the issuance date, and the remaining amount (i.e., theproceeds allocated to the convertible loans less the fair value of the embedded derivative feature) was attributed to the convertibleloans. In accordance with ASC 470-20, “Debt with Conversion and Other Options,” the Company determined that a BCF existed at theissuance date of the 2012 convertible loans. The BCF was recorded in equity and the loans net of the amount of BCF assigned tothem are measured at amortized costs using the effective interest rate method.Accordingly, the Company allocated the proceeds from the 2012 loans between these components as follows:(i)of the $1,448 of 2012 loans received in 2012, $111 were attributed to the embedded derivative, $839 were attributed to theconvertible loans and $498 were attributed to the shares. In addition, an amount of $668 was recognized as a BCF against the2012 convertible loans, resulting in a presentation of these loans (including the embedded derivative) at a net value of $282 atissuance date. The Company used Level 3 assumptions in arriving at fair value in order to appropriately allocate the proceeds:fair value of the issued shares was $1,214 and fair value of the convertible loans $2,319.(ii)of the to $1,500 of 2012 loans received in 2013, $215 were attributed to the embedded derivative, $689 were attributed to theloans and $596 were attributed to the shares. In addition, an amount of $689 was recognized as a BCF against the 2012convertible loans, resulting in a presentation of these loans (including the embedded derivative) at a net value of $ 215 atissuance date. The Company used Level 3 assumptions in arriving at fair value in order to appropriately allocate the proceeds:fair value of the issued shares was $1,752 and fair value of the convertible loans $2,662. 4)The 2014 financing round (see Note 9b) was a qualified round for purposes of the 2011 and 2012 convertible loan agreements.Accordingly, all principal and accrued interest outstanding under such loan agreements were converted into a total of 1,010,350Preferred A Shares and 505,175 warrants to purchase preferred A shares. Refer to note 9d regarding the conversion of the Preferred AShares and warrants into Ordinary Shares and warrants.F - 22FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 8 - LOANS (continued):In accordance with the amended convertible loan agreements, the lenders were entitled to receive, upon conversion, a total of1,010,350 warrants to purchase preferred A shares (hereinafter “the warrants”). However, the lenders, who were also shareholders ofthe Company, agreed to receive only half of the warrants that they were entitled to receive in accordance with the loan agreements.The value of the waiver of 505,175 warrants, amounting to $686, was recorded as a capital contribution.Upon the automatic conversion of the convertible loans, the difference at conversion date between their carrying amount (takinginto account the balance of the remaining beneficial conversion feature (BCF) the discount from the allocation of proceeds to theOrdinary Shares and the embedded derivatives) and their fixed monetary amount used for conversion in the amount of $3,520, hasbeen recorded in the statements of operations as finance expenses.c.Bank Borrowings During 2014 the Company entered into several finance agreements with a bank in order to finance the purchase of vehicles (hereinafter“the loans”). The loans are denominated in NIS and bear interest at a rate per annum equal to Prime minus 0.5%. The loans are repayablein 36 monthly payments. The total amounts received as part of the agreement were $102.In order to secure the loans the bank recorded a lien on the Company’s vehicles. NOTE 9 - SHARE CAPITAL:a.Rights of the Company’s ordinary sharesEach ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds arelegally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.b.Financing roundDuring the second quarter of 2014, the Company completed a private placement (the "2014 financing round") with a group of newinvestors and several of its existing shareholders, raising a total of $8,157, net of $123 issuance costs, in consideration of 1,036,431Preferred A Shares par value 0.16 NIS and 1,061,469 warrants to purchase Preferred A Shares (see also d. below). The 2014 financing roundclosed in two phases, the first on May 13, 2014, and the second on June 3, 2014 (respectively – "closing date"), raising a gross amount of$6,580 and $1,700, respectively.c.Public offeringsIn September 2014, the Company completed an IPO, pursuant to which the Company issued 7,668,200 ordinary shares (includingunderwriters ‘green shoe’), NIS 0.16 par value (“Ordinary Shares”) at $6.00 per share raising a total of approximately $41,100, net ofunderwriting discounts, commissions and other offering expenses. Upon the completion of the Company’s IPO, all outstanding series Apreferred shares were automatically converted into Ordinary Shares.On April 20, 2015, the Company completed a follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price of $9.30per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceedsfrom the sale of shares, after deducting underwriting discounts, commissions and other offering expenses, were approximately $64,202.F - 23FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 9 - SHARE CAPITAL (continued):On September 30, 2016, the Company completed an additional offering in which 5,700,000 ordinary shares were sold at a price of $9.50per share. On October 28, 2016, the underwriters partially exercised their ‘green shoe’ option and purchased 411,959 additional ordinaryshares. The net proceeds, including the underwriters' option, were approximately $54,132, after deducting underwriter’s discounts,commissions and other offering expenses.d.Preferred A shares and warrants conversionIn accordance with the Company’s Articles of association (the “Articles“) the initial conversion ratio of each Preferred A Share was set outto be 1:1. As the conversion rate of the Preferred A Shares was greater than 70% of the price per share of the shares issued at the closing ofthe IPO, the price protection provisions, as defined in the Articles, was triggered and caused the following: (a) the automatic reduction ofthe conversion price of the Preferred A Shares to a conversion price of 70% of the price paid for the newly issued shares; (b) the increase ofthe outstanding warrants granted to the 2014 financing round investors and lenders to a total of 2,716,956 warrants and the reduction ofthe warrants’ exercise price to 70% of the price paid for the newly issued shares which amounted to an exercise price of $5.04 per warrant.Per the above, upon the completion of the IPO, the total amount of 2,046,781 Preferred A Shares were converted into 3,367,244 OrdinaryShares.e.WarrantsPursuant to the IPO, the warrants to purchase Preferred A Shares were automatically converted into warrants to purchase Ordinary Shares.Each warrant can be exercised for one ordinary share at an exercise price of $5.04 per share or through a cashless exercise. The warrantsare exercisable until the fourth anniversary of the closing date of the 2014 financing round (May or June 2018).During the year ended December 31, 2016, 257,137 warrants were exercised into 257,137 ordinary shares. During the year endedDecember 31, 2015, 652,019 warrants were exercised into 546,322 ordinary shares. As of December 31, 2016, and December 31, 2015, thetotal amount of warrants outstanding were 1,807,800 and 2,064,937, respectively.F - 24FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 9 - SHARE CAPITAL (continued):f.Share-based compensationIn June 2009, the Company’s Board of Directors approved a share option plan and reserved a pool of 1,635,694 ordinary shares for grantto Company employees, consultants, directors and other service providers.In May 2015, the Company's board of directors approved a new option plan (the "Plan") replacing the previous plan approved in 2009.The Plan includes a pool of 2,690,694 ordinary shares for grant to Company employees, consultants, directors and other service providers.As of December 31, 2016, 845,858 shares remain available for grant under the Plan. As for the increase of the pool, refer to note 13,Subsequent events.The Plan is designed to enable the Company to grant options to purchase Ordinary Shares and RSUs under various and different taxregimes including, without limitation: (i) pursuant and subject to Section 102 of the Tax Ordinance or any provision which may amend orreplace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through atrustee or not through a trustee; and (ii) pursuant and subject to Section 3(i) of the Tax Ordinance.The fair value of each option granted is estimated using the Black-Scholes option pricing method. The volatility is based on acombination of the Company’s historical volatility, historical volatilities of companies in comparable stages as well as companies in theindustry, by statistical analysis of daily share pricing model. The risk-free interest rate assumption is based on observed interest ratesappropriate for the expected term of the options granted in dollar terms. The Company’s management uses the contractual term or itsexpectations, as applicable, of each option as its expected life. The expected term of the options granted is derived from the output of theoption pricing model and represents the period of time that granted options are expected to remain outstanding.F - 25 Year ended December 31 2015 Award amount Exercise price range Vesting period ExpirationEmployees: Options852,501 $6.77- $10.88 4 years 10 yearsRSU216,050 - 4 years 10 years Directors: Options27,000 $10.80-$11.87 3 years 10 years Consultants: Options4,000 $10.88 4 years 10 yearsRSU83,800 - 4 years 10 years Year ended December 31 2016 Award amount Exercise price range Vesting period ExpirationEmployees: Options715,310 $6.04- $8.54 4 years 10 yearsRSU25,000 - 4 years 10 years Directors: Options24,000 $7.09 3 years 10 years Consultants: Options4,800 $6.34 4 years 10 years Year ended December 31 2014 Award amount Exercise price range Vesting period ExpirationEmployees: Options217,000 $1.92- $7.98 4 years 10 years Directors: Options231,000 $5.88 3 years 10 years Consultants: Options46,875 $1.92- $7.98 0-6 years 6 yearsFOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 9 - SHARE CAPITAL (continued):In the years ended December 31, 2016, December 31, 2015 and December 31, 2014, the Company granted options to employees and non-employees as follows: The fair value of options and RSUs granted to employees and directors during 2016, 2015 and 2014 was $2,816, $6,592 and $1,683respectively. The fair value of options and RSUs granted to consultants during the years ended 2016, 2015 and 2014 was $42, $686 and$183 respectively. The fair value of RSUs granted to employees is based on the share price on grant date.F - 26 Year ended December 31 2016 2015 2014 Value of ordinary share $5.9-$8.35 $6.96-$11.3 $4.8-$6.8 Dividend yield 0% 0% 0%Expected volatility 60.3%-63.2% 60.1%-64.9% 59.0%-66.7%Risk-free interest rate 1.25%-1.86% 1.38%-1.98% 1.87%-2.22%Expected term 6 years 6 years 6-7 years December 31 2016 2015 2014 Value of ordinary share $11.1 $8.11 $5.45-$7.01 Dividend yield 0% 0% 0%Expected volatility 64.8% 69.4% 59.9%-62.0%Risk-free interest rate 2.38% 2.27% 1.81%-2.0%Expected term 9 years 10 years 6 years FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 9 - SHARE CAPITAL (continued):The fair value of options granted to employees and directors on the date of grant was computed using the Black-Scholes model. Theunderlying data used for computing the fair value of the options are as follows: The total unrecognized compensation cost of employee options and RSUs at December 31, 2016 is $6,743 which is expected to berecognized over a weighted average period of 2 years. The fair value of RSUs granted to consultants is based on the share price on December 31, 2016. The fair value of options granted during 2016, 2015 and 2014 to consultants, was computed using the Black-Scholes model. Theunderlying data used for computing the fair value of the options are as follows:F - 27 Employees and directors Consultants and service providers Number of options USD(1) Number of options USD(1) Outstanding at January 1, 2014 462,500 $1.28 220,000 $1.28 Granted 448,000 5.32 46,875 5.96 Forfeited (6,250) 1.92 - - Outstanding at December 31, 2014 904,250 3.28 266,875 2.10 Granted 879,501 7.72 4,000 10.88 Exercised (29,525) 1.92 (150,000) 1.92 Re-Designated(2) (27,000) 5.88 27,000 5.88 Outstanding at December 31, 2015 1,727,226 5.41 147,875 3.24 Granted 739,310 6.55 4,800 6.34 Forfeited (20,000) 6.66 (15,625) 7.98 Exercised (69,444) 1.64 - - Outstanding at December 31, 2016 2,377,092 $5.87 137,050 $2.81 Employees anddirectors Consultants andservice providers Number of RSUs Outstanding at January 1, 2015 - - Awarded 216,050 83,800 Vested (29,250) (20,750)Outstanding at December 31, 2015 186,800 63,050 Awarded 25,000 - Vested (69,117) (21,000)Outstanding at December 31, 2016 142,683 42,050 December 31, 2016 Options outstanding Options exercisable Number of Weighted Number of Weighted options average options Average Exercise outstanding remaining exercisable Remaining prices per at end of contractual at end of contractual share (USD) year life year Life 0.048-1.312 283,125 2.90 283,125 2.90 1.92 291,031 5.19 258,219 4.93 5.46-5.88 279,250 7.98 182,950 7.98 6.04-6.77 753,110 8.95 72,000 8.02 7.093-8.544 757,126 8.82 171,563 8.46 10.8-11.87 150,500 8.60 47,594 8.60 2,514,142 1,015,450 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 9 - SHARE CAPITAL (continued):The following table summarizes the number of options outstanding for the years ended December 31, 2016, December 31, 2015 andDecember 31, 2014, and related information: (1)Weighted average price per share (2)Pursuant to change in status of grantee from ‘director’ to ‘consultant’ during the reporting period.The following table summarizes the number of RSUs outstanding for the years ended December 31, 2016 and December 31, 2015: The following tables summarizes information concerning outstanding and exercisable options as of December 31, 2016: F - 28 Year ended December 31 2016 2015 2014 Cost of revenues $3 $2 $15 Research and development expenses 1,135 588 80 Selling, general and administrative 1,774 1,187 102 $2,912 $1,777 $197 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 9 - SHARE CAPITAL (continued):The aggregate intrinsic value of the total outstanding and exercisable options as of December 31, 2016, is $13,598 and $7,310respectively.The following table illustrates the effect of share-based compensation on the statements of operations: NOTE 10 - INCOME TAX:The Company is taxed under Israel and the United States of America tax laws:a.Tax rates:1)Income from Israel was taxed at the corporate tax rate of 26.5% in 2014, 26.5% in 2015, and 25% in 2016. Capital gains aresubject to capital gain tax, which equals to 25%.In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction ofcorporate tax rate in 2016 and thereafter, from 26.5% to 25%.In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, thelaw also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate will be24% in 2017 and 23% in 2018 and thereafter.2)Income of the subsidiary is taxed according to the federal tax laws in the US and the relevant state laws. The relevant federal taxrates for 2016, 2015 and 2014 were 35%, 30% and 15%, respectively. The relevant state tax rate for 2016 and 2015 was 9%whereas the state tax rate for 2014 was 7.5%.b.Tax assessmentsFoamix has tax assessments that are considered to be final through tax year 2012.c.Tax benefits under the Law for Encouragement of Industry (Taxation), 1969The Company believes that it currently qualifies as an "Industrial Company" under the above law. As such it is entitled to certain taxbenefits, mainly the right to deduct share issuance costs over three years for tax purposes in the event of a public offering.The Company utilizes this tax benefit.d.Losses for tax purposes carried forward to future yearsAs of December 31, 2016, Foamix had approximately $50.1 million of net carry forward tax losses in Israel, which are available to reducefuture taxable income with no limited period of use. F - 29 December 31, 2016 2015 In respect of: Net operating loss carry forward $11,512 $8,142 Research and development 4,147 1,773 Other 332 299 Less - valuation allowance (15,991) (10,214)Net deferred tax assets $- $- Year ended December 31 2016 2015 2014 Loss before income taxes $28,949 $16,478 $11,478 Theoretical tax benefit on the above amount (7,237) (4,367) (3,042)Decrease (increase) in tax refund resulting from: Reduction in corporate tax rate 1,965 - - Non-deductible expenses and other permanent differences, mainly share basedcompensation expenses, issuance costs and finance expenses on convertible loansand warrants (491) (585) 2,706 Net change in valuation allowance 5,777 3,973 1,757 Other 373 1,018 (1,415)Actual tax expense $387 $39 $6 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts)NOTE 10 - INCOME TAX (continued):e.Subsidiary tax liabilityDuring 2016, 2015 and 2014, the US subsidiary incurred a tax expense in the amount of $387, $39 and $6, respectively. f.Deferred income taxes: Realization of deferred tax assets is contingent upon sufficient future taxable income during the period that deductible temporarydifferences and carry forward losses are expected to be available to reduce taxable income. As the achievement of required future taxableincome is not likely, the Company recorded a full valuation allowance. Deferred tax has not been provided on taxes that would apply in the event of disposal of the investments in the subsidiary, as it is theCompany’s intention to hold this investment and not to realize it. Foamix may incur an additional tax liability in the event of an inter-company dividend distribution from its subsidiary; no additionaldeferred taxes have been provided, since it is the Company’s policy not to distribute in the foreseeable future, dividends which wouldresult in additional tax liability. Following is a reconciliation of the theoretical tax benefit, assuming all income is taxed at the statutory corporate tax rate applicable toIsraeli corporations, and the actual tax expense: g.As of December 31, 2016, and December 31, 2015, the Company had not accrued a provision for uncertain tax positions.F - 30Balance at January 1, 2014 $4,484 Additions 1,757 Balance at December 31, 2014 $6,241 Additions 3,973 Balance at December 31, 2015 $10,214 Additions 5,777 Balance at December 31, 2016 $15,991 December 31 2016 2015 Institutions $174 $122 Prepaid expenses 246 346 Other 18 3 $438 $471 Accrued expenses $709 $558 Payroll and related institutions 581 451 Bonus accrual 1,661 1,140 Other 33 20 $2,984 $2,169 Year ended December 31 2016 2015 2014 Development Service Payments $63 $596 $4,814 Contingent Payments 2,500 - 600 Royalties 2,964 253 - Total revenues $5,527 $849 $5,414 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 10 - INCOME TAX (continued):h.Roll forward of valuation allowance:NOTE 11 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:Balance sheets: a.Account receivable - other: b.Accounts payable and accruals - other: Statements of operations:c.Revenues In the year ended December 31, 2016, the Company’s revenues were driven virtually all from one main customer. Based on the agreementwith this customer the Company is entitled to royalty payments with respect to sales of a product developed by the customer incollaboration with the Company. Additionally, the Company was entitled to contingent payments for the achievement of certain saletargets by the customer. The following table provides a breakdown of the Company’s net revenues: F - 31Finance expenses: Finance expenses on convertible loans and warrants $- $- $9,915 Finance expenses on BIRD loan 243 * * Other expenses 17 23 15 Total finance expenses 260 23 9,930 Finance income: Gains from securities, net (401) (180) (11)Interest on bank deposits (536) (289) (28)Foreign exchange gains, net (24) (6) (47)Total finance income (961) (475) (86) $(701) $(452) $9,844 Year ended December 31 2016 2015 2014 Germany $5,464 $253 $2,500 United States 14 587 2,305 France 49 9 - Israel - - 609 Total revenues $5,527 $849 $5,414 Year ended December 31 2016 2015 2014 Customer A $- $86 $732 Customer B $14 $366 $1,032 Customer C $5,464 $253 $2,500 Customer D $- $135 $541 Customer E $- $- $609 FOAMIX PHARMACEUTICALS LTD.NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)(U.S. dollars in thousands, except share and per share amounts) NOTE 11 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (continued):d.Finance expenses (income), net: * Represents an amount less than $1. NOTE 12 - ENTITY-WIDE DISCLOSURE:a.Net revenues by geographic area were as follows:b.Revenues from principal customers - revenues from single customers that exceed 10% of total revenues in the relevant year: NOTE 13 - SUBSEQUENT EVENTSIn November, 2016, the board of directors approved an increase of 900,000 ordinary shares, to the pool included under the option Plan. Theshares were registered in January 2017. F - 32 Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Dov Tamarkin, certify that: 1.I have reviewed this annual report on Form 20-F of Foamix Pharmaceuticals Ltd.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; 4.The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in ExchangeAct Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for thecompany and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by theannual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and 5.The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to thecompany's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the company's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal controlover financial reporting. Date: February 21, 2017By:/s/ Dov Tamarkin Name:Dov Tamarkin Title:Chief Executive Officer Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER I, Ilan Hadar, certify that: 1.I have reviewed this annual report on Form 20-F of Foamix Pharmaceuticals Ltd.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make thestatements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects thefinancial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; 4.The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in ExchangeAct Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for thecompany and have: a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, toensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report is being prepared; b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under oursupervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for externalpurposes in accordance with generally accepted accounting principles; c)Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by theannual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and 5.The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to thecompany's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions): a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonablylikely to adversely affect the company's ability to record, process, summarize and report financial information; and b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal controlover financial reporting. Date: February 21, 2017By:/s/ Ilan Hadar Name:Ilan Hadar Title:Chief Financial Officer Exhibit 13.1 CERTIFICATION OF CEO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Annual Report on Form 20-F of Foamix Pharmaceuticals Ltd. (the "Company") for the year ended December 31, 2016 as filedwith the Securities and Exchange Commission on the date hereof (the "Report"), Dov Tamarkin, as Chief Executive Officer of the Company, hereby certifies,pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of theCompany. By:/s/ Dov Tamarkin Name: Dov Tamarkin Title: Chief Executive Officer Date: February 21, 2017This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required bythe Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and willbe retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. Exhibit 13.2 CERTIFICATION OF CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Annual Report on Form 20-F of Foamix Pharmaceuticals Ltd. (the "Company") for the year ended December 31, 2016 as filedwith the Securities and Exchange Commission on the date hereof (the "Report"), Ilan Hadar, as Chief Financial Officer of the Company, hereby certifies,pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of theCompany. By:/s/ Ilan Hadar Name: Ilan Hadar Title: Chief Financial Officer Date: February 21, 2017 This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required bythe Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and willbe retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.Exhibit 15.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form F‑3 (No. 333-207546) and the Registration Statement on Form S-8 (No. 333-215498) of Foamix Pharmaceuticals Ltd. of our report dated February 21, 2017 relating to the financial statements, which appears in this Form20‑F. Tel-Aviv, Israel/s/ Kesselman & KesselmanFebruary 21, 2017Certified Public Accountants (Isr.) A member firm of PricewaterhouseCoopers International Limited Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel, P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il 

Continue reading text version or see original annual report in PDF format above